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ABSTRACT  
 
Background: The ANCA –associated vasculitides (AAVs) are a group of 
rare, potentially life-threatening conditions which if untreated can be fatal. 
Little is known about the information needs of people with AAV.  
Objectives: To explore what it is like to be diagnosed with AAV and to find 
out the informational needs of this group.  
Study design: A mixed methods approach using focus groups and one-to-
one interviews, then a questionnaire surveying the membership of 
Vasculitis UK (VUK) and the Vasculitis Clinical Research Consortium 
(VCRC). 
Results: Emergent themes from the first phase were: reaction to diagnosis, 
need for information on disease management and access to 
knowledgeable practitioners. There were 314 VUK, 273 VCRC 
respondents. Respondents rated information on diagnosis, prognosis, 
investigations, treatment, and side effects as extremely important. 
Information on patient support groups and psychosocial care was less 
important. There was no difference in the ratings of information needs 
based on group, sex, age, disease duration, disease, or method of 
questionnaire delivery.  
Conclusion: Receiving the diagnosis of a rare, potentially life-threatening 
disease causes anxiety and fear and can impede information retention and 
recall. People with AAV seek specific information concerning their disease, 
treatment regimes and side effects, and the results of investigations. 
Individuals preferred to receive this information from a doctor. 
Recommendations: Patients with AAV should be treated in a similar 
manner to patients with other chronic illnesses in which patient education is 
a fundamental part of care. 
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Chapter 1  
Introduction to vasculitis  
 
This chapter will provide an overview of what vasculitis is and focus on one 
particular type, the anti-neutrophil cytoplasmic antibody (ANCA) –
associated vasculitides (AAVs). It will focus on the diagnosis, epidemiology 
and definitions of these conditions.  
 
1.1 What is vasculitis? 
 
Vasculitis means inflammation of a blood vessel wall. This can occur in any 
blood vessel from arteries, to veins and capillaries, in any organ of the body 
such as the skin, lungs and kidneys. This inflammation can cause blood 
vessels to narrow, occlude or rupture. The significance of this depends 
upon the size and site of the blood vessel involved. There are many 
different types of vasculitis from mild disease to a much more severe 
disease presentation of a systemic vasculitis, that is a potentially life-
threatening multi-system disease (Watts & Scott, 2010). The vasculitides 
are often classified according to their blood vessel size of small, medium 
and large vessels and Jennette and colleagues provide a useful diagram 
below to illustrate this (Figure 1) (Jennette et al., 2013).  
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Figure 1 Types of vessels that are defined as large vessels (A), medium 
vessels (B), and small vessels (C) in the Chapel Hill Consensus 
Conference nomenclature system (Jennette et al., 2013). 
 
There are many types of vasculitis affecting different blood vessel sizes: 
within the small blood vessel group there are three conditions that share 
common features and they are associated with antibodies in the blood 
called anti-neutrophil cytoplasmic antibodies (ANCA) (See section 1.7 for 
further details). These three conditions are Granulomatosis with Polyangiitis 
(Wegener‘s) (GPA), Eosinophilic Granulomatosis with Polyangiitis (Churg 
Strauss) (EGPA) and Microscopic Polyangiitis (MPA) (Figure 2).They are 
often called the ANCA-associated vasculitides. This thesis focuses on this 
group of conditions. 
 
Large vessels are 
the aorta and its 
major branches 
and the related 
veins. 
The kidney is used 
to show medium and 
small vessels. Medium 
vessels are the main 
arteries and veins and 
their initial branches 
Small vessels are 
arteries, arterioles, 
capillaries,venules  
and veins 
 18 
 
 
Figure  2 Classification of the vasculitides (Jennette et al., 2013) 
 
 
1.2 What is ANCA–associated vasculitis? 
 
The ANCA-associated vasculitides (AAV‘s) Granulomatosis with 
Polyangiitis (Wegener‘s) (GPA), Eosinophilic Granulomatosis with 
Polyangiitis (Churg Strauss) (EGPA) and Microscopic Polyangiitis (MPA) 
are a group of rare, potentially life-threatening conditions which if untreated 
can be fatal. They are characterized by systemic illness, multi-system 
disease, with inflammation of blood vessel walls (vasculitis), which can lead 
to aneurysm formation, haemorrhage and infarction (Watts & Scott, 2010). 
Many organs can be affected such as the kidney, heart, lung, upper and 
lower airways and the nervous system. The majority of these conditions are 
associated with a certain type of antibody called anti-neutrophil cytoplasmic 
antibody (ANCA). The definition of AAV vasculitis is in Table 1. Although 
the three conditions are different they share many clinical features and 
treatment regimes. 
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   ANCA Associated 
   Vasculitis (AAV) 
Necrotizing vasculitis, with few or no immune 
deposits, predominantly affecting small vessels 
(i.e., capillaries, venules, arterioles and small 
arteries), associated with MPO-ANCA or PR3-
ANCA.  Not all patients have ANCA. Add a prefix 
indicating ANCA reactivity, e.g. PR3-ANCA, 
MPO-ANCA, ANCA-negative.  
Granulomatosis with 
     Polyangiitis 
(Wegener‘s) 
     (GPA) 
Necrotizing granulomatous inflammation usually 
involving the upper and lower respiratory tract, 
and necrotizing vasculitis affecting predominantly 
small to vessels (e.g., capillaries, venules, 
arterioles, arteries and veins). Necrotizing 
glomerulonephritis is common. 
Eosinophilic 
     Granulomatosis with 
     Polyangiitis (Churg 
     Strauss) (EGPA) 
Eosinophil-rich and necrotizing granulomatous 
inflammation often involving the respiratory tract, 
and necrotizing vasculitis predominantly affecting 
small to medium vessels, and associated with 
asthma and eosinophilia. ANCA is more frequent 
when glomerulonephritis is present. 
Microscopic polyangiitis 
(MPA) 
Necrotizing vasculitis, with few or no immune 
deposits, predominantly affecting small vessels 
(i.e., capillaries, venules, or arterioles). 
Necrotizing arteritis involving small and medium 
arteries may be present. Necrotizing 
glomerulonephritis is very common. Pulmonary 
capillaritis often occurs. Granulomatous 
inflammation is absent. 
Table 1 Chapel Hill Consensus definitions (2013) for ANCA associated 
AAV. 
 
 
1.3 Granulomatosis with Polyangiitis (Wegener’s)(GPA) 
 
Although Heinz Klinger first documented this condition in 1931, it was 
originally named Wegener‘s granulomatosis after the German doctor 
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Friedrich Wegener who provided a detailed description of the condition in 
1936 in his thesis ―Variants of Periarteritis Nodosa―.  He described two 
patients who presented with fever, nasal discharge, arthritis, nephritis and 
pulmonary vasculitis. Post mortem findings revealed a necrotising 
granulomatous vasculitis of the upper and lower airways, together with 
cresentic glomerulonephritis. Godman and Churg in 1954 described the 
classic clinical features of upper and lower respiratory tract involvement 
with necrotizing granulomatous lesions, with a focal segmental necrotizing 
glomerulonephritis and a systemic vasculitis. In 2011 this condition was 
renamed Granulomatosis with Polyangiitis (Wegener‘s granulomatosis) 
(GPA) to better reflect disease pathology (Falk et al., 2011). GPA is defined 
as a small to medium vessel vasculitis that typically affects the upper and 
lower airways and kidneys but can affect other organs (Table 1). It is 
associated with granulomatosis formation in the upper airways and c- 
ANCA detected against PR3  in approximately 90% of patients ( Watts & 
Scott, 2010).    
 
 
1.4 Eosinophilic Granulomatosis with Polyangiitis (Churg 
Strauss)(EGPA) 
 
This condition was first recognized in 1951 by two doctors and was 
originally named Churg Strauss Syndrome (Churg & Strauss, 1951). They 
described a syndrome consisting of asthma, allergic rhinitis, granulomas, 
pulmonary and small vessel vasculitis in 13 post mortem cases. In 2011 
this condition was renamed Eosinophilic Granulomatosis with Polyangiitis 
(Churg Strauss) (EGPA). GPA is defined as a small to medium vessel 
vasculitis (Table 1). This disease is characterized by asthma, eosinophilia 
with granuloma inflammation involving the respiratory tract. The history of 
asthma or sinus disease usually precedes the vasculitis by years. Heart 
and nerve involvement is common but kidney involvement is rare 
(Chumbley et al.,1997, Lane et al., 2005). It is associated with the antibody 
anti-neutrophil cytoplasmic antibody (p-ANCA) in 50% of patients (Watts & 
Scott 2010). 
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1.5 Microscopic Polyangiitis (MPA) 
 
In 1948 Davson and colleagues reviewed 14 post mortem cases of patients 
who presented with clinical features of periarteritis nodosa and histology of 
focal necrotising glomerulonephritis (Davson et al., 1984). They divided the 
group into two according to renal involvement. Group one included those 
with severe and widespread glomerular damage (acute renal failure).  
Group two included those where renal changes were not widespread. They 
named the group with acute renal failure ‗microscopic form of periarteritis‘. 
Today this group is known as Microscopic Polyangiitis (MPA) (Jennette et 
al., 1994). MPA is defined as a small vessel vasculitis which rarely affects 
medium and large vessels (Table 1). It typically affects the kidneys but can 
involve the skin, lungs, digestive system. It is associated with the antibody 
anti-neutrophil cytoplasmic antibody (p ANCA) and particularly detected 
against MPO-ANCA in 90% patients (Wiik , 2003). Although this disease 
shares many clinical features with EGPA, there is less ear, nose and throat 
involvement in MPA (Molloy & Langford, 2006). 
 
1.6 What causes AAV? 
 
The exact cause is unknown but AAV is considered an auto-immune 
disease.  The immune system is the body‘s own defence mechanism 
against foreign invaders and infection (Vamvakopoulous et al., 2010). In 
AAV the immune system starts to attack normal blood vessel cells 
mistaking them as foreign causing inflammation of blood vessels. It is 
thought that an environmental trigger interacting within a genetically pre 
disposed person (in their genes) activates the development of an auto-
immune disease. For most patients the environmental factors are unknown 
but some drugs such as allopurinol, amphetamines, cocaine, 
propylthiouracil, hydrallazinethiazide, sulfonamides, penicillins and thiazide 
have been associated in some patients (De Lind van Wijingaard et al., 
2008). While farming, exposure to hydrocarbon or silica have been 
suggested as possible environmental triggers (Lane et al., 2005, De Lind 
van Wijingaard et al., 2008), the genetic risk factors are still poorly 
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understood and there may be genetic differences between the three 
diseases.  
 
1.7 What is ANCA? 
 
ANCA (anti-neutrophil cytoplasmic antibodies) are antibodies that are found 
in the blood stream. Antibodies fight off viruses, infections and foreign 
invaders and make them harmless. In autoimmune diseases, the immune 
system develops antibodies against various tissues within the body thereby 
reacting against them as if they were a foreign invader. In AAV these 
antibodies stick to parts of the white blood cell instead of attacking the 
foreign invader.  ANCA antibodies can be divided into two kinds:  p-ANCA, 
which are antibodies found in EGPA and in other vasculitides, and c-ANCA, 
which are antibodies mostly seen in GPA. It is not clear whether ANCA 
antibodies cause vasculitis, but a positive result can be very helpful to aid 
diagnosis.  
 
 
Figure 3 Indirect immunofluorescence pattern of cytoplasmic anti-neutrophil 
cytoplasm antibody (c-ANCA) from a patient with Wegener‘s 
Granulomatosis from Miller et al., (2010) 
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1.8 Epidemiology 
 
The European Union's definition of a rare disorder is a condition which 
affects fewer than five people in every 10,000 (European Commission,  
2008) or affects fewer than 200,000 people in the United States (The 
Orphan Drug Act, 1983). Prevalence and incidence are used to measure 
disease frequency. Prevalence is the total number of a population that is 
affected with a specific disease at a given time (Last, 2001). Incidence is 
the number of new cases occurring within a particular time frame (Last, 
2001).   
 
The prevalence of AAV in Norfolk in December 2008 was GPA 146 per 
million, MPA 36 per million (Watts et al., 2012) and EGPA 46 per million 
(unpublished). Thus the AAVs are rare with an estimated annual incidence 
of 20/million in Europe (Ntatsaki et al., 2010). In Norfolk the annual 
incidence of GPA was 11.3 per million, MPA 5.9 per million and EGPA 1-2 
per million (Watts et al., 2012). This translates to approximately 1,200 
people developing AAV per year in the UK, with an overall incidence of 2.5 
per 10,000 in the whole of the United Kingdom (UK).  
There appears to be a difference between populations as GPA is the most 
common with an annual incidence of 10 per million in Northern Europe 
compared to 5 per million in Southern Europe (Watts & Scott, 2013). In 
New Zealand, GPA is more common in the South than the North and in 
Japan, MPA is much more common than GPA despite similar overall 
incidences (Fujimoto et al., 2011). This had led to speculation that there is 
a north south latitude divide. The AAVs are more common in Caucasians, 
with slightly more men than women affected with a peak age of onset 
6574years. AAV is rare but over the last ten years there has been an 
increase in prevalence which could be due to increased recognition and 
better treatment. The next chapter will provide further background 
information on diagnosis, management, prognosis of AAV and a review of 
the relevant literature. 
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Chapter 2 Diagnosis and management   
 
This chapter examines how ANCA-associated vasculitis is diagnosed, the 
prognosis, treatment and management.  
 
2.1 Diagnosis  
 
It is often difficult to diagnose these conditions as early presentation is often 
non-specific, with a wide spectrum of clinical presentations and the clinical 
features can mimic many diseases (Hellmich&Goss, 2005, Berden et al., 
2012). Patients can present acutely unwell with multi-system disease or 
with gradual deterioration with a range of the following signs or symptoms:  
rash, fever, lethargy, joint pains, reduced mobility, abdominal pain, 
shortness of breath, coughing up blood, respiratory distress, acute renal 
failure, sudden deafness, sinusitis, eye problems and peripheral nerve 
involvement (Figure 4).  It is often only when infection and malignancy are 
excluded that a vasculitis may be suspected (Mooney & Scott, 2009).  
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Figure 4 Clinical Features of ANCA associated vasculitis. From Berden et 
al., (2012) Diagnosis and management of ANCA associated vasculitis. 
BMJ; 344:e26 
 
2.2 Common Clinical features  
 
Although AAV can present with an array of clinical features, the three 
diseases share many common clinical features. Lane and colleagues 
studied the first symptom at presentation and found systemic features are 
very common such as fever, malaise, weight loss and myalgia in all three 
conditions (Lane et al., 2005). Ear nose and throat symptoms were the 
most common symptom in GPA (35%), respiratory was the most common 
in EGPA (33%) and renal was the most common for MPA (33%) (Figure 4).   
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Figure 5 First symptom of vasculitis (Lane et al., 2005:p103) 
 
2.3 Investigations 
 
Although, it can be difficult to diagnose AAV, blood tests, urinalysis, x-rays 
and tissue biopsies are all used to aid diagnosis, exclude differential 
diagnosis and assess organ involvement and disease severity. Blood tests 
such as full blood count can indicate anaemia, urinalysis to detect for 
haematuria and proteinuria and raised creatinine is useful to assess kidney 
function/ impairment. Chest radiography may reveal pulmonary infiltrates, 
nodules or cavitating lesions (Berden et al., 2012). ANCA serology may be 
positive in the majority of patients at diagnosis but 5-10% of patients will be 
ANCA negative. Also many other conditions can have a positive ANCA 
such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) 
and inflammatory bowel disease. These are sometimes complex and 
invasive investigations, such as tissue biopsy and all need to be done 
rapidly because of the urgency of the situation.  A tissue biopsy showing 
vasculitis from the kidney, nerve or other organ will confirm the diagnosis 
and is considered the gold standard in diagnosis (Miller et al., 2010).  
 
 
 27 
 
1.Systemic multisystem disease 
 Infection                              Subacute bacterial endocarditis 
                                             Neisseria meningitides 
                                            Rickettsiae 
Malignancy                          Metatastic carcinoma 
                                            Paraneoplastic 
Other                                   Sweet syndrome 
                                            Connective tissue disorders 
2.Vessel occlusion            Cholesterol crystals 
    Embolic                            Atrial myxoma 
                                             Mycotic  (infection) 
   Thrombotic                       Antiphospholipid syndrome  
                                            Procoagulant states 
                                            Calciphylaxis 
   Other                                Ergotism 
                                            Radiation 
                                            Degos syndrome 
                                            Severe Raynaud‘s phenomenon 
                                           Acute digital loss (atheromatous) 
                                 
3. Angiographic appearances 
   Aneurysmal                   Fibromuscular dysplasia  
                                         Neurofibromatosis 
  Occlusion                      Coarctation of the aorta 
Table 2 Mimics of vasculitis (Watts & Dharmapalaiah, 2012) 
 
2.4 Diagnostic delay 
 
Diagnostic delay is common (Huyard, 2009, Jayne, 2009). It is recognized 
that AAV is difficult to diagnose due to the wide spectrum of clinical 
presentations that may mimic many diseases (Berden et al., 2012). 
Patients may have consulted several different doctors and had many 
investigations and tests before a diagnosis is reached. A study of 30 EGPA 
patients found that a delay in diagnosis was associated with more severe 
disease, more hospital admissions,higher use of steroids and patients 
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required increased immunosuppressive therapy (Sokolowska et al., 2012). 
It is important that AAV is considered as a possible differential diagnosis 
and referral to medical experts in the field is considered when patients 
present with a multi-system disease, as a delay in diagnosis and treatment 
can affect the patient‘s outcome (Sokolowska et al., 2012).  
 
 
2.5 Approaches to therapy/ management   
 
Treatment should commence as soon as the diagnosis is made to avoid 
irreversible organ damage. Guidelines have been published for the 
management of AAV (Lapraik et al., 2007, Mukhtyar et al., 2009, Ntataski et 
al., 2103). The aim of treatment is to induce remission, preserve organ 
function, and reduce mortality and toxicity of medication. Treatment is 
mainly split into three phases: 
 
1) Induction of remission 
2) Maintenance   
3) Long-term follow up. 
 
2.6 Medications used in AAV 
 
There are many medications used to treat AAV from cytotoxic agents such 
as cyclophosphamide to immunosuppressive drugs such as azathioprine, 
leflunomide, methotrexate, mycophenolate mofetil (MMF) and steroids. 
Medications are vital to patient survival but are associated with increased 
risk of serious toxicity. The medications are discussed below.  
 
2.6.1 Cyclophosphamide 
 
Cyclophosphamide is a cytotoxic agent which works by preventing cell 
division causing cell death (Monach et al., 2010). It can be given orally or 
intravenously (IV) in pulses. Oral dose is 2mg/kg daily, maximum dosage 
200mgs daily. IV dosage is 15mg/kg, maximum dosage 1500mgs, given as 
two to three weekly pulses. Dosage should be adjusted for age and renal 
function. Side effects are bone marrow suppression, haemorrhagic cystitis, 
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increased risk of infection, bladder cancer, infertility and malignancy 
(Monach et al., 2010, Mahr et al., 2013).  
 
2.6.2 Steroids  
 
Steroids are powerful immunosuppressants. They are very effective at 
controlling inflammation. They are produced by the adrenal cortex and 
exactly how they suppress inflammation is unknown. They can be 
administered orally, intramuscularly, intravenously and by intra -articular 
injection. Dosage varies according to the treatment phase: for induction 
therapy 1mg/kg is used and for maintenance remission the dosage is 
tapered. There are many side effects associated with steroids such as 
thinning of the skin, moon shaped face, cataracts, osteoporosis, diabetes, 
hypertension, weight gain, dyspepsia, peptic ulceration, bruising, impaired 
healing , proximal myopathy, avascular necrosis of the femoral head, 
increased risk of infection and psychosis (Turnbull  & Harper, 2009).  
 
2.6.3 Methotrexate 
 
Methotrexate is a cytotoxic agent that is used to treat some cancers, 
however it is used in very small dosages to treat many rheumatic 
conditions. It is thought to act principally during cell division, preventing 
synthesis of deoxyribonucleic acid (DNA) and cell replication (RCN, 2013). 
The exact immunosuppressive action in inflammatory joint disease remains 
unclear, although it is thought to be as a result of the inhibition of 
lymphocyte proliferation (SPC, 2014). This medication can be prescribed 
orally or subcutaneously, however it must only be taken once weekly, dose 
range 7.5mgs - 25 mg. Methotrexate suppresses the immune system and 
requires regular blood monitoring for potential side effects. Minor side 
effects include nausea and mouth ulcers, more serious side effects include 
bone marrow suppression, elevated liver enzymes and methotrexate 
induced pneumonitis. It is teratogenic so must not be given to those who 
are pregnant or those contemplating pregnancy. This includes both males 
and females.   
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2.6.4 Azathioprine 
 
Azathioprine is a disease-modifying anti rheumatic medication used to treat 
many rheumatic conditions. It works by interfering with DNA synthesis, 
causing cell death or inhibiting cell division. It is given orally and can take 
up to 12 weeks to work. Side effects include liver function abnormalities, 
haematological, rash, mouth ulcers, nausea, loss of appetite, increase risk 
of infections (Oliver, 2009).  
 
2.6.5 Mycophenolate mofetil (MMF) 
 
Mycophenolate mofetil is used to prevent rejection of organ transplantation. 
It is used to treat Rheumatoid Arthritis (RA) and AAV. It works by 
suppressing T and B cell multiplication. The dose of MMF is gradually 
increased over a four week period. Starting dose: 500 mg/day orally for the 
first week, increasing by 500mg a day for second week ( 1gm), third week 
increase by 500 mgs daily to 1.5 mgs/day, fourth week  take 1 g (two 
tablets) twice a day. The maximum dose is 3 gms daily. It takes up to 12 
weeks to work. Side effects: no major organ toxicity associated but can 
cause nausea, vomiting, abdominal cramps, haematological disorders and 
sterile haematuris.  Women should not get pregnant whilst taking MMF and 
should be advised to use effective contraception (Oliver, 2009). 
 
2.6.6 Leflunomide  
 
Leflunomide is an oral disease-modifying anti-rheumatic medication used to 
treat many rheumatic conditions. It works by inhibiting pyrimidine synthesis 
(Saleem & Conaghan, 2010). A loading dose of 100mgs daily is given for 
three days, then 10-20- mgs maintenance dose daily. Due to poor 
tolerability the loading does is often not given. Side effects liver impairment, 
bone marrow suppression, nausea, diahorrea, mouth ulcers and 
hypertension.  
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2.7 Disease assessment 
 
An assessment of the severity of the disease and the organs involved is 
vital as this determines the immunosuppressive regime (Mukhtyar et al., 
2009 Ntataski et al., 2103). There is a validated commonly used instrument 
designed to assess disease activity and severity in AAV, The Birmingham 
Vasculitis Activity Score (BVAS)(Luqmani et al., 1994). This tool  scores the 
clinical features present over the last four weeks in nine organ systems, 
systemic, mucous membranes and eyes, cardiovascular, abdominal, skin, 
renal, chest, ear nose and throat and nervous system. Each feature is 
given a score and organ involvement is weighted, with a maximum score of 
63. This instrument has been used extensively in clinical trials in AAV. The 
severity of AAV has been categorized into five groups namely localised, 
early systemic, generalised, severe and refractory (Table 3) by The 
European Vasculitis Study Group (EUVAS) (Mukhtyar et al., 2009). It is 
vital to identify those patients with severe and life-threatening disease 
requiring urgent treatment ass the more severe the disease, the greater risk 
to life and of permanent organ damage. The kidney is the most common 
organ affected in 70% patients (Jayne, 2009). 
 
Table 3 EUVAS categories of disease severity (Mukhtyar et al., 2009).  
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2.8 Induction of remission 
 
Cyclophosphamide and steroids are commonly used to induce remission. A 
study into which route, either oral or intravenous, was the safest and most 
effective found that both regimes were equal in time to remission (De Groot 
et al., 2009). However, the oral group received nearly double the total dose 
of cyclophosphamide than pulsed group 15.0 g v‘s 8.2 gms. Overall the IV 
route appeared safer, with fewer episodes of leucopoenia 28/59 and less 
severe infection 7/10. Oral cyclophosphamide was associated with more 
severe and life-threatening adverse drug reactions 31v‘s 19 but had fewer 
relapses (De Groot et al., 2009).  
 
There is agreement that cyclophosphamide use should be limited to 3-6 
months and a cumulative dose > 12g in the induction remission phase to 
minimize the risks of side effects (Lapraik et al., 2007, Mukhtyar et al., 
2009). For those patients with non-organ threatening or non-life threatening 
disease, methotrexate (oral or parenteral) and glucocorticoid is a less toxic 
regime to cyclophosphamide (De Groot et al., 2005, Mukhtyar et al., 2009, 
Ntataski et al., 2103). 
 
2.9 Maintenance 
 
Once remission is achieved, azathioprine, methotrexate or leflunomide and 
steroids are used as maintenance therapy. Pagnoux et al., (2008) 
compared azathioprine to methotrexate in maintaining remission in EGPA 
and MPA patients who had achieved induction of remission with IV pulsed 
cyclophosphamide. In an open label prospective multicenter trial,126 
patients were randomized to either receive azathioprine  2.0 mgs kg daily  
or methotrexate 0.3 mgs / kg once a week increased to 25mgs per week for 
one year. There were no statistically significant differences between the 
side effects and relapse rates of both drugs. However, there were more 
relapses in the methotrexate group 13 v‘s 6. How long maintenance 
therapy should be continued for is uncertain and most clinical trials 
continued immunosuppression for 12-18 months (Bosch et al., 2007).  
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There are few clinical trials using mycophenolate mofetil (MMF) as 
remission induction therapy. One randomized controlled trial compared 
pulsed cyclophosphamide to MM in 35 newly diagnosed AAV patients. In 
the MMF arm 14/18 patients achieved remission compared to 8/13 patients 
in the IV pulsed cyclophosphamide group. There were no differences in 
side effects between the two groups. The results are inconclusive as the 
dose of cyclophosphamide used was lower than traditionally used in clinical 
practice (Ntatsaki et al., 2010). A study comparing MMF to azathioprine as 
remission maintenance therapy in 175 patients with AAV found that the 
MMF group had higher relapse rates 44(55%) compared to 3(38%) in the 
azathioprine group (Hiemstra et al., 2010). As yet there is limited evidence 
for MMF use compared to other immunosuppressants such as azathioprine 
or methotrexate. In patients who have no active vasculitis, no relapses and 
are ANCA negative, withdrawal of methotrexate and azathioprine should be 
considered (Bosch et al ., 2007). 
 
 
2.10 Relapse 
 
The AAVs are relapsing conditions with 50% of patients experiencing a 
relapse at five years (Smith et al., 2012). Relapse has been defined as 
‗disease which has been previously well controlled and which has become 
active‘ (Ntatsaki et al ., 2013). Whether the relapse is minor or major will 
determine the treatment regime. Minor relapse (no threat to organs) can be 
treated with an increase in immunosuppressive drugs or steroids. Major 
relapse (threat to organs) will need either cyclophosphamide or Rituximab 
(Ntatski et al., 2013).   
 
2.11 Rituximab 
 
Guidelines have been published for the management of AAV (Lapraik et al., 
2007, Mukhtyar et al., 2009, Ntatsaki et al., 2013) and up until 2012 there 
was general consensus that cyclophosphamide and steroids are the first 
choice for induction of remission. However, the introduction of a new drug 
called rituximab which was used to treat patients with refractory disease 
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and those who were unable to take conventional therapy, provided another 
therapeutic option. However, the exact place in the treatment pyramid for 
rituximab is not certain and many questions remain unanswered as yet. For 
example which patients should receive rituximab and what is the best 
therapeutic dose (Jayne,  2010).  In 2010 the results of two randomized 
clinical trials in ANCA-associated vasculitis using Rituximab were 
published. Rituximab is an intravenous biological agent that depletes B 
cells from the blood steam. The RAVE study (Stone et al., 2010) compared 
Rituximab v‘s cyclophosphamide as induction remission and found that it 
was at least as effective as cyclophosphamide. However, Rituximab was 
superior in achieving remission in those with relapsing disease (67% v‘s 
42%). The RITUXVAS study compared Rituximab with cyclophosphamide 
for induction remission and found that they were comparable (76% v‘s 
82%) and with similar serious adverse events (Jones et al., 2010). The role 
of Rituximab is not clear at present as long-term data are needed to 
establish its safety profile. The NHS Commissioning Board (2013) has 
authorised its use in relapsing disease, those who are intolerant of 
cyclophosphamide, in patients who have received the maximum cumulative 
dose and in women of child bearing age. For maintenance therapy 
azathioprine, methotrexate or leflunomide can be used. Once remission is 
achieved azathioprine continues to have the safest profile for maintenance 
therapy (Ntatsaki et al., 2011).  
 
2.12 Survival 
 
The introduction of modern immunosuppressive therapy has resulted in a 
marked improvement in prognosis of these conditions (Bhamra & Luqmani,  
2012). The natural history of untreated (AAV) is of a rapidly progressive, 
usually fatal disease. Prior to the introduction of corticosteroids in GPA, 
Walton observed a mean survival of 5 months, with 82% of patients dying 
within one year and more than 90% dying within two years (Walton, 
1958).The median survival in GPA was only 12.5 months using 
corticosteroids alone, with most patients dying of sepsis or uncontrolled 
disease (Hollander & Manning, 1967).There was further improvement to 
around 20% following the introduction of corticosteroids and 
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cyclophosphamide (Fauci et al.,1973). Data from Lane et al., (2005) 
suggest a 5 year survival of 76% for GPA, 68% for EGPA and 45% for 
MPA. This is supported in a review of mortality by Phillip & Luqmani (2008) 
who found a 5 year survival rate of 75% for GPA, 68%-100% for EGPA, 
45%- 75 % for MPA.  A retrospective review of 445 GPA patients in 
Germany in 2011 found a reduction in mortality (Holle et al., 2011). In a 
recent review of the long-term outcome of the EUVAS trials the one year 
survival was 88%, two years 85% and 78% at five years (Flossman et al., 
2011). This is supported with data from the Norfolk Vasculitis Register 
which shows an increase in survival of 88% at one year and 78% at five 
years over a 20 year period from 1990- 2010 (Figure 6) (Watts et al .,2013)  
 
Figure 6 NORVAS Survival data Watts et al., (2013) 
 
 2.13 Long-term follow up 
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Due to the complex nature of these conditions, they are unlikely to be 
managed solely by general practitioners, junior doctors or doctors with little 
knowledge or experience in vasculitis. It is recommended that they should 
be managed in conjunction with medical experts in the field, following 
guidelines that incorporate disease-specific outcome measures (Mukhtyar 
& Luqmani, 2007, Mukhtyar et al., 2009, Ntatsaki et al., 2013). These 
patients require regular and careful follow up to assess organ function and 
damage, early detection of disease relapse, management of co-morbidities 
and detection of drug toxicity and side effects of medication (Appendix A). 
The complexities and challenges of the management of AAV are shown in 
figure 7 (Bhamra & Luqmani, 2012). 
 
 
 
Figure 7 Relationship between disease activity, therapy comorbidity and 
damage, organ failure, and death in vasculitis from Bhamra & Luqmani, 
(2012:496). 
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2.14 Disease assessment and monitoring 
 
The diagnosis of AAV is significant and these patients will require long-term 
follow up and monitoring. Despite improvements in survival there is still 
considerable risk associated with treatment.of those who present with 
severe disease and the elderly (Phillip & Luqmani, 2008). Little and 
colleagues studied 524 newly diagnosed AAV patients and found a 
mortality of 11.1% in the first year (Little et al., 2010). The major causes of 
death were active uncontrolled vasculitis, infection secondary to therapy in 
the early stage of disease and cardiovascular disease during the chronic 
follow up phase (Luqmani et al., 2011). Even if patients survive the first 
year, they are at lifelong risk of relapse. Relapse occurs in up to 46% of 
patients treated with cyclophosphamide typically in the first year after 
stopping therapy (Gordon et al.,1993, Jayne et al., 2003; de Groot et al.,  
2005) and 50% of patients with renal involvement relapsing by five years 
(Booth, 2003, Little et al., 2010). 
 
2.15 Side effects of therapy  
 
There are significant side effects of therapy such as increased risk of 
infection, hypertension, osteoporosis and diabetes associated with steroids, 
haematological and skin malignancies (Knight et al., 2004, Phillip & 
Luqmani, 2008, Bhamra & Luqmani, 2012, Mahr et al., 2013). In the first 
year after diagnosis infection rates of 25% have been reported (Little et al., 
2010) compared with 12-72% in long-term follow up (Vamvakopoulous  et 
al., 2010). Increased risk of infection is associated with the elderly, 
leucopenia and declining renal function (Harper & Savage, 2005). All 
immunosuppressants and cytotoxic therapies used in AAV can cause bone 
marrow suppression (Appendix A) and steroid use is also known to 
increase the risk of infection and osteoporosis. A study of 99 AAV patients 
found that  21% developed osteoporosis, 8.2% new onset diabetes, 29% 
gained >10kgs in weight, 2.5% developed a peptic ulcer and 2% developed 
a steroid induced cataract (Boomsma et al., 2002).   
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The adverse effects of cyclophosphamide therapy are well known with 46% 
of patients developing a serious infection, 57% will become infertile and 
43% will suffer haemorrhagic cystitis (Geetha & Seo, 2012). Long-term use 
of cyclophosphamide also increases the risk of bladder cancer by 33 fold, 
lymphoma 11 fold and non -melanoma skin cancer 10 fold (Geetha & Seo, 
2012). A large study of AAV patients found that 57% of women reported 
infertility, (Hoffman et al., 1992). The WEGET study reported 5% gonadal 
failure, 0.5 % impotence and 4/35 males were infertile and amenorrhoea in 
3/ 8 women (Seo et al., 2005). Other treatment related side effects were 
diabetes 6.7%, hypertension 5-10%, cataracts, osteoporosis and muscle 
weakness / atrophy (Seo et al., 2005). 
 
2.16 Osteoporosis 
 
Osteoporosis is a condition in which the bones become weak and are 
susceptible to fracture. There are several risk factors for osteoporosis: 
female, low body weight, the elderly, smoking, post-menopausal women, 
prolonged use of steroids, amenorrhoea and history of fragility fracture. 
AAV is a risk factor for osteoporosis due to the inflammatory response, 
exposure to high dose steroids and renal impairment (Turnbull et al., 2009). 
Prophylaxis treatment against osteoporosis is now standard practice for 
patients with AAV (Jayne, 2009).   
 
2.17 Disease activity / damage  
 
In the assessment of any patient with AAV it is important to distinguish 
active disease from disease damage (Bhamra & Luqmani, 2012). Damage 
due to vasculitis is irreversible such as kidney impairment and saddle nose 
deformity and does not need immunosuppression.  Active disease however 
does require immunosuppression and this will depend on whether it is a 
minor or major relapse. There is a validated tool, the Vasculitis Damage 
Index (VDI), which is used to monitor long-term outcome (Luqmani et al., 
1994, Exley et al.,1997). This tool records organ damage that has occurred 
since diagnosis or has become worse, including damage due to drugs. It 
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focuses on eleven organ systems and each item of damage is scored one 
point with a total score of 68.The higher the score the more organ damage. 
 
Despite improvements in survival, damage to organs is irreversible: for 
example 20% of patients will develop end stage renal disease (Jayne, 
2009). Up to 80% of patients with EGPA will have permanent damage to 
the ear, nose and throat (Seo et al., 2005). The WEGET trial of 180 
patients with EGPA found that at the end of the first year 25.6% had 
hearing loss, 18.9% nasal blockage, 5-10% suffered pulmonary fibrosis, 
renal impairment and peripheral neuropathy as measured by the VDI (Seo 
et al., 2005). 
 
2.18 Co/morbidities: Cardiovascular risk 
 
Patients with AAV are at increased risk of cardiovascular events than the 
general population (Suppiaha et al., 2011).This is thought to be due to 
endothelium activation and damage but the actual process unknown.  It 
may be due to the interaction of ANCA with neutrophils and the 
endothelium (Mukhytar et al., 2009). High dose steroids are needed for 
inducing remission but are associated with hypertension, diabetes and fluid 
retention which can contribute to increased risks for cardiovascular 
disease. The inflammation of arteries may also contribute another risk 
factor for cardiovascular disease. Prevention and management of 
cardiovascular disease is recommended and cardiovascular risk 
assessments should be performed yearly (Ntatsaki et al., 2013).  
 
2.19 Structured clinical assessment  
 
The aims of management are: 
1) To assess disease severity and activity 
2) To monitor any relapse 
3) To measure the extent of disease damage 
4) To evaluate the response to therapy 
5) Early detection of drug toxicity 
6) To assess functional impairment  
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7) To provide psychosocial support and education to patients 
Adapted from Luqmani et al., (1997) 
 
To achieve this it is recommended that a structured clinical assessment is 
performed for all AAV patients including blood tests, histology, radiology, 
use of disease assessment tools, measures of function, psychosocial 
status and quality of life (Flossman et al ., 2007, Miller et al., 2010). These 
are complex multisystem diseases which relapse and remit needing careful 
assessment and monitoring (Appendix B).  
  
2.20 Monitoring treatment  
 
Medications are vital to patient survival but are associated with increased 
risk of serious toxicity. Therefore, patients need to be monitored carefully 
with regular blood and urine tests so that early treatment toxicity is 
recognized. Patients will therefor require information about their medicines 
and possible side effects at each stage of their treatment phase so that 
they can be involved in their care. It is essential that patients are fully 
informed of the reason and need for the medication, possible side effects 
and the monitoring process. They should receive information on which 
signs or symptoms to look out for and what to report to the doctor or nurse 
so that prompt treatment or early recognition of toxicity occurs. They will 
require education on how to help prevent some of the risks associated with 
treatment, such as refraining from smoking, avoiding sunbathing and 
wearing sun block (Turnbull & Harper, 2009, Ali et al., 2014).  
 
 2.21 Impact of the disease  
 
Modern therapies have changed the AAV from conditions with a poor 
outcome (death) to chronic diseases that relapse and remit. Relapse 
occurs in up to 46% of patients treated with cyclophosphamide typically in 
the first year after stopping therapy (Gordon, 1993, Jayne et al., 2003; de 
Groot et al., 2005). At five years the risk of relapse is 38%-50%, patients 
with anti-pr 3 antibodies, cardiovascular disease and a creatinine < 200 are 
 41 
 
associated with an increased risk of relapse (Walsh et al., 2012, Smith et 
al., 2012).  
 
 
2.22 Quality of life 
 
The diagnosis of AAV has a physical, psychosocial and financial impact on 
patients‘ lives (Cotch, 2000, Newall et al., 2005, Carpenter & DeVillis, 
2011). The physical impact and permanent damage from the disease can 
cause a range of problems from hearing loss, blindness, shortness of 
breath, saddle nose deformity and nerve damage (Langford, 2005, Seo et 
al., 2005, Walsh et al., 2011, Herlyn et al., 2011).Disease related 
complication such as stroke, myocardial infarction, kidney failure, cancer, 
blindness, stomach ulcer and seizures have been reported in 10% patients 
(Herlyn et al., 2011). Medications used to treat AAV are associated with 
serious toxicity and side effects. Some of these side effects such as moon 
shaped face, weight gain and hair loss are known to cause upset to 
patients (Hoffman et al.,1992, Seo et al., 2005, Herlyn et al., 2011). 
 
When Hoffman et al.,(1998) assessed the effects of GPA on health and 
function in 60 patients using a questionnaire, 80% patients reported 
reduced levels of daily activities and 78% patients needed long-term 
immunosuppression medication. A study of 51 patients with AAV (GPA, 
EGPA, MPA) found that 25% were depressed, 43% were anxious and they 
had reduced levels of  physical and social functioning (Koutantji et al., 
2003). Moderate depression was reported in 10% of patients and severe in 
4% and 16% of patients were classified as having moderate anxiety. 
Additionally, AAV patients had three times more depressive symptoms and 
were one and a half times more anxious compared to cancer patients. This 
study had a small sample size recruited from one hospital with a short 
disease duration of 3.4 years. There were differences in the three disease 
types: the GPA group were significantly younger than the MPA group and 
had more functional impairment than the EGPA patients. There were 
statistically significant differences between symptom severity between the 
different diseases, with GPA patients reporting more symptom severity than 
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EGPA patients (p>0.05) and MPA (p>0.001) and EGPA patients expressing 
greater symptom severity than MPA (p>0.05). The results may not be 
generalizable to the wider vasculitis population and those with long 
standing disease. Boomsma et al., (2002) compared GPA patients with 
systemic lupus erythematosus (SLE) patients and found that in both groups 
68% had reduced levels of daily activities. The SLE group reported 
somewhat more depression 47% compared to the GPA group 33%. The 
exact reasons for this are unclear but SLE predominately affects young 
females and depressive symptoms may impact on an individual‘s ability to 
work and social participation.  
 
A study of AAV patients and their spouses found that patients had reduced 
health-related quality of life both physically and emotionally, in contrast to 
spouses who reported no reduction (Carpenter et al., 2009). A population 
based casecontrol study by Basu et al., (2010) in Scotland found that 
people with AAV had significant impaired physical health and suffered twice 
as much fatigue, but not mental health compared to the general population. 
This is supported by Hajj-Ali et al., (2011) who found that EGPA patients 
suffered significantly greater frequency of fatigue and depression.  A 
questionnaire survey of 264 people with AAV asked them to rank from 0-5 
the impact of the disease on their life. Respondents ranked the highest 
items fatigue (3.5), no energy (3.4), weight gain (3.1) musculoskeletal pain 
(3.0) and sinusitis (3.0), additionally 19% reported anxiety (Herlyn et al., 
2010). A large multicentre cross sectional study of 410 AAV patients found 
that high CRP, poor sleep, pain, being female, non-engaging behaviour and 
denial are associated with fatigue (Basu et al., 2013). Fatigue is often 
linked to active disease but this study demonstrated no correlation with the 
BVAS. A German study of 122 vasculitis patients found that just health-
realted quality of life was reduced compared to the general population and 
just under half reported mild depression and 19% severe depression 
(Brezinova et al., 2013). A large study of 692 vasculitis patients including 
AAV found that vasculitis patients believed that their condition had affected 
their functional ability and emotional well –being (Grayson et al., 2013).   
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A study of 346 newly diagnosed AAV patients found that they had reduced 
physical functioning compared to the general population and that 
neurological involvement at presentation is associated with reduced heath 
related quality of life (Walsh et al., 2011). Although this was a large study 
pooling the results of four clinical trials, those patients who failed to 
complete the Short Form 36 (SF36) had more severe disease and were 
acutely unwell. This underrepresentation of this group may have biased the 
results. Health related quality of life was found to be reduced in GPA 
patients measured by the SF36 (Tomasson et al., 2012). Another study 
found that just over half (33) of young GPA patients (<40 years) were 
admitted to hospital as a consequence of their disease and more than 50% 
of patients had consulted a doctor at least once a week and over 90% had 
consulted a doctor at least once a month (Reinhold –Keller et al., 2002). 
 
2.23 Financial Impact  
 
Only a few studies have looked at the financial impact of AAV. Hoffman and 
colleagues (1998) found that 26% of GPA patients had reduced income 
one year after diagnosis. A small study by Reinhold –Keller et al., (2002) 
found that 27% of young GPA patients (<40 years) employed at diagnosis 
had to give up work due to disability within 39 months. This is supported by 
Boomsma et al., (2002) who found that 23% of GPA patients had reduced 
income and 25% of patients were in receipt of disability benefits. A further 
study reported that just over half (54%) of patients with GPA stated that 
they had lost between 25%-75% of their income, with 14% retiring on ill 
health grounds (Abdou et al., 2002). A recent large study of 405 AAV 
patients found that 25% were unemployed as a result of their illness (Basu 
et al., 2014). 
 
One author has estimated the annual costs for hospital admissions for AAV 
in the USA to be $150 million per year but this did not take into account 
costs associated with outpatient visits and medications (Cotch, 2000). 
There appear to be differences in the financial concerns expressed by 
patients in the USA compared to the UK and Germany, with more USA 
patients concerned about finances (19%), compared to 10% in the UK  and 
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6% in Germany (Herlyn et al., 2010). A possible explanation may be the 
differences in the health care systems: in the UK health care is free but in 
many other countries patients need to have purchased health care 
insurance or pay for care themselves. Furthermore, disability and 
employment benefits vary from country to country. The true financial impact 
for patients in many countries is largely unknown.   
 
AAV can have a significant effect on an individual‘s quality of life. The 
majority of studies in AAV have used outcome measures designed by 
doctors which assess disease activity and damage but there is a dearth of 
research into patient-reported outcome measures. Patients and doctors 
may have different views on the impact of AAV. There is limited data 
available on the impact of AAV from a patient‘s perspective. This area of 
research has received little attention until now and there is general 
agreement that vasculitis outcome measures should also include what is 
important to patients (Merkel et al., 2009). A study of patient-reported 
outcome measures of 246 vasculitis patients from the UK, Germany and 
the USA identified several aspects of the disease that are not covered in 
the existing disease outcome measures used in clinical trials (Herlyn et al., 
2010). Patients ranked fatigue, reduced energy and musculoskeletal 
symptoms as the most important factors associated with the disease. 
Although the majority of patients in this study had AAV (81%), it included 
19% of patients with other types of vasculitis and it is not known if these 
conditions truly represent similar conditions to AAV. For example Giant Cell 
Arteritis is almost in a category of its own, is relatively common, easy to 
diagnose and relatively easy to control and affects mainly the elderly. 
 
It is clear that the impact of a diagnosis of AAV is significant and patients 
will need information and advice in order to help them manage their 
disease. It is vital therefore that patients receive education and counseling 
to help them to self-manage and participate in informed decision making 
(Mukhtyar & Luqmani, 2007). There is no research into what it is like to 
receive the diagnosis of AAV or what the informational needs of this group 
are. Whilst there are tools available for assessment of disease activity, 
such as the Birmingham Vasculitis Activity Score (BVAS)(Luqmani et al., 
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1994), and damage, the Vasculitis Damage Index (VDI) (Luqmani et 
al.,1994, Exley et al.,1997), as yet there is no instrument available to 
assess patients‘ informational needs in  AAV. This chapter examined the 
literature on the impact of AAV on individuals‘ lives physically, 
psychologically and financially. The next chapter will focus on patient 
education in long-term inflammatory conditions.  
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Chapter 3 Patient education 
 
The previous chapters illustrated that the impact of a diagnosis of AAV is 
significant and patients will need information and support in order to help 
them cope with and manage their disease. This chapter will provide an 
introduction to patient education and the different methods of delivering it. 
The AAVs as already described are long-term inflammatory conditions and 
as there is little knowledge about education programmes in AAV, this 
chapter therefore will focus on the evidence base for education 
programmes in other similar long-term inflammatory conditions.  
 
3.1 Patient education 
 
Patient education has been defined by Lorig (1996) as:  
 
‗any set of planned educational activities designed to improve patients‘ 
health behaviours and / or health status. The purpose is to maintain or 
improve health, or, in some cases, to slow deterioration‘ (Lorig, 1996:13). 
 
Although this definition might be considered broad, it defines patient 
education as having to be planned.  It fails to account for any opportunistic 
learning that occurs during routine clinical practice in the context of 
consultations and also any learning that patients have undertaken. In 1998 
The World Health Organisation added the term ‗therapeutic‘ to patient 
education and defined it as:  
 
―Therapeutic patient education should enable patients to acquire and 
maintain abilities that allow them to optimally manage their lives with their 
disease. It is therefore a continuous process, integrated in health care. It is 
patient-centred; it includes organized awareness, information, self-care 
learning and psychosocial support regarding the disease, prescribed 
treatment, care, hospital and other health care settings, organisational 
information, and behaviour related to health and illness. It is designed to 
help patients and their families understand the disease and the treatment, 
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cooperate with health care providers, live healthily, and maintain or improve 
their quality of life‖ (WHO, 1998:9). 
 
This definition is much broader and acknowledges that it is not just planned 
education, that it is a continuous patient centred process and covers a 
range of activities that focus upon informing patients and their families 
about their condition. However, it assumes that patients with complex 
conditions like AAV will be able to understand complex immunology, 
pathophysiology and pharmacology of their condition and furthermore that 
health care professionals are able to relay this information in a simple form 
that patients can understand. In order to do this health care professionals 
need to have sufficient knowledge of AAV and be able to explain it in 
simple terms avoiding the use of jargon. 
 
Lorig and colleagues highlight the fact that self-efficacy is a vital component 
of patient education if patients are to achieve better health outcomes (Lorig 
et al.,1999). Self-efficacy is the confidence in one‘s own ability to be able to 
carry out a specific activity or achieve a change in mental state. The aim of 
patient education is to provide patients with the skills and knowledge to feel 
confident to be able to monitor and manage their disease, to improve or 
maintain their quality of life.  
 
3.2 Traditional patient education 
 
Patient education is delivered in many ways from giving information, 
supplying written materials, structured one-to-one education, group 
education and the use of behavioural approaches such as cognitive 
behavioral therapy (CBT).Traditionally, patient education was provided by 
doctors on a need to know basis, or in response to patients‘ questions. This 
didactic approach was a one-way process and patients were seen as 
passive recipients and not involved in decision making about their care 
(Hoving et al., 2010).  
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3.3 Patient education programmes 
 
In the 1990s patient education programmes emerged and there was a 
move to active involvement of patients in shared decision making (Charles 
et al., 1999, Entwistle & Watt, 2006). Education programmes are now well 
established in chronic conditions such as diabetes, chronic obstructive 
pulmonary disease (COPD), asthma and rheumatoid arthritis (RA) and 
have been shown to have positive outcomes for patients (Davies et al., 
2008, Gallefoss, 2004, Barlow et al., 2000, Albano et al., 2010).  A 
structured group diabetes education programme compared to usual 
diabetes education demonstrated a greater reduction in smoking, weight 
loss, depression, blood lipids and an increased understanding of diabetes 
(Davies et al., 2008). Patients with COPD randomised to group education 
versus usual care showed a reduction in general practitioner (GP) visits 
and a decrease in the use of reliever medication (Gallefoss, 2004). 
 
3.4 Patient education in rheumatic disease  
 
Patient education is routinely provided for a number of rheumatic conditions 
as part of standard care. Structured patient education programmes are 
often facilitated by members of the multi-disciplinary team and cover areas 
such as diagnosis, disease management, coping and self-management 
(Hammond, 2004, Hurley & Beane, 2008). Patient education is a key 
component of the role of rheumatology nurse specialists (Phelan et al., 
1992, Ryan & Hill, 2004, Carr, 2001, Ryan et al., 2010, Oliver & Leary, 
2012).   
 
3.5 Which method of patient education is effective? 
 
Much of the evidence of patient education in rheumatic conditions comes 
from patients with rheumatoid arthritis and osteoarthritis (OA). Rheumatoid 
arthritis is a symmetrical, chronic, debilitating, inflammatory arthritis which 
is treated with drugs that suppress the immune system. Osteoarthritis is a 
syndrome of joint pain with functional limitation (Conaghan et al., 2008) and 
reduced quality of life (NICE, 2008). It is treated with paracetamol, topical 
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non-steroidal anti-inflammatory drugs (NSAIDs), oral NSAIDs and 
sometimes with joint replacement surgery. 
   
3.5.1 Written materials  
 
Written information leaflets are frequently used to inform patients about 
their illness, treatment and management. The Arthritis Research UK 
(ARUK) (formerly the Arthritis Research Campaign (arc)) has produced 
written patient information materials for a number of musculoskeletal 
conditions, medications used to treat these conditions and information on 
how to live with arthritis, amongst many others. They are available in most 
rheumatology departments and can be down loaded from the ARUK web 
site.  These are routinely used to supplement verbal information given to 
patients during consultations. These materials have been designed by 
doctors for patients and are in the main written clearly and without jargon. 
 
3.5.2 The effectiveness of written materials 
 
Studies have evaluated the effectiveness of written materials in 
inflammatory arthritis (Maggs et al.,1996, Barlow & Wright,1997,Hill & Bird  
,2002, Walker et al.,2007). Maggs and colleagues studied the effect of a 
written educational leaflet for patients with inflammatory arthritis (Maggs et 
al.,1996). One hundred and fifty patients (118 RA, 20 inflammatory arthritis 
and 20 with other types of arthritis) were randomised to one of three 
groups. Group one had routine follow up, group two received routine follow 
up and an educational booklet and group three received routine follow up, 
an educational booklet plus educational teaching individually from a health 
care professional, lasting 30-60 mins. The two groups that received the 
booklet increased their knowledge but the group that received routine care 
did not. Participants given the educational teaching did no better than those 
who received the booklet. There was no improvement in health outcomes in 
any group but the duration of the study was short (six weeks) and this is 
probably too soon to see significant changes. The educational teaching 
intervention could be considered costly and time-consuming. Similarly, face 
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to face teaching is influenced by an individual‘s personality and motivation 
to learn (Golay et al., 2007).  
 
Barlow and Wright conducted a randomised control trial evaluating the 
effectiveness of the ARUK written information leaflet on RA (Barlow et 
al.1997). Fifty three patients received the ARUK leaflet compared to 55 who 
did not, and both groups received standard care. After three weeks the 
group who received the leaflet statistically increased their knowledge 
(p<0.001) and had reduced pain and depression compared to the control 
group. Although the study demonstrated positive results, this was over a 
very short time period.  A subsequent study to compare the effects over six 
months was conducted with 84 patients from the original study.  Results 
demonstrated that knowledge was statistically maintained (p<0.01) at six 
months (Barlow & Wright,1998). Hill and Bird (2003) conducted a 
randomised controlled trial comparing the effectiveness of a written drug 
information leaflet plus verbal information to RA patients. Patients were 
randomised to receive the drug information leaflet or the drug information 
leaflet plus a verbal explanation. At 24 weeks both groups had statistically 
improved their knowledge of the medication (p<0.001), however there was 
no statistical difference in knowledge gain between the two groups 
(p=0.109). In this study 12% of patients had difficulty reading, therefore the 
use of written materials may not be the most appropriate method for those 
with low reading levels. 
 
 3.5.3 Low health literacy 
 
A study in Glasgow found that one in six RA patients attending 
rheumatology out-patient clinics were illiterate (Gordon et al., 2002). A 
recent review reported that the prevalence of low health literacy in 
musculoskeletal conditions is between 7%-42% (Loke et al., 2012). Low 
health literacy may impair an individual‘s ability to understand written 
educational material. Health literacy is defined as: 
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 ―the degree to which individuals have the capacity to obtain, process and 
understand basic information and services needed to make appropriate 
decisions regarding their health ― (Nielsen-Bohlman et al., 2004:6).  
 
Tools are available to estimate the readability of health information,with  the 
two most commonly used being the Flesch Reading Ease scale (Flesch, 
1948) and the Flesch-Kincaid Grade (Kincaid et al.,1975).  They calculate 
how easy or difficult passages are to read, based upon word and sentence 
length. The Flesch Reading Ease scale scores from 0-100, 0 being 
unreadable and 100 most readable. The Flesch-Kincaid Grade calculates 
the reading level using USA school grade levels as the measure (Friedman 
& Hoffman-Goetz, 2006). A grade of six is considered suitable for patient 
education materials and this is the equivalent of year seven or first year of 
secondary school in the UK (Doak et al.,1996) 
 
 A recent American study evaluating the readability and suitability of patient 
education materials used in osteoarthritis, rheumatoid arthritis, systemic 
lupus erythematosus and vasculitis found that most materials were written 
at readability levels above the recommended sixth-grade reading level and 
have only adequate suitability (Rhee et al., 2013). This study evaluated 
credible web-based and written materials from different organisations such 
as the American College of Rheumatology (ACR), Mayo Clinic Health 
Information, National Institute of Arthritis and Musculoskeletal and Skin 
Diseases (NIAMS), Up-to-date Basics, Up-to-date Beyond the Basics, 
Vasculitis Clinical Research Consortium (VCRC), and the Vasculitis 
Foundation.  A total of five to six resources for each condition were 
evaluated. The Flesch-Kincaid Grade was used to measure readability. The 
mean readability scores were 0A 9.5, RA 10, SLE 9.9 and vasculitis 12.5. 
When the scores were re-calculated after taking out disease names, drug 
names, web links and illustrations, all the scores did improve slightly  0A 
8.2, RA 8.6, SLE 8.9 and vasculitis 10. However, collectively all the 
materials are still above the recommended reading level of grade six, with 
vasculitis scoring the most difficult at 12.5. Individually, only one source, 
Up-to-date Basics, met the recommended reading age for OA, RA and SLE 
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(4.8). The Vasculitis Foundation resource had the highest reading age of 
12.5.  
 
Suitability of the materials was measured using the Suitability Assessment 
of Materials (SAM) created by Doak et al.,(1996). This is a validated tool to 
assess the content, literacy required, graphics, layout and typography, 
learning stimulation and motivation of materials. There are 21 questions 
which are scored superior (2 points), adequate (1 point), or not suitable (0 
points). Therefore, the highest score possible is 42 and the lowest 0. The 
given score is divided by the total possible score to obtain a percentage. A 
score of 0–39% is considered not suitable, 40–69% is considered 
adequate, and 70–100% is considered superior (Doak et al.,1996). The 
mean suitability scores were 68% for 0A, 56% for RA, 57% for SLE and 
vasculitis 45%. The lowest suitability score was for the VCRC material on 
vasculitis 32%. The range of scores for readability and suitability may 
reflect the different complexities of the conditions studied, with OA 
considered not as complex as the others. This study also only evaluated a 
small number of educational materials for each disease. 
 
There is a dearth of research into the most effective way to teach patients 
with low health literacy skills (D‘Eath et al., 2012). Health care professionals 
need to think about the methods they use to teach patients with poor 
reading skills. A pictorial mind map in which information is presented 
diagrammatically with key words and images has been used in patients 
with RA (D‘Eath et al., 2012). A randomised controlled trial of the ARUK 
printed leaflet for RA, compared to a mind map and the ARUK leaflet, found 
that both formats significantly increased knowledge. However, there was no 
significant difference between the leaflet and the mind map, compared with 
the leaflet alone (D‘Eath et al., 2012).The mind map did not improve the 
knowledge of the 15% of patients with low health literacy. One explanation 
may be that although the mind map has pictures and words, it can still be 
perceived as complex by individuals.  Whilst written leaflets are easy to 
produce and relatively cheap, they may not be applicable for people with 
poor reading skills. People with low health literacy therefore may benefit 
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from other educational strategies where individual verbal education is 
critical.  
 
3.5.4 Educational interventions   
  
Reimsma and colleagues studied the effect of an educational intervention 
alongside routine follow up by a rheumatology specialist nurse (Reimsma et 
al.,1997). Two hundred and sixteen patients with RA were randomised to 
one of three groups: group one received educational materials plus an 
arthritis passport with individual support from a nurse; group two just had 
the educational materials; and group three received standard care. The 
arthritis passport is an individual record of all encounters and activities with 
health care professionals and contains information on medications, results 
of blood tests and an individual management plan.  At six months there was 
no difference in knowledge, disease activity, self-efficacy or behaviour 
change in any of the three groups. One possible explanation might be the 
fact that patients had long standing RA (average 13 years), where 
established behaviour is difficult to change.  Another reason is that the 
group may have been very knowledgeable about their condition and self- 
management. Although the nurses in this study received training in 
delivering the educational intervention, many nurses find it challenging to 
cover everything in a routine follow up appointment due to time constraints.  
Also, the intervention was originally designed for use in group settings and 
therefore may not be transferrable for use in one-to-one education.   
  
3.5.5 Internet  
 
In the UK approximately 77% of people have access to the internet (Office 
of National Statistics, 2011). It is increasing being used as a medium for 
accessing health information. A study in Glasgow found that 43% of 
patients attending rheumatology outpatient clinics had access to the 
internet and 27% had used it to access medical information (Gordon et al., 
2002). In Germany 56% of patients had access to the internet and 27% 
used it to find health information (Ritchter et al., 2004).  A study by Hay et 
al.,(2008) found that 87.5% of American patients used the internet to find 
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information about their symptoms prior to their first outpatient appointment 
in rheumatology. However, only one in five discussed this with the doctor: 
reasons given were that patients did not want to challenge the doctor, with 
several respondents reporting that information on the internet was 
confusing and unreliable.  
 
A survey carried out in 1998 revealed that only 16% of 1912 rheumatology 
websites were directed at patient education (Tench et al.,1998). Van der 
Vaart and colleagues (2011) explored what patients wanted from a hospital 
based rheumatology web portal. A total of 227/ 484 patients completed a 
questionnaire survey, response rate of 47%, female 143 (63%), mean age 
52 years, 44% of the respondents had RA, 50% other rheumatic conditions 
and 6% did not know their diagnosis. Of these, 87% had access to the 
internet, over half (53%) used it daily and 22% once a week. The most 
common reason patients used the internet was to find information about 
their disease 82%, lifestyle issues 63%, medications 62%, treatments 49%, 
care providers 35%, support groups 34% and law regulations 32%. 
Approximately two thirds of patients stated that if the web portal was 
available, they would use it to find information on their disease, treatment 
and for care and support. Younger patients and women were more likely to 
use e-consultations. This study had more elderly patients and this may 
have influenced the results.  
 
A survey of rheumatology health care professionals to determine computer 
use for education reported that 40% had used it to educate patients and 
97% had used it at some time for personal education (Nicolaou et al., 
2012). This maybe an under-representation as it was based upon their 
perception and not actual use. Although many patients use the internet to 
access information, it is not known if the services provided are what 
patients want (Wilson & Lankton, 2004). Many websites have been 
developed with no input from patients and without knowing what patients 
require (Pagliari, 2007). 
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3.5.6 Group education 
 
Group education is one method of providing patient education. There have 
been a number of studies evaluating the effectiveness of group education. 
Hawley (1995) conducted a review of 34 randomised control trials using 
psychoeducational interventions in rheumatology. Sixty percent of 
participants were recruited from outpatient clinics, 52% had RA and 8% 
OA, with the rest recruited from the community where the diagnosis was 
unclear. The majority of interventions used in the studies were self-
management or cognitive behavioural therapy (CBT). The four main 
outcome measures used were knowledge, health and psychological status 
and behaviour. The psychoeducational interventions demonstrated a small 
improvement in pain, depression, self-efficacy, coping abilities, self-
management and knowledge. The studies using self-management 
demonstrated an increase in self-efficacy at three months compared to 
controls. At the end of three months the CBT group demonstrated an 
improvement in coping skills. Due to a lack of homogeneity in the groups 
and the wide variety of interventions used it is difficult to make direct 
comparisons and determine the most effective intervention. None of the 
studies reported a reduction in drug toxicity, employment status or 
morbidity.     
 
A Dutch study compared group education in RA patients, with and without 
partners plus booster sessions (Riemsma et al., 2003). The education 
programme consisted of a five sessions once weekly for two hours  for 
eight patients, plus or minus their partner, led by specially trained 
rheumatology nurses, followed by a refresher sessions at three, six, and 
nine months. Two hundred and eighteen RA patients plus partners were 
randomised to one of three groups. Group one (79) received the 
educational intervention with their partner; group two (79) received the 
educational intervention without their partner and group three (80) were just 
provided with a written copy of the self-help educational materials. Those in 
the education group without their partner demonstrated higher scores for 
coping with their symptoms and reduced fatigue, compared to those in the 
group with their partner. The benefits at six and twelve months were only 
 56 
 
seen for self-efficacy and fatigue. Including partners in the group education 
appeared to have a negative effect of increasing fatigue and patients not 
adopting coping strategies. The exact reasons for this are unknown.     
 
A Swedish randomised control trial evaluated the effect of using a problem-
based learning approach to educate people with rheumatic conditons 
(Arvidsson et al., 2012). Paricipants were randomised to either the 
experimental group or the control group. There were 54 participants in the 
experimental group, 11 men, 27 women, mean age 56.4 years,148 
participants in the control group ,33 men and 91 women , mean age 55.2 
years who received usual care. The experimental group was divided up into 
seven small tutorial groups of 7-8 participants. The tutorials lasted one and 
a half hours delivered ten times over a one year period. At one year the 
experimental group had increased empowerment and reduced fatigue 
compared to controls. There were no differences between the groups for 
pain and self-care ability but two thirds of the experimental group had made 
lifestyle changes. There was a high dropout rate in the experimental group 
(13) compared to the control group (17). Although problem-based learning 
may be a useful approach to patient education it is labour intensive and 
expensive. More research is needed to evaluate this approach in the future.  
 
Grønning et al., (2012) evaluated the benefits of combining both individual 
and group education in an open randomised controlled trial of inflammatory 
arthritis patients. One hundred and forty one were randomised to either 
usual care (70) or the educational intervention (71). The educational 
intervention was three group education sessions lasting three hours, 
alternate weeks in groups of 8-10 with mixed conditions, supported with a 
45 minute individual education session at the end of the programme. The 
intervention group demonstrated an increase in their global wellbeing 
p<0.01 and small effect for self-efficacy in managing their symptoms. None 
of the participants showed a reduction in their learning needs at the end of 
the programme as measured by the The Educational Needs Assessment 
Tool (ENAT) developed by Hardware and colleagues (Hardware et al., 
2004).This was a surprising finding as most education programmes 
increased patients‘ knowledge. There is a possibility that the ENAT was not 
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an appropriate measure as it asks ―how much do you want to know now‖.  
Although the patients still had educational needs at the end of the study, 
one explanation is that patients want to stay updated. Another explanation 
could be that the usual care group received a high level of care. A 
weakness of this study is that it did not measure patients‘ knowledge before 
or after the intervention. Also, the study had a high rate of non-recruitment 
with only 141 /536 were recruited (26.3%) but the reasons why so many 
patients declined are not reported. Therefore it is not known if the study 
group are representative of the population studied. 
 
 
3.6 Self-management programmes 
 
Self-management is crucial to enable patients to cope with and make 
decisions about their condition on a daily basis. Barlow (2002:178) 
describes self- management as the: 
 
‗individual‘s ability to manage the symptoms, treatment, physical and 
psychosocial consequences and life style changes inherent in living with 
a chronic condition‘. 
 
Self-management programmes have been developed with the aim of 
providing people with the skills to be able to live with and manage their 
chronic condition. The Arthritis Self-Management Program (ASMP) was 
developed in the USA by Kate Lorig and colleagues (Lorig et al., 1998).The 
programme is delivered in six weekly small group sessions lasting 2- 2.5 
hours by trained lay educators. The topics include self- management 
techniques, disease information, exercise, depression, how to 
communicate with health care professionals and families, how to deal with 
pain fatigue, isolation, symptom management and goal setting.  
 
A long-term evaluation of participation in the  ASMP demonstrated 
continued improvement in self-efficacy, some use of self- management 
techniques and reduced anxiety and depression (Barlow et al .,2009). 
There was a 44% response rate 125/282, 87% female, mean age 65 years, 
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disease duration mean 19 years, 48% RA, 485 OA others not specified. 
Over an eight year period, maintained improvements were seen for self-
efficacy, anxiety and depression, pain and fatigue. In contrast there was a 
decline in physical function, with an increase in the health assessment 
questionnaire (HAQ) score from baseline 1.5 to 1.7. There was no 
difference in visits to health care professionals over the time period. The 
sustained improvements cannot be attributed soley to the programme as 
there was no control group and they would have received ongoing health 
care over that timeframe.The programme has been evaluated in the UK 
and Canada showing no improvement (Barlow et al., 2000, Solomon et al., 
2002). This could be due to the fact that studies carried out in the USA 
cannot be directly transferrable to the UK or Canada because of the 
different cultures and health care organisations.   
 
A review of self-management programmes in rheumatology of OA, RA and 
fibromyalgia included 27 studies (Iverson et al., 2010). Seven of the studies 
included all conditions OA (50-75%), RA (15-35%), fibromyalgia (15-17%), 
eight only OA, five inflammatory arthritis and seven fibromyalgia. Of the 
seven studies including all diseases, six evaluated the Arthritis Self- 
Management Programme (ASMP) in various different formats from group 
provision, mailed format and internet delivery. The final study evaluated the 
personalised programme delivered in home visits by health care 
professionals ‗I‘m Taking Charge of My Arthritis‘ (ITCA) (Nour et al. 2007). 
The other studies were run by peers or were self-directed. All the ASMPs 
included CBT aiming to change behaviour, apart from the ITCA. At one 
year five studies demonstrated improvements in self-efficacy, four in 
function, two in pain and one in mood. African-Americans enrolled in the 
ASMP were shown to benefit least (Goeppinger et al.,2007) and non-
Hispanic white individuals gained the most, either taking part face-to-face 
or on the internet (Lorig et al.,2004).  
 
3.7 Systematic Reviews 
 
Niedermann and colleagues conducted a systematic review of patient 
education in RA (Niedermann et al.,2004). The review focused on two 
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types of education programmes. Those that solely used education to 
increase knowledge and improve function and those that used a 
psychoeducational approach of teaching intervention activities with 
behavioural techniques to improve coping and bringing about a change in 
behaviour. Eleven randomised control trials were included, seven 
educational, four psychoeducational and one included both. The seven 
educational programmes demonstrated an increase in knowledge and 
adherence to medications and exercise regimes at six months and at one 
year but did not show any improvement in health status (Bradley et al.,1987 
,Brus et al.,1998,Taal et al.,1993,Lindroth et al.,1997, Helliwell et al.,1999, 
Hammond et al.,1999, Scholten et al.1999). The four psychoeducational 
programmes showed an improvement in coping short term, with two of 
them having a positive outcome on physical and psychological wellbeing 
(Bradley et al.,1987, Parker et al.,1995, Kraaimaat et al.,1995, Parker et 
al.,1998). The authors concluded that there is evidence that education can 
improve patients‘ knowledge both in the short and long-term and that 
pyschoeducational progammes can increase coping especially pain short 
term but probably not long-term.  
 
A Cochrane review of 31 randomised control trials of patient education 
programmes in RA found that there were statistically significant short term 
results, namely a 12% reduction in disability, anxiety and depression and 
patient global assessment, a 9% reduction in joint counts, a 5% reduction in 
psychological status and a 4% reduction in pain (at 3 months) but this was 
not sustained long-term (at one year) (Riemsma et al., 2009). A criticism of 
many of the studies was the lack of detail of the educational intervention, 
the wide variety of outcome measures used and a lack of disease-specific 
programmes. Also, access to patient education programmes can be difficult 
due to the time commitment and it is possible that only motivated patients 
attend. The majority of studies included individuals with long standing 
disease and did not examine adherence to therapy as an outcome measure 
of the educational intervention. They concluded that research into 
education programmes should be disease-specific and tailored to meet 
individual patient‘s needs. 
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A systematic review to evaluate the effectiveness of patient education in 
several different chronic illnesses including rheumatic conditions found 
variable results (Lagger et al.,2010). The review included 35 meta-analyses 
which reported on a total of 598 studies. They found that 64% of studies 
demonstrated an improvement in health status, although 30% showed no 
effect and 6% of studies reported deteriorating health outcomes. The 
authors concluded that the majority of the study interventions were poorly 
described, the content of the educational sessions was not able to be 
replicated and the control group was not adequately described. In their 
opinion therapeutic patient education is complex and many of the study 
results may be understated. This is due to the fact that it is impossible not 
to give information as part of routine care in any control group in a patient 
education programme.  
 
 An international analysis by Albano et al .,(2010) of patient education 
programmes in rheumatology for RA from 2003-2008 demonstrated 
positive results in 28/37 studies, namely a reduction in pain, disability, 
fatigue and disease activity scores. The other nine studies showed no 
improvement in reducing anxiety and depression or improving coping skills. 
Of the 22 studies evaluating the effect on psychosocial improvement, 11 
demonstrated an improvement in function/ pain and other symptoms, six an 
improvement in coping, four a reduction in depression and reduced anxiety 
in another four.  Although positive results were reported in most studies, six 
studies reported no improvement and two studies worsening effects. Only 
three studies examined the economic effect with conflicting results one 
study showed a reduction in GP visits (Chui et al., 2004) whereas the other 
two reported no better use of the health care system (Siu et al., 2004, Nour 
et al., 2006).   
 
The studies used a variety of educational strategies, with group education 
the most popular 20 (54%) of these six used problem solving techniques 13 
(35%) and one used self- learning with printed materials including a mind 
map 1(2%) (Walker et al., 2007), one-to-one education 5 (13%), 3 (8%) 
counselling,  printed leaflets, 2 (5%) telephone coaching, 1 (2%) web, 1 
(2%) video and one computer instruction (2%).  
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3.8 Adherence  
 
Medications are the mainstay of treatment for inflammatory rheumatic 
conditions and are vital to patients‘ survival with AAV.  However, 50% of 
patients with a long-term condition do not adhere to medicines (Horne & 
Weinman, 1998, Osterberg & Blashe, 2005). The definitions used to 
describe whether patients are taking medications as prescribed have 
changed from ‗compliance‘ to ‗concordance‘ and now ‗adherence‘. 
Compliance was the term commonly used up until the 1990s (Nunes et al., 
2009). 
 
Compliance is: 
 
 ‘ a willingness to follow or consent to the wishes of another person, 
whereas adherence is the action of sticking to, supporting or following a 
person or an idea‗  (Buchmann, 1997:3).  
 
The problem with the term ‗compliance‘ was that the literature tended to 
ignore the patient‘s perspective or saw their view as a problem. Compliance 
assumes that the patient is obedient, unquestioning of medical instructions 
and that it is irrational not to follow orders (Stimson,1974).  
 
‗Concordance‘ replaced the term ‗compliance‘ in 2003 (Medicines 
Partnership, 2003). Concordance is a new approach to the prescribing and 
taking of medicines.  Concordance is:  
 
‗an agreement between a patient and a health care professional that 
respects the beliefs and wishes of the patient in determining whether, when 
and how medicines are to be taken. Although reciprocal, this is an alliance 
in which the health care professional recognise the primacy of the patients‘ 
decisions about taking the recommended medications‘. 
(www.concordance.org) 
 
Adherence is defined by the NICE guidelines (2009:4) as: 
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‗the extent to which the patient‘s behaviour matches agreed 
recommendations from the prescriber‘. 
 
Non- adherence is a behaviour that can be intentional or non-intentional. 
Non-intentional is when patients forget to take medication, may not have 
enough money for medications or forget to renew a prescription. Intentional 
non-adherence is when patients feel better so stop their medication, do not 
take their medication because they are worried about side effects and are 
frightened of the risks associated with that medication.   
  
Non –adherence is linked to a patient‘s beliefs, attitudes and fears about 
medications. Donovan & Blake (1992) found that fear of side effects was 
the most common reason for rheumatology patients not taking medications.  
A questionnaire study investigating the beliefs and attitudes of RA patients 
taking medications found that half of patients had strong concerns about 
potential long-term effects, 47% were worried about side effects, 56% 
about dependence and 50% reported that they had experienced side 
effects (Neame & Hammond, 2005). Despite two thirds of them agreeing 
that medications were essential for health. Patient involvement in decisions 
regarding treatment is vital, particularly medication as Bitten et al.,(2000) 
found that not exploring the patients‘ thoughts and preferences led to 
misunderstandings and non-adherence with medication.  
 
 
3.8.1 Education to improve adherence 
 
Education interventions to improve adherence to medications have 
produced mixed results.  Hill conducted a randomised control trial of a 
patient education programme to improve medication adherence in 100 RA 
patients (Hill et al.,2001). Forty nine patients were randomised to routine 
care and 51 to the education intervention. The intervention consisted of 
seven 30 minute sessions with a rheumatology nurse practitioner using a 
self-efficacy approach. Patients were provided with information on RA, drug 
treatment, coping strategies and pain control. They also received a written 
information leaflet on D penicillamine. The patients in the routine care 
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group also received the same leaflet. The educational intervention 
demonstrated a small statistical improvement in medication adherence 86% 
v‘s 76% at six months but no improvement in clinical outcome. This study 
used a pharmacological marker to measure adherence. One criticism of 
this study is that the intervention is costly and time-consuming and 
therefore not generalizable.  
 
A systematic review of persistence and non-adherence of biological therapy 
in RA patients was carried out (Marissa et al., 2011). Fifty two studies were 
included, 38 from Europe, 11 from the USA and 3 from other countries. In 
25/38 studies in Europe, 66% patients were still taking medication at one 
year. In eight out of eleven USA studies that reported persistence 44 -62% 
patients were still taking medication at one year. In two of the other three 
studies persistence was 76% at the end of one year. Only four USA studies 
measured adherence with rates of 41- 68%. The methods used to measure 
persistence and adherence were not clearly defined in most of the studies 
and if reported varied considerably across studies. The majority of studies 
reported < 75% persistence at one year. Rates for individual drugs ranged 
from 42%-89% in Europe and 44 -62% in the USA. Another systematic 
review of medication adherence by Harold & Andrade (2009) in 
inflammatory arthritis patients found wide-ranging results. Self-reported 
adherence rates were between 30-99% compared to adherence rates of 
18-26% measured by pharmacy dispensing. The high reported rate for self-
reported adherence could be due to bias recall and overestimation by 
patients. The studies varied enormously in design, making direct 
comparisons difficult: the majority of studies included only one medication 
for a short time frame and some studies used medications that are not used 
now such as D penicillamine and salicylates. Patient education 
programmes designed to improve adherence with medications have been 
criticised, as often the patients are not given the authority to make changes 
to medications as this is seen as the responsibility of the doctor or nurse 
(Albano et al., 2010).   
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3.9 Which is the most effective patient education method?  
 
Patient education is a key component of the management of many chronic 
diseases (Barlow et al., 2000, Reimsa et al., 2009, Albano et al., 2010). 
Provision of high-quality information and education can empower patients 
to become active partners in the management of their condition (Coulter, 
1997, Opie, 1998, Spalding, 2003), reduce anxiety, and improve 
satisfaction with care (Marcusen, 2010).  
 
The evidence presented above for the effectiveness of patient education 
programmes has shown mixed results. Patient education is complex and it 
is difficult to separate out the effects of the intervention. There are other 
difficulties in assessing the effectiveness of the studies in that many of the 
interventions cannot be directly compared since there is no consensus on 
the specific outcome measures that should be used.  A variety of 
educational interventions have been used.  Many of the outcome measures 
assess clinical outcomes such as disease activity, inflammatory markers 
and disability, all of which are influenced by medications taken by patients 
(Li, 2007).  Also, patients will seek information independently from a variety 
of sources and receive education as part of routine care.  
 
Patient education is generally accepted as worthwhile and something that 
should routinely be carried out. It is often mentioned in clinical guidelines, 
however it is unclear as to the best method of providing patient education. 
There is little research into the effectiveness of one-to-one education in 
rheumatology (Hammond & Niedermann, 2010). One-to-one education is 
influenced by many factors: the setting, personalities, social and 
educational background, prior knowledge, anxiety levels and motivation to 
learn. The strongest evidence is for written materials from whatever source, 
as this improved knowledge in most studies. The evidence to support either 
individual or group education programmes in addition to written materials is 
variable. Cognitive behavioural therapy has shown to improve pain, 
adherence and disease knowledge (Hawley,1995), educational behavior 
interventions demonstrated a small improvement in pain, depression, self-
efficacy, coping abilities and self-management (Hawley,1995, Albano et al., 
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2010). A weakness of the research into patient education is that it fails to 
acknowledge the process of adult learning, how patients understand the 
messages and how they acquire the skills and knowledge to be able to 
manage their disease competently (Albano et al., 2010). Similarly, most 
studies have not tested the readability or suitability of the educational 
materials used.  Many of the studies of patient education in rheumatology 
may not be applicable to AVV, due to the inherent differences in the 
conditions studied.  
 
Furthermore, there is a self-selecting bias in patients recruited to 
educational interventions: they tend to be female, elderly and well educated 
(Hawley,1995), making it difficult to identify who would most benefit from an 
education programme, the exact nature of this and the timing of it. Overall 
provision of high quality information can improve knowledge, however what 
is less clear is the impact of knowledge levels on disease outcomes. It is 
also important to develop educational materials from a patient‘s 
perspective. According to Li we first need to understand the patient‘s 
information needs in order to improve the educational strategies and 
outcome measures used (Li, 2007). Ormandy (2010:99) describes a patient 
information need as:  
 
―the recognition that their knowledge is inadequate to satisfy a goal, within 
the context / situation that they find themselves at a specific point in time.‘   
 
For the purpose of this thesis, information need is defined as ―information 
that patients require during their disease pathway‖. The next chapter will 
focus on a review of the literature on what it is like to receive a diagnosis of 
AAV and identification of the informational needs of this group of patients.  
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Chapter 4 Literature review 
 
It is clear that the impact of a diagnosis of AAV is significant and patients 
will need information and education to help them to self- manage and 
participate in informed decision-making. The aim of this chapter is firstly to 
review the literature on what it is like to receive a diagnosis of AAV; 
secondly, to identify the information needs of this group, including 
educational interventions and self-management behaviours. Lastly, 
toidentify gaps in knowledge and provide justification for this study. 
 
4.1 Literature search 
 
An electronic search of the literature was undertaken. The databases 
searched were; EMBASE, Medline , Cumulative Index to Nursing and Allied 
Health Literature (CINAHL), PsycINFO, PubMed, The Cochrane Library, 
Web of Science and  Web of Knowledge. Search terms used were: patient 
information, patient education, educational needs, information needs,  self-
management, AND ANCA associated vasculitis, primary systemic  
vasculitis, vasculitis, Wegener‘s granulomatosis, microscopic polyangiitis, 
Churg Strauss syndrome, experience of receiving a diagnosis of ANCA-
associated vasculitis, without language bars from 1990- 2013. The reason 
1990 was chosen as the start date was because until the 1990‘s most 
patients died relatively quickly.   A hand search was also undertaken of the 
references in papers and abstracts from conference proceedings such as 
the ANCA  workshop , the British Society of Rheumatology, The Americam 
College of Rheumatology and The European League Against Rheumatism  
were considered. The literature was monitored over the period of the study 
and another intensive literature review took place in January 2014 and the 
same search strategy was used. 
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Inclusion criteria    Exclusion criteria       
Published between1990 and 2014 Comment/ editorial 
Abstract or full text published in 
English 
No focus on AAV 
Quantitative and qualitative studies Case reports 
Patient education / patient 
information 
 
Receiving a diagnosis of AAV  
Information needs  
Sources of information  
Self-management  
Table 4 Inclusion and exclusion criteria for reviewed papers 
 
 
The initial search revealed 107 citations. All citations were reviewed to 
determine if they met the inclusion criteria above.  A total of 95 papers were 
excluded and these included 50 case reports, 29 duplications, 12 papers 
with no focus on AAV, one editorial, one personal opinion, one patient page 
and one patient summary (Figure 8).    
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Figure 8 Results of literature search  
 
The literature search revealed that there were no papers describing the 
experience of receiving a diagnosis of AAV. A total of 10 papers and two 
abstracts met the inclusion criteria for review. There were two papers 
describing an evaluation of a patient education programme for vasculitis in 
Germany. Two papers were found on the subject of self –management and 
six papers regarding medications. One abstract described a vasculitis web 
page and one reported patients‘ knowledge of side effects of therapy.   
Key search terms
Key words: :”patient information‖,‖ patient education‖  
, ―Vasculitis‖, ― self-management‖, ‖ ANCA 
associated vasculitis‖ , ―Wegener‘s granulomatosis 
―, ―microscopic polyangiitis ―, ―Churg Strauss 
syndrome‖ ― experience of receiving a diagnosis‖  , 
without language bars
107  citations 
Apply criteria to title and abstract
Total included for review 12 
2 papers: Evaluation of Patient Education 
Programmes
2 abstracts: knowledge of treatment side 
effects and one web page  
2 self-management
 6 Medication 
Reason for exclusion
Duplication n=29
Editorial n=1
Personal opinion=1
Patient Page=1
No focus on AAV=12
Case reports 50
Patient summary=1 
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4.2 Results 
 
As shown in figure 8 there were two studies conducted in Germany 
evaluating a patient education programme for AAV. Herlyn and colleagues 
developed an education program for use in an in-patient hospital 
rehabilitation setting (Herlyn et al., 2002). The programme consisted of five 
ninety minute lectures on diseases, therapies, side effects, coping 
strategies, nutrition and physiotherapy delivered by the multidisciplinary 
team of doctors, nurses, psychologist and nutritionists. The lectures were 
given daily over a two week period in groups of 10-15 patients. Patients 
were also provided with handouts of the slides.  An evaluation of the 
programme was undertaken using a knowledge questionnaire at four 
weeks. The questionnaire consisted of 16 questions, with a minimum score 
of 0 and a maximum of 45. The SF36 was used to measure quality of life.  
An initial evaluation of the programme at the end of four weeks 
demonstrated a statistically significant improvement in knowledge overall 
from 24 points at baseline to 28 at four weeks (53.3%- 62.2%). Improved 
knowledge was also seen in the areas of medical (18 v‘s 21) (40%-46.6%) 
and nutrition (4v‘s 6) (8.8%-13.3%). Although improvements were seen, 
these could be considered small as the patients already had a satisfactory 
overall knowledge of vasculitis at baseline. Their knowledge of nutrition was 
poor at baseline and after the intervention. The actual numbers of 
participants are not given, making it difficult to interpret these findings.  At 
four weeks participants reported statistically improved health-related quality 
of life in some domains of the SF36, namely social functioning, emotional 
role functioning and psychological care. There was no difference in pain, 
general health status or physical functioning. This could be partly explained 
by the short time frame and the fact that we do not know if these patients 
were receiving treatment for induction of remission, maintenance or 
relapse, and it can take up to 3-6 months to achieve disease remission with 
treatment. The article is written in German with the abstract translated in 
English. The rehabilitation setting is a specialist vasculitis center to which 
patients are referred and treated as in- patients. They have dedicated 
resources available to look after AAV patients and have a captive audience.  
Very few clinicians looking after patients with AAV will have access to this 
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type of service provision.  Most patients in the UK are managed as 
oupatients apart from during the initial acute illness. Therefore, this type of 
inpatient education programme may not be transferrable to other settings. 
The content was designed by doctors, health care professionals and 
patients. The programme is delivered by ninety minute didactic lectures and 
this method has been cited by patients as one of the least preferred 
methods of education (Neville et al., 1999). Ninety minutes could be 
considered a long time for patients to remember and process information.  
A problem with group education is that it is difficult to check patients‘ 
understanding and some patients may feel embarrassed to ask questions 
in a group setting. The groups included many different types of vasculitis 
and it is not known if they were educated in disease specific groups. 
Interpretation of this paper is very difficult for several reasons: the 
knowledge questionnaire has not been validated, there was no control 
group and the mention of small numbers of participants but no exact figures 
are given. 
 
Furthermore, this educational programme was delivered in an inpatient 
setting and it is not known if the programme was delivered on an out-
patient basis whether the results would be comparable. It could also be 
considered costly. This type of educational delivery may not meet all the 
needs of the group. The length of disease duration is not known and this 
may have influenced the results. Patients with long-standing disease may 
be more knowledgeable than those who are newly diagnosed. Currently, 
patients are staying in hospital for shorter periods and there are reduced 
opportunities to spend time educating patients so this method may not be 
the most suitable for the UK.    
 
This inpatient programme was updated in 2003 to include five multi-
disciplinary modules (Herlyn et al., 2003).  Module one is delivered by a 
doctor covering vasculitis, immunology and diagnostic procedures. Module 
two includes information on treatment, side effects and monitoring run by 
either a doctor or nurse. In module three a psychologist deals with 
acceptance, stress and coping strategies. A physiotherapist provides 
information on mobility and prevention of osteoporosis. Lastly, a dietician 
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provides advice on diet and inflammation and what a healthy diet is. The 
delivery was changed to include a 20 minute lecture, followed by group 
discussions and interaction between patients.  A longitudinal evaluation of 
this programme was carried out in a prospective pre and post design study 
(Herlyn et al., 2008). Assessments were carried out before the programme, 
at four weeks, six months, and 12 months after participation. One hundred 
and two patients participated in 10 groups from 2001-2006. The majority 
were female (70%), mean age 55 years (range 23-87), mean disease 
duration 3 years (range 3months- 3 years) GPA 30, EGPA 16, small vessel 
vasculitis 12, MPA 9, leucocytoclastic  vasculitis, 10, GCA 10 and 16 
unclassified. The results showed a statistically significant increase in 
patients knowledge in three domains: treatment and side effects 
(p>0.0001), diet (p>0.0001) and physiotherapy (p>0.0003). There was also 
an increase in health-related quality of life. There appeared to be no 
increase in knowledge in the areas of disease, immunology and diagnostic 
procedures. This could be due to the fact that these are complex areas to 
cover and one 20 minute session may not be enough time to cover this. Or 
it could be due to the fact that patients were taught in small groups of 10-15 
patients, where it is more difficult to test individuals‘ understanding, 
particularly of complex theories.  A strength of this education programme is 
that it included some elements of CBT, 100 patients were involved in the 
design and psychosocial aspects were included.  It also demonstrated 
improved results from the earlier study. It is not known if one-to-one 
teaching methods would have produced different results. Inpatient 
education programmes could be considered costly and the majority of 
education programmes are now delivered in an outpatient or community 
setting. 
 
4.2.1 The Internet  
 
The internet is increasing being used as a medium for accessing health 
information. One abstract was found of an online questionnaire survey of 
visitors to a web page for vasculitis education (UhIfelder et al.,1999). Three 
hundred and four visitors to the website completed online questionnaires, 
205 (67.1%) had vasculitis and 77 (25.3%) were family members of 
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patients with vasculitis. The majority of responders were female 188 
(64.6%), male 103 (35.4%), mean age was 44years (range 16-83 years), 
mean age at time of diagnosis was 43.3 years. Twenty-five (10.0%) were 
from Maryland or surrounding states, forty-two (16.8%) were from 21 
different countries outside of the U.S.A., including Canada, India, Vietnam, 
Italy, Brazil, and Australia. No visitors were from the UK. Visitors‘ 
diagnoses, central nervous system vasculitis 3.5%, leukocytoclastic 
vasculitis 8.2%, RA vasculitis 5.3%, Behcet's 3.6%, Henoch-Schönlein 
purpura 3.6%, giant cell arteritis 3.0%, and hypersensitivity vasculitis 3.0%. 
This study collected basic information on self-reported disease types but 
only a few respondents reported having AAV, 10.5% had PAN, and 6.7% 
GPA. Surprisingly 78 (25.6%) visitors were unsure of their diagnosis.  
Although respondents used the website to access information, it is not 
known if the information posted on it was information that the respondents 
were looking for (Wilson & Lankton,  2004). This website may have been 
developed without knowing what respondents want from an internet site 
(Pagliari, 2007). There is limited detailed information in the abstract to 
derive any meaningful conclusions. The sample is biased towards females 
and younger people.  
 
4.2.2 Self-management  
 
A vasculitis self-management scale (VSMS) was developed by Thorpe and 
colleagues (Thorpe et al., 2007). It is a 43 item questionnaire covering eight 
adherence behaviours (medication adherence, following advice from health 
care providers, infection avoidance, diet, exercise, symptom monitoring , 
prompt reporting of symptoms and side effects and adjusting activities). A 
total of 205 patients with self-reported AAV and small vessel vasculitis 
completed the questionnaire. There was a good response rate of 75%, 
internal consistency of the subscales as measured by Cronbach‘s alpha 
was found to be >0.70 for all subscales apart from the adjusting activities. 
 
Thorpe and colleagues used the VSMS to examine the self-management 
behaviours of 202 patients with self-reported AAV in the USA (Thorpe et 
al., 2008). Patients were asked to rate their perceived difficulty on a scale 
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of 0-6 (0= no difficulty, to 6=extremely difficult) in performing the self-
management behaviours described above and their experience of the 
barriers to carrying out these activities on a 5 point scale (1=no barriers to 5 
=all of the time).  
 
Approximately half the respondents were female, 93% white, mean age 55 
years, mean disease duration 6 years and mean of 15 years education. 
Seventy two percent had GPA, 8% MPA, 5% EGPA and the remainder had 
renal vasculitis and the mean number of medications prescribed was 6.7 
(range 0-18). Patients ranked taking medications (mean 5.9) and 
attendance at follow up visits as extremely important (mean 5.7) and they 
felt that they had little difficulty in performing these activities (medications 
mean 1.5 and follow up visits 2.0). However, they reported having several 
difficulties regarding medications, they had difficulty adhering to complex 
medication regimes, understanding when to take their medication and were 
slow to report symptoms and medication side effects (Thorpe et al., 
2008).They believed that medication side effects would go away and they 
did not want to trouble their doctor about these. They reported having 
difficulty accessing their doctor and would just wait until their next 
appointment. One explanation for the reluctance to report medication side 
effects may be attributed to a lack of understanding or a lack of information. 
This is worrying as some treatment side effects are serious and one aim of 
educating patients is early recognition of side effects of medication. This 
study also found that patients had difficulty following exercise regimes and 
only followed advice if they thought it was important. The findings may not 
be generalisable as this was a convenience sample, biased towards 
patients with kidney involvement and longer disease duration. Even so, this 
study provides a valuable contribution to the understanding of some of the 
difficulties patients experience and insight into their health beliefs. Further 
research is needed to discover what type of information and knowledge 
patients need to help them self-manage their condition.  
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4.2.3 Medications 
 
Medications are crucial to patients‘ survival in AAV and Carpenter and 
colleagues studied the effect of conflicting information on medication 
adherence in 228 vasculitis patients of whom 59% had AAV (Carpenter et 
al., 2010). The data collected was part of the Assessing Social Support in 
Symptom Treatment (ASSIST) study which is a longitudinal observational 
study which examined the medication management of vasculitis patients 
(Carpenter et al., 2010, Carpenter et al., 2013). Respondents completed 
two online questionnaires three months apart, 232 / 253 patients (92%) 
completed the baseline questionnaire and 228 (98.2%) at three months. 
The questionnaire included several subscales of which one was the 
Vasculitis Self-Management Survey (VSMS) medication adherence 
subscale. The scale has six questions which asks respondents to rate their 
medication-taking behaviour over the last four weeks on a five-point Likert 
scale from 1= none of the time to 5 all of the time. A further question asks 
respondents to rate the percentage of medication taken exactly as 
prescribed from 1= 0-24% and 5= 100%. 
 
The difficulty subscale The Self- Efficacy for Appropriate Medication Use 
Scale (SEAMS) was used to assess how confident they were in taking their 
medications using a three point Likert scale (1= not confident, to 3= very 
confident).  The Beliefs about Medicines Questionnaire (BMQ) was used to 
test respondent‘s beliefs about whether their medication would have an 
effect on their disease now and in the future, using a five point Likert scale 
(1= strongly disagree, to 5 = strongly agree). As there is no published 
conflicting medications scale in the literature, a conflicting medications 
scale was created to find out if respondents had ever received any 
conflicting information from two sources (two doctors or a doctor and the 
internet). Lastly, respondents were asked to rate four items relating to their 
specialist vasculitis doctors‘ encouragement regarding medication 
adherence.  Questions asked were: how often their doctor supported them 
in taking their vasculitis medication, if they provided them with new 
information about vasculitis treatments, if they were they given advice on 
how to deal with side effects side of medication and if they were they given 
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enough support to take drugs as prescribed. This was rated on a four point 
Likert scale (1=does not do this, to 4=does this a lot). The questionnaire 
took one hour to complete. 
 
A total of 228 respondents participated ,70% female, 91% white, mean age 
of 51 years, disease duration 6.4 years and  college education of 15.6 
years. This study found that just over half of vasculitis patients reported 
receiving conflicting medication information (51.3%) and were less 
adherent than those who did not receive contradictory advice. They 
reported several areas where there was often a conflict of information, 
seriousness of side effects of medications (35.5%), types of side effects 
(35%) and length of treatment (30.7%). In this study a large number of 
respondents were experiencing a flare or relapse (28.4%), therefore this 
group would be seeing their doctor more frequently and their medications 
would be assessed and most likely changed or an increase in dosage 
advised. The frequency of conflicting information was a surprising finding 
as there are significant seriou side effects of therapy such as increased risk 
of infection, infertility, bone marrow suppression, haemorrhagic cystitis and 
cancer.  However, a recent study of the opinions of 50 vasculitis experts 
found that doctors differed greatly in what information they gave patients 
about the risks and side effects of rituximab and cyclophosphamide 
(Cozmuta et al., 2013). One area where they differed in opinion was 
whether to disclose to patients the possibility of rare side effects such as 
multifocal leukoencephalopathy and serious mucocutaneous reactions.  
 
There are a few limitations of this study: the conflicting medications scale 
has not been validated, there are other respected sources of medication 
information such as nurses and pharmacists and this was not tested. Recall 
bias is a weakness of this study as 15% of respondents could not 
remember if they had received any conflicting information. The accuracy of 
receiving conflicting information was not assessed. When asked how 
confident they were that their medications would work, this group had high 
expectations of their medicines being effective (4.4 /5) but this was linked to 
decreased medication adherence. The reasons for this are not fully 
understood but a possible explanation given by the authors is that 
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individuals who believe their medications will work are more likely to 
remember instances where they have forgotten to take them. Doctor 
support was associated with better medication adherence but did not 
correlate to patients‘ expectations of medications. This study reports high 
conflicting information, twice as many from a previous study in 
rheumatology (Lim et al., 2007). However, it does not report if there was a 
difference between conflicting information received between doctors or 
between doctors and the internet. Using the internet may increase the risk 
of conflicting information as the sources may not be reliable or up to date. 
The sample was biased towards female and white and respondents had a 
self-reported diagnosis of AAV.  Although 228 respondents completed the 
study and the response rate is reported as 98%. This needs to be 
interpreted with caution as a total of 683 were invited to take part, of which 
only 67/ 361 mailed respondents participated. The very low mail response 
rate represents a selection bias, therefore the results may not be 
generalisable to AAV patients.  
 
A study by Carpenter et al., (2011a) examined the sources of information 
which patients with vasculitis used to find out about medication and 
assessed their perceived credibility. This was an online survey and part of 
the ASSIST study, 232 of 253 patients (92%) completed the questionnaire, 
81 % self-diagnosed AAV, 70% female, mean age 51 years, average 
disease duration 6.5 years. Males and females cited doctors as the most 
used information source, followed by the internet. Nurses and support 
groups were used less frequently. The least used sources were family and 
friends. There were gender differences with males reporting that they would 
use their spouse/ partner much more than females mean (3.11 v‘s 1.62). 
Males were more likely to seek information from nurses than females (2.65 
v‘s 2.14). The group was highly educated with 66% males and 58% 
females being college graduates. It is not known if the same results would 
have been obtained with less well educated patients.  Also, non-internet 
users may have different opinions regarding sources of information and 
possible concerns about the credibility of internet sources. The quality of 
information on the internet is variable and quality was not judged in this 
study. A weakness is the recall bias of medication sources used over a one 
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year period. The sample is biased towards females 69% and is 
predominately white 91%, 59% had AAV but with a self- reported diagnosis 
of vasculitis. This study needs to be replicated using a postal survey to 
compare results.  
 
Using the same sample population as the ASSIST study described earlier, 
Carpenter and colleagues examined the effect of medication-related 
support on the quality of life of patients with vasculitis in remission and 
relapse (Carpenter et al., 2011b). Health-related quality of life was 
measured using the SF 36 questionnaire.  In this study 28.4% were 
experiencing a relapse and 71.6% were in remission.  Medication support 
was measured by asking four questions: how often their doctor or partner 
helped them with taking their medications, gave additional information 
about their drugs, offered advice on how to deal with side effects and 
provided support to take their medications as recommended by their doctor. 
This was graded as 1=does not do this to 4=does this a lot. Both groups 
reported equally moderate amounts of support from their doctor and 
partners (mean=2.1). Those experiencing a relapse had reduced quality of 
life in seven out of the eight domains, apart from physical role limitations. 
Greater doctor support was associated with better quality of life in six 
domains of the SF36 apart from the bodily pain and energy domains.  
Similar results are seen with partner support. The reasons why support did 
not influence pain and energy is surprising as one might expect analgesic 
medication to influence symptoms such as pain. However, we do not know 
if the pain was related to their vasculitis or whether the patients were taking 
any analgesia.  A recent study of 410 AVV patients found that 74.8% 
reported high levels of fatigue and this was associated with several factors, 
of which disturbed sleep and pain were the most important (Basu et al., 
2013). A raised inflammatory marker (CRP) was also linked to fatigue.  
Fatigue is a multi-faceted phenomenon and more research is needed to 
explore the reasons for fatigue so that strategies can be developed to help 
patients manage this difficult symptom.  
 
Again, using the same sample population as the ASSIST study described 
earlier, Carpenter and colleagues examined what sources vasculitis 
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patients used to find out information about their vasculitis medications 
(Carpenter et al., 2012). Participants were asked how often they consulted 
pharmacists, doctors and the internet to seek information about their 
medications. This was rated on a five point Likert scale (1= never, 2= 
rarely, 3=sometimes, 4=often and 5= always). Using two questions from the 
McCroskey and Teven Credibility Scale respondents were asked to rate 
how knowledgeable these sources were on a scale of 1-9 (1= not at all 
knowledgeable to 9=extremely knowledgeable) and how expert the source 
was from 1-9 (1= not at all expert to 9= extremely expert). A total of 232 
/253 respondents participated (91.7% response rate), of the sample 96 had 
used a pharmacist for information, 217 had used the internet, 87 had used 
all three, unfortunately the paper does not give numbers for how many 
used a doctor. But they do report that doctors were the most frequently 
used source of medicines information, followed by the internet and lastly 
pharmacists.  
 
Pharmacists were only used occasionally as a resource for information and 
this was statistically significant (p=0.004). This is a surprising finding as 
pharmacists have a wealth of knowledge about medicines. However, in this 
study a third of respondents used a mail pharmacy service thus reducing 
the opportunities for exchange of information.  
 
Respondents believed that the doctor was the most credible source of 
information (mean 7.83), followed by the internet (mean 7.09) and 
pharmacists were seen as the least credible (mean 6.44). Just over a 
quarter of respondents were experiencing a flare or relapse therefore this 
group would be seeing their doctor more frequently and their medications  
would be assessed and most likely changed or an increase in dosage 
advised and this could have influenced the results.  A possible explanation 
that  the internet was viewed as a more credible source than pharmacists 
could be due to the fact that 58.8% of participants reported using credible 
vasculitis websites such as the Vasculitis Foundation and the Churg 
Strausss Syndrome Association and 34.8% used well-known vasculitis 
hospital centres‘ websites. Moreover, these websites have a wealth of 
information written by vasculitis experts for patients. The results need to be 
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interpreted with caution as the views of non-internet users may be different. 
A weakness is the recall bias of medication sources used over a one year 
period. The sample was predominantly females and white ,with a self- 
reported diagnosis of vasculitis. This study needs to be replicated using a 
postal survey to compare results.  
 
4.2.4 Medication adherence 
 
Pepper and colleagues tested the Informational – Motivation Behavioral 
Skills (IBM) model of adherence originally developed to test medication 
adherence in individuals with human immunodeficiency virus (HIV) on 172 
vasculitis patients (Pepper et al., 2012). In this model, adherence 
information (information on when to take drugs, dosage and side effects) 
and motivation (attitudes and beliefs to medication, support and confidence 
to take it) are key influences that impact adherence. They wanted to know if 
depressive symptoms and motivation to be adherent had any influence on 
support and adherence behaviour. They also investigated, whether doctors 
or partners had any effect on adherence. The sample population was from 
the ASSIST study of 232 respondents but 42 were excluded because they 
did not have a partner and a further 18 because of missing data.The Self- 
Efficacy for Appropriate Medication Use Scale (SEAMS) was used to 
assess how confident individuals felt they were in taking their medications 
as recommended.  
 
Depression was measured using the Centre for Epidemiological Studies 
Depression Scale (CES-D). The four-item Morinsky scale was used to 
assess adherence. The sample was biased towards female 70% and 
Caucasians 94%, and respondents reported low disease severity and 
medication regimes as not complex. Good support from doctors was 
associated with a better self-efficacy and improved adherence but how 
much support participants received from doctors is not known. However, 
good partner support was only associated with better adherence. 
Respondents had known their doctor for approximately two years and their 
partners 24 years. A weakness of the study is that adherence to medication 
was not formally tested via pill boxes and the measure used was self-
report. How often participants were reviewed is not clear. The respondents 
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in the study had low disease activity and could be considered in remission, 
therefore may not be taking many medications or following complex 
regimes and thereforemay not be representative of many vasculitis patients 
who are taking complex medication regimes, including 
immunosuppressants, steroids and prophylactic medication for 
cardiovascular disease, osteoporosis and infection.  
 
A recent study examined what factors are associated with medication non 
adherence in vasculitis patients (Carpenter et al., 2013). They used the 
same sample population as the ASSIST study described earlier. They 
recruited 106/228 patients, exploring whether demographic, depressive 
symptoms, support and experience of side effects influenced non-
adherence.  In addition, they wanted to find out if this was related to any 
particular medication. Depression was measured using the CES-D, the 
VSMS assessed adherence and medication support was evaluated as 
previously described (Carpenter et al., 2011b). Patients were asked to 
report if they experienced side effects (yes/no) to eight medications, 
steroids, cyclophosphamide, azathioprine, methotrexate, ciclosporin, co-
trimoxazole, mycophenolate mofetil and rituximab. A total side effect score 
was calculated by the number of yes responses (0-8). Sixty percent of 
respondents had GPA, 12.7% EGPA, 7.9% MPA and one fifth of 
respondents other types of vasculitis. The majority of patients were taking 
steroids 173 (75.9%), followed by co-trimoxazole 83 (36.4%), then 
azathioprine 74 (32.5%), cyclophosphamide 63 (27.6%), methotrexate 58 
(25%), mycophenolate mofetil 42 (18.1%), rituximab 27(11.6 %) and a 
small number 11(4%) ciclosporin. The group perceived their disease 
severity as moderate (mean 4.2) and their medication regime as not 
complex (mean of 3) as measured on a scale from 1-10. Over half (55%) of 
the respondents experienced depressive symptoms.  
 
Nearly all respondents (97.7%) experienced side effects due to steroids 
and a significant number with cyclophosphamide (79.4 %), approximately 
half  with azathioprine (47.3 %) and only 25.3 % with co-trimoxazole. 
Patients reported to be most adherent to azathioprine (mean 1.8/ 5) and 
steroids (mean 1.69/ 5).  This could be attributed to the fact that they 
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recognised that medications are vital to their survival. However, those 
patients who experienced side effects from any of the drugs were less 
adherent than those patients who did not experience side effects.  
 
Several factors were associated with medication non adherence, being 
female, younger age, experience of side effects and low mood. It is difficult 
to interpret the findings from this study as it is not clear from the figures 
cited how many patients were taking more than one medication and 
whether patients were prescribed oral or intravenous cyclophosphamide.  
The route of administration of cyclophosphamide may have influenced the 
results:  as patients have to attend day unit facilities regularly to receive 
intravenous cyclophosphamide and those taking oral do not, it could be 
considered more difficult to be non-adherent when receiving intravenous 
therapy. The small numbers taking some of the medications also make it 
difficult to generalise the findings. It is not known if the side effects 
experienced by respondents were mild or serious, as patients may 
legitimately stop taking medication due to recognised side effects and may 
have been instructed to do so. Unfortunately, the researchers did not 
measure adherence with individual drugs. Despite this, this study raises 
awareness that vasculitis patients are just as likely to be non-adherent as 
other groups of patients and health care professionals should discuss 
patients‘ medications with them and address any concerns that they might 
have.     
 
4.2.5 Patients’ knowledge of side effects 
 
One abstract was found relating to patients‘ knowledge of medication side 
effects in AAV (Brown et al., 2012). A total of 700 questionnaires were 
distributed to the membership of Vasculitis UK , 347 were returned of which 
306 had  AAV, GPA 241(79%), EGPA 41(13%), MPA 15 (5%) and other 
9(3%).There were 190 females (62%), males 38%, mean age 61.7 (range 
15-87), medication use was oral steroids 96%, oral cyclophosphamide 49% 
, intravenous cyclophosphamide 41%, AZP 69%, MMF 28% and rituximab 
14%. Knowledge of side effects of treatments, osteoporosis (20.9%), 
weight gain (19.3%), increased risk of infection (10.5%), increased risk of 
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cancer (7.5%) (skin 6.5% and bladder 3.9%). A small number were aware 
of the need for skin protection (13%). There are some limitations to this 
study: the respondents had a self- reported diagnosis of AAV, the sample 
was biased towards GPA and an unvalidated questionnaire was used. 
However, this study does demonstrate that respondents had poor 
knowledge of the side effects of medications used to treat AAV, indicating 
there is a need to educate patients on the risks associated with medications 
used to treat AAV.  
 
4.3 Gaps in Knowledge  
 
 
Research in AAV has concentrated on the areas of epidemiology, disease 
outcomes, classification systems, drug trials, adherence to medication, self-
management behaviours and quality of life. The subject of patient 
education has been evaluated in one inpatient education programme in a 
tertiary referral centre in Germany (Herlyn et al., 2002, Herlyn et al., 2008).  
However this was not a randomised controlled trial. A tool has been 
developed and used to assess the self-management behaviours of AAV 
patients (Thorpe et al., 2007, Thorpe et al., 2008). However, as yet there is 
no self-management programme specifically for AAV patients. Several 
studies have explored medications in relation to conflicting information, 
credibility of information sources,  medication support and adherence 
(Carpenter et al., 2010, Carpenter et al., 2011a, Carpenter et al., 2011b, 
Pepper et al., 2012., Carpenter et al., 2012, Carpenter et al., 2013). Whilst 
these studies provide valuable new data on the subject of medications and 
provide some insight into patients health beliefs, all of these studies used 
the same sample population of the ASSIST study. These studies need to 
be replicated in a wider population,  to include equal numbers of men and 
women, equal numbers of participants in remission and relapse and include 
participants taking complex medication regimes.  
 
The educational needs of patients with AAV have not been fully addressed.  
Whilst there are examples of printed leaflets for vasculitis from ARUK, the 
leaflet is generic and not disease specific (ARUK , 2011). There are 
examples of excellent written patient education materials produced by 
 83 
 
patient organisations e.g. Vasculitis UK and the Vasculitis Foundation. 
However, the majority of these materials are written at readability levels 
above the recommended sixth-grade reading in the USA and year seven in 
the UK (Rhee et al., 2013).The valuable role and contribution that patient 
organisations provide for patients has received little research attention and 
is an area for future research.   
 
No study has explored the patients‘ experience of receiving a diagnosis of 
AAV and we know very little about the informational needs of this group. 
There may well be significant unmet needs for these patients. 
Understanding what it is like to be diagnosed with a rare condition can help 
clinicians prepare patients better for receiving the diagnosis and improve 
the patient experience. In November 2013 the UK Government launched its 
―Rare Disease Strategy‖, unveiling five key areas for improvement across 
the whole patient journey: empowering patients, recognition and prevention 
of rare diseases, early diagnosis and treatment, co-ordination of care and 
the role of research (DH, 2013). If we are to achieve the first aim of 
empowering patients, first we need to understand what patients want to 
know about their illness so that information and education can be tailored to 
meet their needs and priorities, so that they can truly participate in shared 
decision-making and make informed choices. The next chapter will discuss 
the methodology and methods of the proposed study. 
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Chapter 5 Methodology and methods  
  
 
The earlier chapters identified the limitations of current knowledge, in that 
no study has explored the patients‘ experience of receiving a diagnosis of 
AAV and that we know very little about the informational needs of this 
group. The aim of this chapter is to examine the methodology and methods 
which will be used to explore the patients‘ experience and informational 
needs. The first part will identify the aim of the research, the research 
questions and purpose of the study. The second part will describe the 
research methods used in the study and provide a rationale for the chosen 
method. Lastly, to identify how the data were analysed and describe the 
methods used to ensure trustworthiness and rigour.  
 
 
5.1 Aim of the research 
 
The aim of this study was:  
1) To understand the patient‘s experience of being diagnosed with AAV  
2) To develop a Vasculitis Informational Needs Questionnaire 
3) To survey the membership of Vasculitis UK (a patient support group) and 
The Vasculitis Clinical Research Consortium (VCRC) (an online registry 
with self-reported AAV) to find out the informational needs of people with 
AAV. 
  
5.2 Research questions 
The research questions were: 
  
1) What is the experience of receiving a diagnosis of a rare potentially life 
threatening condition such as AAV? 
2) What are the informational needs of patients with AAV? 
3) How do patients with AAV prioritise their informational needs? 
4) How is information provided to patients and by whom? 
5) What sources of information are preferred? 
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6) Are there any differences in the informational needs of patients in the UK 
and USA?. 
 
 
5.3 Theoretical/Philosophical Orientation 
 
Research has a complex system of terminology, concepts and meanings, 
with a wide range of different methods and approaches. It is represented by 
an overarching research perspective which is referred to as a paradigm; a 
paradigm is an agreed set of shared beliefs and practices that guide the 
research (Morgan, 2007). The paradigm influences the research approach, 
as it is used as a framework to guide the study question, the study methods 
and data analysis. Researchers belong to one of three paradigms: 
quantitative, qualitative or mixed methods (Biesta, 2010, Freshwater & 
Cahill, 2012, Greene & Hall, 2010).  
 
The positivist paradigm is used in quantitative research. Positivists believe 
that only one reality exists (ontology) and they aim to find out the truth 
(Lincoln & Guba, 1985, Creswell & Plano Clark, 2007). The epistemology 
(how we came to know) of the positivist paradigm is based upon the 
deductive methodology of the scientific approach (O‘Hear, 1989). It is 
objective, it separates facts from values, numerical data is used, 
hypotheses are tested, results are generalisable and the researcher and 
participant are independent (Robson, 2002).   
 
Conversely, the Interpretive/constructionist paradigm that underpins 
qualitative research opposes the idea of the scientific approach. It is driven 
by a philosophy that in order to comprehend this world one must interpret it 
through the lived experiences of those in it (Polit & Beck, 2004). A theory is 
built upon what individuals perceive exist, data collection is narrative 
(Teddlie & Tashakkori, 2009).  
 
The pragmatic paradigm is used in mixed methods research:  the 
philosophy is that many different approaches can be used to answer the 
research question. It values both objective and subjective data 
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(Cherryholmes, 1992, Tashakkori & Creswell, 2007). As a method it 
collects and analyses both quantitative and qualitative data in the same 
study. Numerical and narrative data are used because they are best suited 
to answer the complexity of research questions. 
  
5.4 Study design 
 
 
In planning the design of a research study, it is crucial to think about the 
best method of data collection in order to answer the research question.  As 
no study in the UK or abroad has explored the patients‘ experience of 
receiving a diagnosis of AAV, or identified the informational needs of this 
group of patients, a mixed methods approach was chosen as the study 
design.  
 
5.5 Mixed methods  
 
Greene and colleagues identify mixed methods as an approach to 
answering research questions using  a combination of qualitative and 
quantitative methods to collect data for analysis (Greene et al., 1989). The 
qualitative method collects the spoken word and   aims to discover rich 
experiential data from the patients‘ experiences in order to provide an in-
depth understanding of their views. The quantitative element collects 
numbers and allows for comparisons to be made, hypothesis to be tested 
and results are generalisable (Robson, 2002).  As more researchers began 
incorporating qualitative and quantitative methods into their research 
design, many different names were given to this method of research over 
the years. It has been called ―quantitative and qualitative ― methods 
(Fielding & Fielding, 1986), it has been referred to as ― integrated ― or 
―combined‖ research by Steckler and colleagues (Steckler et al.,1992), 
―hybrid‖ research (Ragin et al., 2004) and ―combined research‖ (Cresswell, 
1994). All of these authors acknowledge the two different methods in their 
terminology and some have considered a broader view of how these 
methods are combined in a study. It was clear that more thought was 
needed to clarify exactly what mixed methods research was and the 
categories for describing the mixed method design (Bryman, 1988, Greene 
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et al.,1989, Cresswell,1994,Tashakkori & Teddlie, 1988, Morgan, 1998). To 
help clarify the different terminologies used, authors began to provided 
definitions of what mixed methods are (Creswell & Plano Clark, 2007,  
Burke et al ., 2007,Tashakkori & Creswell, 2007).  
  
Tashakkori & Creswell, (2007:4) defined mixed methods as: 
 
 ―research in which the investigator collects and analyses data, integrates 
the findings and draws inferences using both qualitative and quantitative 
approaches or methods in a single study‖ 
  
Creswell & Plano Clark (2007:5) provide a similar definition of mixed 
methods research as: 
 
 ‗a research design with philosophical assumptions as well as methods of 
inquiry. As a methodology, it involves philosophical assumptions that guide 
the direction of the collection and analysis of data and the mixture of 
qualitative and quantitative approaches in many phases of the research 
process‘. 
 
Burke and colleagues analysed 19 different mixed research definitions in 
the literature and provided this statement of what mixed methods research 
is:   
 
―Mixed methods research is the type of research in which a researcher or 
team of researchers combines elements of qualitative and quantitative 
research approaches (e.g., use of qualitative and quantitative viewpoints, 
data collection, analysis, inference techniques) for the broad purposes of 
breadth and depth of understanding and corroboration‖ (Burke et al., 
2007:123).  
 
All of these definitions are broadly similar and a criticism of mixed methods 
research was that it was often not clear how these methods were 
combined, the reasons for choosing them in a study and the sampling 
method (Fielding & Fielding, 1986, Bryman, 1988, Cresswell, 1994, 
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Onwuegbuzie & Collins, 2007). It is important to justify the mixing of 
qualitative and quantitative research in the same study. Greene et al., 
(1989:) distinguishes five categories for carrying out mixed methods 
research: 
 
1. Triangulation:  the data can be used from different methods to 
confirm, confound or corroborate findings; 
2. Complementary: use one method to explore, illustrate or enrich the 
results from another; 
3. Development:  when the results from one method are used to guide 
and inform the development of another; 
4. Initiation: to discover any contradictions or new understandings, 
used to modify any research questions;    
5. Expansion: to use different methods to expand the depth and 
breadth of the research. 
 
Bryman (2006) analysed 232 mixed method articles and applied Greene et 
al‟s (1989) categories for carrying out mixed method research, finding that 
the majority used were complementary (28.9%), followed by expansion 
(25.4%) then development (10.3%), triangulation (7.8%), initiation (0.4%) 
and in over a quarter (27.2%) no reason was given.  From this analysis he 
added to Greene‘s list that mixed methods can also be useful in obtaining 
diversity of views, illustrating concepts and developing instruments. 
Although these provide useful guidance on the reasons for conducting a 
mixed methods study,  the researcher needs to consider how the process 
of the two different approaches are integrated in the same study 
(Tashakkori & Teddlie, 1988).  
 
 As many different mixed methods designs can be implemented, most 
designs use timing to guide the different data collection phases of the study 
(Onwuebbuzuie & Collins, 2007). Timing is used to explain how the 
qualitative and quantitative elements of the study are to be undertaken, for 
example whether data collection is to occur at the same time (concurrently) 
or one after the other, so that the results from the first phase are used to 
inform the other (sequential) (Onwuebbuzuie & Collins,  2007). It is also 
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essential to stipulate how the data interpretation has informed the study 
(NIH, 1999). This integration requires a clear methodological approach so 
that it does not resemble a ‗pick and mix‘ (Gilbert, 2006). Therefore, a 
rationale for the inclusion of both qualitative and quantitative methods and 
analysis in the study will be provided. 
 
5.6 Rationale for using mixed methods 
 
Reflecting on which paradigm to use in this research caused the researcher 
great angst, as they felt forced to choose from two very different but 
opposing paradigms, namely positivism and constructionist/ interpretive. 
The researcher struggled to fit the research questions neatly into one or 
other of these paradigms. Tashakkori & Teddie (2003) believe that the 
focus should be on the research question as this drives the method rather 
than philosophical viewpoints and the researcher should not be made to 
choose between competing paradigms. The key is that a practical approach 
should be adopted to guide methodological choices. 
 
This is supported by Johnstone & Onwuegbuzie (2004) who suggest that 
mixed methods is the third paradigm and that taking a non-purist approach 
enables the researcher to design studies which use both qualitative and 
quantitative methods in order to answer the research question. The 
researcher felt that the competing paradigms restricted the approach to the 
study design and so adopting a pragmatic approach which values both 
objective and subjective data and respects different paradigms was suitable 
for this study since the research questions in this study could not be 
completely answered by either qualitative  or quantitative  methods alone.  
Mixed methods were chosen in this study to provide a greater and broader 
understanding and explanation of the research question rather than using 
one method alone (Creswell & Plano Clark, 2007). It allows a more flexible 
approach to the study design and has greater potential to extend the impact 
of the research to a wider community (Sandelowsk, 2000).  
 
Recently there has been an increase in the use of mixed methods in 
nursing and healthcare research, largely due to the recognition that using 
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either qualitative or quantitative methods alone is inadequate to portray the 
complex nature of the environment (Creswell et al., 2003, Howe, 2004, 
Johnstone, 2004).  
 
5.7 Two phase exploratory sequential design 
 
 A two phase exploratory sequential design has been chosen as the mixed 
methods approach (Creswell & Plano Clark, 2003, Tashakkori &Teddlie, 
1998). This approach uses a qualitative first phase where results are used 
to inform and guide the second quantitative phase (Greene et al., 1989). 
The underlying philosophy is that an exploration is needed first because 
there is little known about the subject and there are no specifically designed 
or validated tools or instruments available (Creswell & Plano Clark, 2007). 
This design is frequently used for the development of new instruments 
(Greene et al., 1989) and often used to investigate components of 
emergent themes (Morgan, 1998). The advantages of this design are that 
the two phases are distinct and make data collection easier. However, it 
can take a long time to start both phases. 
 
The first qualitative phase of the study used three focus groups and eight 
one-toone interviews to explore the informational needs of patients with a 
diagnosis of AAV. The findings from the first phase were used to guide and 
develop the Vasculitis Informational Needs questionnaire. This was used in 
the second quantitative phase to conduct a patient survey using the 
membership of the support group Vasculitis UK and the membership of the 
VCRC (Figure 9). 
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Figure 9 Overview of study design 
 
5.8 Ethical Approval and Research Governance 
 
Ethical approval for the study was obtained from the East Norfolk and 
Waveney Research Ethics Committee (ref 07/Q0603/9) (Appendix D), 
together with local site specific approval in Birmingham and Romford.  
Ethical approval was also obtained from the University of South Florida 
Institutional Review Board for the Vasculitis Clinical Research Consortium 
e-mail survey (USF IRB Pro00006828) (Appendix E). Informed consent 
was obtained from all patients participating in the focus groups and the 
face-to-face interviews. Consent was not obtained individually from 
members of Vasculitis UK, as return of the questionnaire was taken as 
implied consent.  All participants had to agree to participate in the study 
prior to the participant accessing the online survey. The participant‘s 
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willingness to participate in the study was documented. The informed 
consent documented that the participants were free to refuse entry into the 
study and free to withdraw from the study at any time without prejudice to 
future treatment. The online system did not collect the subject‘s name, only 
the fact that the participant agreed to take part (Appendix F). 
 
It was explained to the participants that if at any time during the focus 
groups or individual interviews they experienced any distress when 
recalling a particularly sensitive situation, the participant could terminate the 
interview and would be offered access to support systems for counselling. 
Similarly, if the researcher witnessed disclosure of unsafe/unethical medical 
practice, the researcher would have to follow up the issue with the 
appropriate professional body.  
 
5.9 Qualitative First Phase  
 
A qualitative approach was chosen for the first part of the study, to answer 
the research question number 1 ―What is the experience of receiving a 
diagnosis of a rare potentially life threatening condition such as AAV?‖.  
Qualitative methods are suitable to explore perceptions, opinions and 
experiences and are often used to study phenomena about which little is 
known (Polit & Beck, 2004). It enables the researcher to seek the views 
and opinions of individuals and gain an understanding and insight of their 
social world (Parahoo, 2006). They can explore topics in greater depth and 
are able to offer explanations and understanding which are missing from 
the traditional scientific quantitative approach (Mason, 2002). Qualitative 
methods allow a more flexible and sensitive approach to data collection 
than quantitative, where strict parameters are identified and set and cannot 
be deviated from. Focus groups and one-to-one interviews have been 
chosen as the qualitative methods. 
 
5.10 Focus groups 
 
Focus groups are one qualitative approach of data collection (Kreuger, 
1998).  A focus group is a method of interviewing a small selected group of 
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individuals to explore a specific subject in depth. The individuals are 
purposively chosen because of their experience and knowledge of the 
subject area. The aim of the focus group is to facilitate discussion between 
the individuals, so that they can share their experiences, opinions and 
attitudes, thus allowing the researcher to gain insight into their world.   
 
The purpose of the focus groups in this study was to explore what it is like 
to receive a diagnosis of AAV, by facilitating participants to share their 
experiences. This was carried out by a facilitator, whose role was to 
prepare and manage the group, ask questions, encourage active 
participation by all and observe the interactions within the group. Individual 
participation is vital and a key element of focus groups (Webb & Kevern, 
2001).  
 
5.10.1 Rationale for using the method 
 
Focus groups have been chosen because they are particularly suited to 
gather rich, in-depth information when little is known about a subject. Focus 
groups allow participants to share their experiences and knowledge (Powell 
& Single, 1996). The group interaction allows a high level of face validity 
through the discussion which permits confirmation, reinforcement or 
contradiction and thus generate a rich and complex data set (Kitzinger, 
1995, Greenhalgh & Taylor, 1997). This type of interaction would not be 
possible in a one-to-one interview, questionnaire or by direct observation. 
This method encourages individuals to participate who may feel vulnerable 
on a one-to-one basis, it allows participants to express negative aspects of 
care in a non -threatening environment (Avocella, 2011). It also enables the 
facilitator to observe the interaction of the group members where this is not 
possible with one-to-one interviews (Madriz, 2000). However, there are 
disadvantages in using focus groups as sometimes one person can 
dominate the conversation and influence the others. It is possible that not 
everyone will have the opportunity to share their views and they can be 
hard to control and manage (Avocella, 2011). It is an important role of the 
moderator to encourage everyone to join in the discussion and everybody 
should be encouraged to speak so that different viewpoints can be heard. 
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The moderator should emphasise that there is no right or wrong answers 
and that everybody‘s viewpoint is important and valuable. The moderator 
can use probing questions such as ‗how did that feel at that moment ‗to 
explore issues further and also to learn more about participant‘s reactions.    
 
5.10.2 Vignette  
 
A vignette was chosen as a tool to aid discussion at the start of the focus 
group as a sort of ‗ice breaker‘. A vignette is a short story designed to draw 
out responses to a given situation (Finch 1987). Traditionally used in 
quantitative surveys to find out opinions and beliefs, they are increasingly 
used in qualitative research (Eskinlen & Caswell, 2006). A vignette was 
written to capture the essence of some patients‘ experiences. It was 
appreciated however that it might not be representative of all participants‘ 
experiences.   
 
The narrative centered on a person with AAV having difficulty getting a 
diagnosis and information. Because AAV is rare and many patients have 
never met anyone else with these diseases, it was felt that this would help 
with the group interaction and stimulate discussion and sharing of 
experiences. The participants will be sent the vignette one week prior to the 
focus group. The reason for starting the focus group with a vignette is that 
participants will have had some time to think about the story and formulate 
their opinions and beliefs in advance, instead of the facilitator beginning the 
focus group with a general question directed at the group.  
 
5.10.2.1 Vignette: Jane’s Story  
 
‗I had been feeling unwell with aches and pains and tiredness for some 
time and no-one really knew what was wrong with me. I had various blood 
tests and investigations. I was seen by several doctors and finally I was 
given this diagnosis of ‗Vasculitis‘. This made me feel rather frightened as I 
had never heard the name before. But, I didn‘t want to bother the doctor 
with questions as he was too busy. I became really worried and wanted to 
find out more about this rare condition but didn‘t know where to start‗. 
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Thinking about Jane‘s Story 
Before you attend the discussion group could you please think about what it 
may have been like for Jane to be told she had an unusual disease like 
vasculitis and then think about what information she may have needed? 
A focus group interview guide was prepared to help facilitate participants to 
share their experiences, opinions and attitudes (Appendix G).   
 
5.11 One-to-one interviews 
 
One-to-one semi- structured interviews were chosen to explore in greater 
depth the emerging themes from the focus groups with different individual 
patients to find out if the themes generated are familiar with other patients 
and to find out if there were any differences.  Interviews are widely used as 
a qualitative approach of data collection (Mishlers, 1986). Loftland & 
Loftland (1995) describes an interview as a purposeful conversation that 
allows an in-depth exploration of a particular subject or experience. There 
are three types of interview, structured, semi-structured and open ended. 
The structured interview usually follows a structured questionnaire, 
whereas the semi-structured interview uses open ended questions and the 
in –depth interviews uses only one or two questions but explores them in 
much more depth (Britten, 1995). Kvale & Brinkman (2009:3) define a semi-
structured interview as: 
 
‗an interview with the purpose of obtaining descriptions of the life world of 
the interviewee in order to interpret the meaning of the described 
phenomena‘  
 
5.11.1 Rationale for using the method 
 
The semi-structured one-to-one interviews allow the researcher to explore 
topics in-depth and discover rich experiential data from the patients about 
their experiences. It allows the researcher to follow up interesting 
responses and adapt questions, which is not possible with self- 
administered questionnaires (Robson, 2002). In addition, during a one-to-
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one interview the researcher can observe the participant‘s body language 
and  eye contact which can help interpret the participant‘s emotion (Tod, 
2006) which may add to the depth and richness of the data gained (Mason, 
2002). For example body language is more powerful than the spoken word. 
Field notes were taken in order to record this data. Tod (2006) 
recommends a less structured approach to interviews where the aim is to 
explore a particular phenomenon, or to explain a social process or 
relationship. 
 
A structured approach was considered to be too rigid and would not give 
the opportunity to be flexible and explore the patient‘s responses in more 
depth. However, an open-ended interview was too uncontrolled, in that it 
would not be possible to ask all the desired questions and there was a 
danger that all of the topics would not be covered. Therefore, a semi-
structured approach was used to give some structure to the discussion and 
to ensure that all potentially relevant topics were covered. An interview 
guide was prepared with a list of questions to facilitate this (Appendix H). 
The interview guide was developed following a meeting with 10 AAV 
patients and three health care professionals (one nurse, one consultant and 
one qualitative researcher) to agree the topics for discussion.     
 
5.12 Recruitment   
 
Patients for the focus groups and one-to-one interviews were recruited from 
three centres, Norfolk & Norwich University Hospital, City Hospital 
Birmingham and Harold Wood Hospital, Romford. These centres were 
chosen as each has a medical expert in AAV with a pool of 60-120 patients 
with AAV. Three centres were used to ensure a broader spread of social 
and educational backgrounds. In each centre the rheumatology consultant 
approached potential participants, provided them with an information sheet 
about the study and a consent form (Appendix I). If the patient agreed to 
participate, they posted the signed consent form back to the researcher. 
The researcher telephoned each individual to find out their gender, age, 
disease status and length of diagnosis, to decide if they met the study 
inclusion criteria.  If suitable, the researcher provided them with an 
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explanation of the study and what would be expected of them. The 
researcher thanked them for their valuable contribution to the study. In 
addition each participant was sent detailed written patient information 
materials regarding the study. 
 
5.13 Inclusion criteria for focus groups and one-to-one interviews 
 
Patients with AAV (GPA, EGPA, MPA and PAN) who fulfilled the American 
College of Rheumatology (ACR) classification criteria (Fries et al., 1990) 
and the Chapel Hill Consensus Conference definitions (Jennette et al., 
1994) were included (Appendix J). Participants were aged 18 years or over 
(AAV is rare < 18 years). Adequate command of the English language was 
necessary to participate in the focus groups and one-to-one interviews. 
Participants had to be capable of giving informed consent.  
 
5.14 Exclusion criteria 
 
Participants with concomitant severe medical problems, those with life 
threatening disease and participants unable to give informed consent were 
not included.  Also, those with limited command of English and being aged 
less than 18 years were excluded. This was determined by the participant‘s 
consultant rheumatologist. Those participants with other types of vasculitis 
such as Giant Cell Arteritis, Takayasu's arteritis, Polyarteritis nodosa, 
Kawasaki's disease, Behcets, Henoch-Schönlein purpura, Essential 
cryoglobulinemic vasculitis and Cutaneous leukocytoclastic vasculitis were 
also excluded. 
 
5.15 Focus Group Information 
 
One week prior to the focus groups, all participants who had agreed to 
attend were sent the following information: a covering letter to explain what 
the study was about, information on what a focus group is and their 
involvement, the vignette and details of the venue. 
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5.16 Focus group participants  
 
Participants were invited to participate in a focus group for 1 to 1 ½ 
hours to discuss their experiences when given a diagnosis of AAV and to 
think about what their informational needs were. Three separate focus 
groups from different locations Birmingham, Romford and Norwich were 
used to ensure the broadest possible spread of social and educational 
backgrounds. Each focus group consisted of minimum 6 (maximum 10) 
participants, chosen to represent different disease subtypes of AAV (EGPA, 
GPA, MPA) and disease duration.  A group of 6-12 members is an optimum 
size, as it is a manageable size for group discussion without being too large 
(Merton et al., 1990, Stewart & Shamdasani, 2007). Smaller groups of 4-6 
however are more appropriate to explore subjects where the participants 
have had a profound experience (Kreuger, 1988).This enables enough 
variation of characteristics but sufficient shared experience to allow shared 
discussion. Purposive sampling was used but care was taken to ensure a 
representative spread of age, disease duration and disease subtype, so 
that all diseases were represented.This was carried out by the researcher 
using a grid and separating individual diseases out by gender and age.   
 
5.17 Facilitator 
 
As participants arrived, names were checked, consent forms were collected 
and refreshments were served which allowed people to talk to each other 
informally, creating a relaxed atmosphere. At the start introductions were 
made to familiarise the participants with the facilitator, the moderator and 
the rest of the group. The role of the moderator was to observe the group 
dynamics, facilitate participants sharing ideas, opinions and experiences. 
The facilitator read a prepared welcome statement which explained that the 
purpose of the study was to explore the informational needs of patients with 
AAV, so that the information from the study can be used to develop an 
education programme that reflects patients‘ needs. The facilitator also 
advised the group that the focus group would be tape recorded and 
transcribed. It was explained to the group that under each seat was a 
 99 
 
number and that this number would be used to identify who was speaking 
when the tape was transcribed. After everyone introduced themselves, 
including the moderator, ground rules were agreed as described by 
Krueger & Casey (2000), namely to respect each other, to keep confidential 
any material disclosed in the interview,  to use first names only and finally 
to enjoy the session. 
 
To start the focus group the facilitator asked everyone if they had received 
the vignette and read it out aloud, then they paused and asked the group, 
―What struck you most about this story?‖ This generated much discussion 
from individuals in the group and one participant revealed that she had not 
had a particularly good experience.  Once the participants had finished 
discussing the vignette, the semi-structured focus group interview guide 
was used to elicit patients‘ expectations, views and ideas on their 
informational needs (Lorig, 2001). 
5.18 Data Analysis 
 
A criticism of qualitative research is that many researchers have failed to 
explain how they analysed their data (Lee & Fielding, 1996, Huberman & 
Miles, 1994). With many relying on only one method, that of constant 
comparative analysis developed by Glaser & Strauss (1967) (Onwuegbuzie 
& Leech,  2006), a weakness of this method is that by using just one 
approach could lead to misinterpretation of the data thus affecting validity.  
It should be acknowledged that data analysis of qualitative data is a 
subjective process and there are inherent difficulties in the reliable 
interpretation of it. This has led researchers to develop techniques and 
tools to systematically guide data analysis, so that the process is 
transparent (Corbin & Strauss, 1990, Glaser & Strauss, 1967, Ritchie & 
Spencer, 1994, Bryman & Burgess, 1994, Cresswell, 1997,Denzin & 
Lincoln, 1998, Feldman, 1995, Miles & Huberman, 1994, Silverman, 1993). 
A popular method of data analysis is the framework technique developed 
by Ritchie & Spencer (1994). This is a five step process which involves: 
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1. Familiarisation with the data. 
2. Identification of a thematic framework. 
3. Indexing. 
4. Charting. 
5. Mapping and interpretation. 
 
The framework technique is a systematic and comprehensive method for 
researchers to analyse data and make sense of it by mapping emergent 
themes or concepts that explain the data.The focus groups were digitally 
recorded and transcribed as verbatim text, then the transcripts were read 
thoroughly and analysed by the researcher using the framework technique 
(Ritchie & Spencer, 1994). The first step in the process is familiarisation 
with the data: the focus groups transcripts were read and re-read so that 
the researcher was familiar with emerging ideas and recurring themes. 
Recurring words and sentences were underlined and notes were made in 
the margins of the transcripts. This enabled the researcher to understand 
the data and cross reference it to the study aims and objectives (Ritchie et 
al., 2003). The second step is identification of a thematic framework, with 
the notes, key issues, concepts and initial recurring themes from the first 
step used to build a thematic framework. Similar ideas or themes are 
grouped together onto large pieces of paper, helping to begin to organise 
and classify the data (Appendix K). This framework was then applied to the 
other transcripts and the themes refined. 
 
The third step in the process is indexing, where the framework is applied to 
the data and searched for sections of data that match a theme. Once 
indexing was complete, the data from the focus groups was coded into 
developing descriptive categories.  This was then recorded onto charts, 
where under each theme or heading a summary of the participant‘s 
accounts was provided. This process is known as charting (Appendix L).  
 
Finally the last step of mapping and interpreting the data occurred. This 
involved reviewing the data and charts as a whole, with each chart checked 
against sub headings and themes. The themes and sub headings were 
condensed further (Figure 10p118). In order to ensure that the 
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interpretation of the data was an accurate representation and 
understanding of participants‘ views, a summary of the identified themes 
was sent to the participants in the focus groups and they were invited to 
discuss their views on their clarity and authenticity either by post or in a 
telephone conversation with the facilitator (Appendix M and N). Participants 
agreed with the themes and subheadings and no new categories emerged 
and no existing ones were amalgamated. The identified themes were then 
used to guide the in-depth semi-structured interviews with individual 
participants.  
 
5.19 One-to-one interviews 
 
Different participants were invited to take part in a one-to-one semi-
structured interview for approximately 30 minutes to 1 hour to explore their 
experiences in relation to their informational needs. Participants were 
recruited from the three same centres as the focus group participants: 
Birmingham, Romford and Norwich. Participants were chosen to represent 
the different disease subtypes of AAV (EGPA, GPA, MPA) , duration of 
disease and disease subtype, so that all diseases were represented. One 
week prior to the interviews, all participants who had agreed to take part 
were sent the following information: a covering letter to explain what the 
study was, information on what a one-to-one interview is and their 
involvement, and details of where the interviews would take place 
(Appendix I).  
 5.20 Data Analysis 
 
The interviews were digitally recorded and transcribed as verbatim text. 
The transcribed tapes were read thoroughly and analysed by the 
researcher using the framework technique (Ritchie & Spencer, 1994). The 
data was then mapped against the framework headings and subheadings 
from the focus groups. The framework headings and subheadings identified 
were member-checked, a summary of headings identified was sent to 
participants in the interviews (Appendix M). They were invited to discuss 
their views on their clarity and authenticity either by post or in a telephone 
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conversation with the facilitator. No new data emerged and the existing 
themes generated were validated by the participants.  
 
5.21 Credible inferences and trustworthiness of data analysis 
 
It can be difficult to measure the quality of mixed methods studies and 
authors have discussed this at length (Teddie &Tashakkori, 2003, Greene, 
2007, Lincoln & Guba 1985). However, this does not mean that it does not 
receive the same rigour as a qualitative or quantitative study alone, just that 
different terminology is used to describe this process. The term ‗inference‘ 
has been used by some authors to describe the process of measuring 
quality in a mixed methods study (Tashakkori &Teddie, 1998, Eisenhart & 
Howe, 1992, King et al., 2004). Inference refers to the process of the study 
and how the results are interpreted and used to answer the research 
question (Teddie & Tashakkori, 2009). Similarly, it is important to consider 
the outcome of the study, whether the findings are consistent or different to 
previous literature, whether it adds new knowledge and understanding  to 
the field or build upon existing knowledge (Krathwohl, 1993, Teddie & 
Tashakkori, 2009). 
     
A number of methods were used to establish credible inferences and 
trustworthiness of the data analysis of the first phase. The first was 
triangulation of data sources, including using three geographical sites with 
different demographics, using both focus groups and individual interviews 
to explore and triangulate experiences (Cresswell, 2007). This included 
three researchers with qualitative and clinical expertise, who individually 
analysed the transcripts, followed by a meeting to agree themes. Member 
checking, each participant was invited to comment on the clarity and 
authenticity of the transcripts and the identified themes by letter or by a 
telephone conversation (Lincoln & Guba, 1985). Any such comments were 
used to validate or to review the emphasis given to themes interpretation. 
The results were felt to answer the research question and were found to be 
consistent with the literature for rare diseases. For a more detailed 
explanation see the discussion in section 6.      
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5.22 Quantitative second phase 
 
The findings from the first phase were used to inform and guide the second 
quantitative phase of the study (Greene et al., 1989). A Vasculitis 
Informational Needs questionnaire was developed and this was used to 
survey the membership of Vasculitis UK and the membership of the 
Vasculitis Clinical Research Consortium. In order to answer the research 
questions in 5.2 a quantitative approach was chosen. Quantitative methods 
allow for comparisons and hypothesis to be tested and results are 
generalisable (Robson, 2002). The most suitable method to find out the 
informational needs of patients with AAV was to conduct a questionnaire 
survey of Vasculitis UK (a national support group of 600 people with AAV) 
and to survey The Vasculitis Clinical Research Consortium (VCRC) (an 
online registry with self-reported AAV predominantly based in the USA). 
These two particular groups were chosen because they have a large 
membership of people with self-reported ANCA associated vasculitis from 
the UK and largely America. 
 
A quantitative survey is defined as ―a set of scientific procedures for 
collecting information and making quantitative inferences about a 
population‖ (McColl et al., 2001).  Surveys are a valuable method of 
collecting data which are not easily observable or measurable (Bowling, 
2002). They are useful for finding out information on beliefs, opinions, 
knowledge and satisfaction (Schofield & Knauss, 2011). Data can be 
obtained quickly and relatively cheaply. Surveys can be carried out by 
telephone, interview, post or via the internet. It was felt that it was not 
feasible to conduct a telephone survey as they are often less effective (Polit 
& Beck, 2004). Respondents are less likely to participate if they do not 
know the interviewer and gaining access to individuals‘ telephone numbers 
would be too problematic and costly. An interview survey was not felt to be 
appropriate due to the time involved, the cost of interviewing a large 
number of patients and the problems of accessing a large number of 
participants over a wide geographical area.  
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Two methods were considered appropriate to survey the two different 
groups. Firstly a mailed self- administered questionnaire was considered 
the most suitable method to survey VUK as they do not have an online 
membership. They distribute a quarterly newsletter to their membership 
and the questionnaire would be included with this. This would permit 
access to a large number of people from a wide geographical area.  A 
strength of this method is that individuals are familiar with this process and 
the questionnaire can be filled in at their leisure (Fink,  2006) and face-to-
face contact is not required (Sarantakos,  2005).The disadvantages are that 
respondents must be able to see and read, be motivated to fill it in and 
remember to post it back. Another weakness is that people with low 
education and low literacy skills and those who do not like writing are less 
likely to respond (Czaja & Blair, 2005). 
 
Online surveys are relatively new but with the increased use and access to 
technology, are becoming more popular for several reasons: they are 
extremely efficient, quick, economical, any destination in the world can be 
reached and most importantly data collection is immediate. There are some 
disadvantages: not all households have access to a computer or the 
internet, individual responders may lack the technical ability to complete the 
questionnaire and they may not be suitable for sensitive topics (Fink, 2006, 
Czaja & Blair, 2005). For the reasons highlighted above, an online survey 
was considered the most suitable method to reach the membership of the 
VCRC, as this is an online registry and individuals are familiar with using 
this type of technology.  
 
5.23 Informational needs tools  
 
A search of Medline, Evidence-Based Medicine (EBM) to find a tool to 
assess the informational needs of people with AAV revealed nothing. One 
tool had been developed to assess the educational needs of patients with 
arthritis in general (Educational Needs Assessment Tool (ENAT) (Hardware 
et al., 2004). It contains 39 items grouped into seven domains, managing 
pain (6 items), movement (5 items), feelings (4 items), arthritis (7 items), 
treatment (7 items), self-help measures (6 items) and support systems (4 
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items). Respondents were asked to rate each item ―how important is it for 
you to know more about‖ using a five-point scale (1 = not at all important, 
2= fairly important, 3 = a little important, 4 = very important and  5 = 
extremely important). Some of the questions related to pain, such as the 
use of hot and cold techniques, may not be recommended in AAV. The 
questions related to movement are more focused for OA or RA, although all 
of the questions about feelings are appropriate in AAV.  Many of the other 
questions were not suitable for patients with a rare, complex multi-system 
disease and thus the tool was felt to be too simplistic and not in-depth 
enough to address the information needs of patients with AAV. 
 
An information needs questionnaire was developed to establish the arthritis 
information needs of patients prior to setting up a community resource 
centre in Birmingham (Adab et al., 2004). The questionnaire asked 
respondents to rank on a four point scale (1= not at all useful to 4=very 
useful) how valuable different types of information sources and resources 
were in four domains: support information, non-medical health information, 
skills related information and medical information.  Although this 
questionnaire has not been validated, the domains contain many questions 
that are relevant to AAV and care was taken to ensure that these were 
represented in the final questionnaire (Appendix O).   
 
A tool was found which measured the unmet psychosocial needs of SLE 
patients, the SLE care needs and support assessment tool (SLENQ) 
(Moses et al., 2005). It has 97 items in seven domains: physical (10 items), 
daily living (8 items) psychological / spiritual / existential (10 items), health 
services (10 items), health information (10 items), social support (10 items) 
and employment / financial (4 items) and others (35). Respondents are 
asked to rate each item using a five-point scale (1 = no need, 2= need 
already satisfied, 3 = low need, 4 = moderate need and 5 = high need). In 
addition, 13 questions assessed the need for information on: disease, tests 
and information about results, treatment, knowing when to see a doctor, 
exercise and sports, support groups, occupational therapy, dental health, 
dietary information, counseling services, home (nursing) care. The focus of 
this tool is psychosocial and it asks very little about diagnosis and treatment 
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and is very lengthy (Moses et al., 2005). Therefore it was felt to be too 
simplistic in nature and it would not cover all the topics that emerged from 
the themes in the first qualitative phase particularly information about the 
disease, medications and side effects.  
 
Due to the paucity of published material, the cancer literature was drawn 
upon as these conditions share some similarities with AAV, as they are 
serious, complex, potentially life threatening illnesses and require intensive 
immunosuppressive therapy. The informational needs of cancer patients 
have been studied using survey methodology (Galloway et al., 1997, Yi et 
al., 2007). The researcher felt that it was not appropriate to develop an 
educational needs questionnaire from scratch as a suitable one was found 
for adaptation in the cancer literature. A tool suitable for adaption was 
found in the cancer literature, with the most appropriate felt to be 
theToronto Informational Needs Questionnaire (TINQ-BC), which is a 
validated and reliable self-administered questionnaire designed to elicit the 
informational needs of women with recently diagnosed breast cancer 
(Galloway et al., 1997; Graydon et al., 1997). It has 52 items, grouped 
under five domains: disease (9 items), investigations (8 items), treatments 
(16 items), physical (11items) and psychosocial (8 items). The items are 
scored using a five point scale from 1= not important to 5 = extremely 
important.  It takes twenty minutes   to complete and internal consistency 
was assessed by Cronbach‘s α with a score of 0.96 (Galloway et al., 1997). 
The TINQ- BC has been adapted for use in Korean women with breast 
cancer and shown to be reliable (Yi et al., 2007). The questionnaire has 
been adapted for use in men with prostate cancer in the UK and also for 
use in colon cancer in Ireland and has been shown to be reliable with a 
Cronbach‘s α of 0.92 (Templeton & Coates, 2001, O‘Connor et al., 2010). 
In prostate cancer the number of items was reduced to 29 removing 
irrelevant items such as item 24: If I can wear a brassiere and item 51: 
when to have a mammogram. The final 24 items are:  disease (n=3), 
investigative tests (n=6) physical (n= 3), treatment (n=10) and psychosocial 
(n=7). In colon cancer two items were removed: item 24 and 51 but three 
additional items were added resulting in a 53 item questionnaire. The final 
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53 items are disease (n=9), investigations and tests (n=8), treatment 
(n=15), physical (n=11) and psychosocial (n=10).  
 
The reason that the TINQ-BC was chosen as suitable for adaptation was 
that most of the items, grouped under the five domains of disease, 
investigations , treatments, physical and psychosocial, mapped very closely 
to the themes and subthemes generated from the first phase of the study. 
They also related to the domains of support information, non-medical health 
information, skills-related information and medical information included in 
the needs assessment questionnaire developed by Adab and colleagues 
(Adab et al., 2004). However, the questions in the TINQ-BC are more 
comprehensive than those of Adab as the domains contained more 
relevant questions that reflected many of the concerns of participants from 
the first phase of the study. Furthermore, the questionnaire has been 
validated and is suitable for use in other disease groups (Templeton & 
Coates, 2001, O‘Connor et al., 2010). Permission was sought from 
Springer Publishing Company to use the questionnaire and confirmation is 
shown in Appendix P.  
 
5.24 Adaptation of theTINQ-BC 
   
The first stage in the adaptation of the TINQ-BC to a Vasculitis Information 
Needs Questionnaire (VINQ) was to remove any irrelevant questions 
(Buckingham & Saunders, 2004). Starting with the full set of 52 items, 
those that were solely related to breast cancer were removed. A total of 
nineteen irrelevant items were removed: 
 
Item  2:  If the breast cancer will come back 
Item  4:  When to examine my breasts 
Item  7:  How breast cancer acts in the body 
Item 12: If there is cancer anywhere else in my body 
Item 17: Who to talk with if I hear about treatments other than surgery,     
radiation or chemotherapy 
Item 21: How to care for my wound/ incision 
Item 22: What to do if I am concerned about dying 
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Item 24: Did I need to wear a brassiere 
Item 31: How long will my wound/ incision take to heal? 
Item 34: Where I can get help, if I have problems feeling as attractive as 
before?  
Item 35: How the treatment works against the cancer 
Item 36: If there are any special arm exercises to do 
Item 39: If I am going to need help to take care of myself   
Item 41: If the treatment will alter the way I look 
Item 42: How to tell if the cancer has come back 
Item 43: Which foods I can or cannot eat  
Item 44: If I can take a bath or shower 
Item 48: How to prepare for tests 
Item 51: When to have a mammogram 
 
A further three items were also removed: 
Item 15:  How the tests are done 
Item 16:  Why they need to test my blood 
Item 20 : Where my family can go to get help dealing with my illness 
 
Four questions were amalgamated into two questions: 
 
Item 1: ‗How I will feel during the tests‘ and item 33: ‗How I will feel after the 
tests‘ were combined to ‗How I will feel during/ after tests‘. 
Item 38: ‗If there are any physical things I should not do‘ was combined with 
item: 52 ‗If I can continue my usual social activities‘ to ‗If I can continue with 
my usual social and physical activities‘.  
 
Three items were reworded: item 46: ‗Why the doctor suggested this 
treatment plan for me‘ was changed to ‗Hhow my treatment was chosen‘. 
This was amended because patients in the first phase wanted to know the 
names of their medications and why their medications were often changed. 
Item 45: ‗What types of treatment are available‘ was amended to‘The 
names of drugs used to treat vasculitis‘ for the same reasons above. 
Item 49:‘What to do if I feel uncomfortable in social circumstances‘ was 
changed to ‗Hhow to access psychological support‘ in response to the 
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comment made by participant eight ―Counselling. Or some form of 
psychological help‖. 
  
Five items were added: Is it important for me to know:  
 
What the symptoms of vasculitis are  
If it is contagious 
How is it diagnosed? 
How often should I have blood tests?   
How to access other services eg. benefits, social services 
 
These were all questions that emerged from the qualitative first phase of 
the study and were highlighted by participants as important to them. The 
last question is also one of the items included in the arthritis informational 
needs questionnaire developed by Adab et al., (2004). Care was taken to 
ensure that the themes from the first phase, reaction to diagnosis, the need 
for information on disease, investigations and treatment and access to 
knowledgeable practitioners, were represented in the VINQ (Mooney et al., 
2013).  Similarly, that the subscales of the Vasculitis Self-Management 
Scale were integrated (Thorpe et al., 2008, Thorpe et al., 2007) (Appendix 
M). Below is a comparison of the previous adaptations of the TINQ-BC, 
including the VINQ)(Table 5).  
 
 
 No 
Items 
Disease  Investigations 
and tests                  
Physical    Treatment  Psychosocial  
TINQ- BC 52  9 8 11 16 8 
Prostate 
cancer 
29        3 6 3 10 7 
Colon 
Cancer 
53        9 8 11 15 10 
VINQ 33 7 5 3 13 5 
Table 5 Comparison of adaptations of the TINQ-BC 
 
5.25 Questionnaire Design  
 
 110 
 
Although, the TINQ-BC was chosen for adaptation, it does not contain any 
information on demographics, diagnosis, diagnostic delay, time since 
diagnosis, who provided information at diagnosis and the preferred mode of 
education delivery.  All of these questions needed to be added to the VINQ. 
The order in which questions are asked is important and requires careful 
consideration. There is controversy about whether demographic data 
should be placed at the beginning or end of a questionnaire (Fink, 2006). 
Those who feel that it should be at the beginning (Dillman,  2000, Bradburn 
et al ., 2004) would argue that it is easy for these questions to be answered 
and those respondents that fail to complete questionnaires generally leave 
the questions unanswered at the end. Therefore by having the 
demographics at the start you have full demographic details of the 
respondent. Those who support placing it at the end would argue that 
demographic questions are mundane and respondents will become bored 
with the questionnaire and fail to complete it (Bourque & Fielder, 1995). It 
was decided that the demographic data would be at the beginning, so that 
any respondent not meeting the inclusion criteria could be identified quickly 
and not entered into the study.   
 
The layout of the questionnaire is important: the length should be no more 
than twelve pages, with enough space between questions (Fink, 2006).  
The design of the questionnaire was to have most questions set out on a 
vertical format with the exception of the rating scale questions where a 
horizontal format was used.  For clarity, boxes were used where 
appropriate and instructions and questions were not split between pages. 
The final questionnaire was six pages long.  
 
The VINQ had information about the study at the beginning of the 
questionnaire rather than a separate participant information sheet. This was 
because information about the study was announced in the Vasculitis UK 
newsletter and on the VCRC website, followed by instructions on how to 
complete the questionnaire.  
 
The VINQ (Appendix Q) was divided into 3 main sections, the first section 
contained the demographic data such as:  
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1): Age, gender, education status, diagnosis, time to diagnosis, disease 
duration from diagnosis. 
The second section contained the informational needs of participants. In 
this section there were 33 items covering the following five domains: 
disease, investigations, treatment, physical, psychosocial care. 
Respondents were asked to rank each using a 5 point scale (1= not 
important, 2=slightly important, 3= moderately important, 4=very important 
and 5=extremely important). The stem question was ―it is important for me 
to know‖.   
The third section contained questions related to preferred mode of 
education delivery: such as written, by a health care professional, internet, 
CD, group programme. 
A free text box was included so that participants could provide details of 
any type of information that they found useful.  
 
5.26 Content validity 
  
The content validity of the VINQ was established by asking three doctors 
with expertise in the care of patients with vasculitis (two consultants and 
one specialst registrar) and a vasculitis specialist nurse to review the VINQ 
items for subject matter, use of language and patient understanding. The 
reviewers had not otherwise been involved in the design of the 
questionnaire. No further changes were made to the questionnaire at this 
stage. The questionnaire was then pilot tested in 20 patients with AAV,( 
eleven females and nine males, age range 25-75, mean age 60 years, 
disease 10 EGPA, 8 GPA and 2 MPA). The questionnaire was posted to 
them and the following questions were asked: 
 
1) Were the instructions clear and easy to follow? 
2) How much time did it take to complete? 
3) Were there any questions that were confusing? 
4) Did you object to answering any questions? 
5) Was the layout clear and attractive? 
6) Any other comments 
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Participants found it easy to complete and follow, the average time taken to 
complete it was twelve minutes, there were no objections to answering any 
questions and they found the layout clear and attractive. One question was 
found to be confusing and that was item 10, ―what the results of blood tests 
/ ANCA mean‖, as none of the participants had heard of ANCA. Following 
the pilot test, the VINQ was modified to clarify language and remove 
medical jargon for example, ―ANCA‖ was removed. The VINQ language 
and terms were slightly modified for use internationally, but these changes 
did not alter the content of the questions and were mainly linguistic (e.g. 
‗leaflet‘ was replaced with‘ pamphlet‘, educational attainment levels were 
changed from the UK system to the US system, ‗tick‘ was changed to 
‗check‘ and more options for ethnic origin were added  
(Appendix R). 
 
5.27 Reliability and validation of the VINQ  
 
The reliability of the VINQ was assessed by the test –retest method 
(Fink ,2006). The questionnaire was distributed to a group of 20 
patients at two different time points (3 months apart). No differences 
in the scores were seen for the different time frames. Consistent 
results are associated with good reliability. The VINQ was assessed for 
internal consistency using Cronbach‘s α (Table 6). The reliability of the 
questionnaire was high, with an overall score of 0.94 which indicates a high 
degree of internal consistency. There was also a high degree of 
consistency for each of the five domains (Table 6, Appendix S).The 
readability of the questionnaire as measured by the Flesch reading ease 
scale and was 73.8, considered fairly easy to read, with a reading grade of 
4.4 (Doak et al.,1996). 
 
 
 
 
 
 
Table 6 Cronbach‘s α value of subscales of VINQ 
Subscale in VINQ Cronbach‘s 
α 
Items 
Disease 0.81 7 
Investigations and tests 0.84 5 
Treatments 0.92 12 
Physical 0.83 3 
Psychosocial 0.89  5 
Total 0.94 33 
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The face validity of the questionnaire was assessed by the 
researcher, a consultant with a specialist interested in vasculitis and 
a qualitative researcher to determine if the questions in the VINQ 
measured what we wanted to. Threre was general agreement that it 
was fit for purpose.  Another method of assessing concurrent validity 
would have been to compare the results of the VINQ with the TINQ.  
      
5.28 Recruitment for the survey   
 
The VINQ was used to survey the membership of VUK and the VCRC. 
Participants were recruited for the mail survey from the membership of 
Vasculitis UK. Inclusion criteria: member of VUK with a reported diagnosis 
of Granulomatosis with Polyangiitis (Wegener‘s granulomatosis), 
Microscopic Polyangiitis, Churg-Strauss Syndrome (EGPA), 18 years of 
age or older and English speaking. Exclusion criteria: inability to provide 
informed consent and complete survey. 
 
Participants were recruited for the online survey from the VCRC Patient 
Contact Registry which is part of the Rare Diseases Clinical Research 
Network (RDCRN).  More than 2000 patients, representing all the different 
types of vasculitis, are currently enrolled in the web-based registry (Table 
7). Inclusion criteria: enrolled in VCRC Contact Registry, a reported 
diagnosis of EGPA, MPA, GPA , 18 years of age or older and English 
speaking. Exclusion criteria: inability to provide informed consent and 
complete survey. 
 
Disease N Percent 
Granulomatosis with Polyangiitis 
(Wegener‘s) 
1424 46% 
Microscopic Polyangiitis 151 5% 
Churg-Strauss Syndrome 526 17% 
Other 989 32% 
Total 3115 100% 
Table 7 VCRC Contact Registrants with AAV (as of July 2011) 
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The VINQ was distributed with the regular mailed newsletter to the 
membership of VUK.  Information about the study was included in the 
newsletter and a stamped addressed envelope was provided for return. No 
reminder was sent to complete the survey and respondents did not receive 
any financial incentive for completing the questionnaire. Unfortunately at 
the time of the survey VUK did not have any accurate figures of the 
numbers of members with the different types of vasculitis.  
 
Members of the VCRC Contact Registry were surveyed in March 2012 
using an email invitation to log onto the VCRC website and then complete 
an online survey. The email ―shot‖ was repeated twice, to non-responders 
after three and six weeks. Potential participants were able to read the 
consent information in the privacy of their own home or other location 
where they access the internet. Potential participants could take as much 
time as needed to read the consent form. In the introductory email, as well 
as on the VCRC website, study staff contact information (both phone and 
email) was provided so participants could contact the study staff with any 
research related questions. The VCRC Contact Registry and the survey are 
voluntary. The study was not presented to the participant by the person 
who controls the health care of the participants. Potential participants who 
could not read English were not able to participate.  
 
5.29 Data Analysis of the Questionnaire 
 
Data obtained from the questionnaires was analysed by computer using the 
Statistical Package for the Social Sciences (SPSS Version 19.0, IMB, 
Armonk, NY, USA). Both descriptive and inferential statistics were used in 
the analysis and description of the data set. The median scores were 
calculated for the domain subscales in the VINQ to determine if there were 
any differences between the VUK and the VCRC cohorts.  As the data set 
was not normally distributed non-parametric tests were used to test for 
differences between the median of two samples. The Mann –Whitney U 
test was used to compare any differences between different groups and a p 
value of  p< 0.05 was used to reject the null hypothesis.   
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In summary, a two phase exploratory sequential design has been chosen 
as the mixed methods approach (Creswell & Plano Clark, 2003, Tashakkori 
& Teddlie, 1998). The first qualitative phase of the study used three focus 
groups and eight one-to-one interviews to explore the informational needs 
of patients with a diagnosis of AAV. The findings from the first phase were 
used to guide and develop the Vasculitis Informational Needs 
questionnaire. This was used in the second quantitative phase to conduct a 
patient survey using the membership of the support group Vasculitis UK 
and the membership of the VCRC. The next chapter will present the 
findings from the first qualitative phase of the study.  
 
 
  
 116 
 
Chapter 6 Results of the qualitative first phase   
 
This chapter will present the results from the qualitative first phase of the 
study which was to answer to the research question 1) What is the 
experience of receiving a diagnosis of a rare potentially life threatening 
condition such as AAV?. The characteristics of the sample, the emergent 
themes and how the findings were used to guide and inform the second 
quantitative phase will be provided.  
 
6.1 Respondent Characteristics  
 
A purposeful sample of 15 patients participated in the focus groups (see 
table 10). Three focus groups were held, one in each hospital location. The 
Norwich focus group had seven participants and both Birmingham and 
Romford had four, each focus group lasted 90 minutes. There were 10 
women and 5 men, 3 had EGPA, 9 GPA, 2 PAN and one MPA. Three male 
patients declined to participate in the focus groups, one due to partner care 
commitments, one due to work commitments and the other having no 
means of transport.The age of participants ranged from 48-80 years, 
disease duration ranged from less than one year to 20 years.  
 
Participant  Disease  Age  Gender Disease 
duration 
years 
P1 EGPA 67 F 12  
P2 GPA 69 F 15  
P3 GPA 56 F 11  
P4 EGPA 63 M 13  
P5 EGPA 48 M   2  
P6 GPA 67 F   9  
P7 GPA 56 M   3  
P8 GPA 39 F   5  
P9 GPA 62 F 19 
P10 GPA 80 F   3 
P11 PAN 75 F   7  
P12 GPA 57 M >1 
P13 GPA 62 F 14  
P14 PAN 80 M 20  
P15 GPA 73 F 20  
Table 8 Focus group participants 
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6.2 One-to-one interviews 
 
A purposeful sample of eight different participants was selected for the 
face-to-face interviews, to ensure a mix of gender, age, disease and 
disease duration from each centre (see table 11).These participants were a 
separate sample to the focus group participants and no participants took 
part in  both. Participants were interviewed in the hospital setting and the 
interviews lasted 30–45 minutes. There were 5 female and three males, 4 
had GPA, 3 EGPA and one MPA. The age of participants ranged from 26-
78 years, disease duration ranged from less than one year to 12 years. 
 
Patricipant Diagnosis Age  Gender Disease 
duration 
years 
P16 EGPA 26 F   4  
P17 GPA 28 M 10 
P18 MPA 60 F >1 
P18 EGPA 78 M   5  
P20 GPA 52 F >1  
P21 GPA 52 M 12  
P22 GPA 51 F  4  
P23 EGPA 70 F  6  
Table 9 Participants in one-to-one interviews 
 
6.3 Results  
The emergent themes from the first qualitative phase were: experience of 
receiving  a  diagnosis, the need for more information on disease, 
investigations and treatment and access to knowledgeable practitioners. 
These themes were mapped into an interpretative framework that explain 
the data (Figure 10).  
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Figure 10 Mapping and interpretation of a diagnosis of AAV 
 
6.31 The experience of receiving a diagnosis 
 
The first theme to emerge from the data analysis was ― the experience of 
receiving  a diagnosis‖ under this theme participants described 
experiencing a range of emotions when first diagnosed with AVV.  
 
P22   “Well, first of all I didn‟t quite understand – you know, I‟d never 
heard of it or anything, and then when it was explained what I had 
and that I‟d need chemotherapy and steroids it was a bit 
devastating, but I was quite ill at the time and I‟d been admitted to 
hospital and I was in so much pain. So I think the first few days after 
 119 
 
I‟d been told I was on morphine so it was a bit sort of hazy, if you 
see what I mean”. 
 
P15  “I was just scared, I just thought, at one point in hospital, I thought I 
was going to die, because I had all this going on, with clots as well, 
which wasn‟t normal, I was told I was out of the medical books, 
because of what was happening to me, it shouldn‟t be happening, 
so it was scary because I had never been ill in my life, never, never 
ever been ill, I was just scared, scared of if I was going to die, when 
you‟re 51 and told you have got that”. 
 
Many respondents used common phrases to convey the depth of their 
shock and trauma such as “Devastated, shock, scary time, fear”. 
 
However, for some participants it was a relief to know that someone knew 
what was wrong with them and that they had a diagnosis.  
 
P16    ―Relief, to know what it was‖. 
 
P18    ―I‟ve got a label at last‖. 
 
P5  “Well I must have had a different sort of reaction because I was 
elated because I was being fed anti-depressants and treated like I 
was mental going off my head‖. 
 
When consulting with health care practitioners, participants described both 
negative and positive experiences. Negative experiences were linked to 
patients‘ symptoms not being listened to or not taken seriously and being 
told that ―you‘re not ill‖.  
 
P15 ―Oh you have nothing wrong with you, then my leg blew up, then I 
came into hospital, thought deep vein thrombosis, did chest x-ray,I 
was bleeding into my lungs, realised I‟d got a big problem. Oh yes 
its vasculitis (dr‟s).Scary, thought I was going to die‖. 
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P11  ―Angry, I„m ill, kept going back, saw someone else, getting worse   
and worse‖. 
 
P2 ‖I thought I just have to try again, and I went down to GP and I said  
look I‟m not depressed, there‟s nothing wrong with my marriage, 
nothing wrong in the family, I‟m ill. Please do something‖. 
 
P18    ―Passed from one consultant to another, begged last one 
don‟t pass me over‖. 
 
P13   ―Please take me seriously I‟m ill‖. 
 
P1     ―I‟m still raw about the whole thing‖. 
 
Positive experiences were often associated with validation of participants 
symptoms, confirming that there was something wrong with them.   
 
P3  ‖Very unusual, he said but I‟m going to ask them to test for 
Wegener‟s, I had never heard of it, didn‟t mean anything to me, I felt 
so relieved”. 
 
P5  ―I think I know what you‟ve got, its very rare, very unusual, I‟m going 
to ask then to test for vasculitis”. 
 
When given the initial diagnosis all participants described being too ill to 
take in information and were trying to make sense of what had been said to 
them at the time.  
 
P12  ―You‟re brain is working at double time because of what is 
happening to you, you don‟t know what questions are and 
depending on your doctor it maybe that you have to prod very hard 
for information, some are more willing to give information than 
others. Even when information is coming to you, you‟re trying to 
understand this language you‟ve not heard before, and how is that 
going to affect me by that time you‟ve got that the doctors  gone on 
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to something else. You‟ve missed all of that. So you have to gather 
information little globules of information as you go along absorb 
them take them into your life. Assimilate them and go on but you 
never know what the question is, is the major problem for me”.   
 
P3     ―Too ill to take information in“. 
 
P11    ―Numb, can‟t remember, felt out of it ―. 
 
P7 ―The talk went over my head, in one ear and out the other, I just 
couldn‟t remember things. My wife heard things. I would prefer 
somebody to talk to you and go through a leaflet”.  
 
Many participants experienced a delay in receiving a diagnosis of AAV and 
some gave a detailed account of their symptoms. 
 
P21 ―Took a long time to get diagnosed, I had been quite ill for a long 
time. I had   various problems that could indicate vasculitis for about 
18 months, when in fact I had six operations on my nose, and it was 
thought that there was a deviation in my septum at one point, so I 
guess I didn‟t find out what it was for a long time. It was a relief that 
I now knew what the condition was‖. 
 
P7  ―Took about three years to diagnose me, a long long time, a lot of 
tests and a lot of other things went on, and I was just going downhill 
all the time‖. 
 
P15    ―Two years to get a diagnosis‖. 
     
P12  “Mysterious symptoms, difficult to walk, difficult to eat, difficult to 
use my hands, difficult to get up and down stairs, hearing going, 
ache all over. Polyps in my nose again, foot drop”. 
 
P9  “High temperatures, hearing had gone, chest infection, sinuses 
,urinary tract infection, attacked my kidneys and lungs‖.  
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In contrast, there were some for whom their condition was diagnosed 
quickly.  
 
P20 ―Dr X , he gave me it verbally as the result of a blood test, em that 
my doctor had sent me for, it was my doctor that picked it up, well 
all he said to me was that you have got a lot of inflammation going 
on and I  just thought that he thinks it Polymyalgia. So I had an 
appointment to see Dr X and also an appointment to see the 
rheumatologist but I saw Dr x first and that came as a complete 
shock that I was going to the renal specialist, he said well you won‟t 
need to see a rheumatologist. Because I know what it is you‟ve got 
from you‟re blood test. So then he explained to me em the sort, 
basically what vasculitis was, he didn‟t at that stage, he might have 
mentioned Polyangiitis but I was suddenly taken aback really, to 
discover I had something different to what I thought I had. I was 
very impressed I saw him on the Tuesday morning after we had got 
back from a week‟s holiday and was admitted the next day, he 
would have admitted me that day but It was not just convenient I 
can come in the morning, have the biopsy on the Wednesday, 
results on the Thursday, started the treatment on the Friday, So you 
know within 3 days they stared the treatment. Which was absolutely 
wonderful?”. 
 
P12    ―GP was on the ball, got me an appointment the next day”. 
 
P18     ―He thought straight away that I had got MPA, so it was spotted  
 quite quickly”      
 
P6     ―It took three months‖. 
 
This participant recognized that is is difficult for GP‘s to be experts in every 
health care condition and stated:   
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P6  “Only when my liver started going wrong and that it showed in the 
blood test, they started to take me seriously, I‟m not criticising GP‟s 
who have a tough job in my opinion, you are going to have to go to 
experts, we don‟t know what‟s wrong with you“.  
 
6.32 Finding out about Disease Management 
 
The second theme to emerge from the data analysis was ― finding out about 
disease management‖. It was clear that participants wanted information 
about their disease, medications and how to manage their condition.  
 
P13  ―I was given no information, you have to prod very hard for 
information. Some are more willing to give information than others‖. 
 
BP ―Not many people who know anything about it. The lack of 
information when I was diagnosed, my GP said the best route is to 
go on the internet, which I did and to be quite honest it frightened 
me what I read.There wasn‟t much information at all. Those 
American internet sites, some people they don‟t pull any punches.‖  
 
P1        ―No understanding of treatments‖. 
 
P2  ―Regime of drugs, I used to ask the nephrologists what does this 
do, why does this happen and why do these drugs do this and all 
that‖. 
 
P7  ―Lack of information, on a cancer ward without any explanation, took 
you off medication‖. 
 
P13    ―Gave me chemotherapy, has it got a different name”. 
 
P16    ―Chemo terminology confusing”. 
 
P6      ―That‟s for people with cancer, frightening, just that word alone”. 
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P14  ‖It‟s only what we read on the bottle isn‟t it. I suppose all the tablets 
you take if they could give you a list of what they are for”. 
          
 
P1  ―Need for powerful medication explained, now I‟m not trying to be 
critical I would like to understand why on earth we get all this 
treatment in the first place‖.  
 
P1  ―Over head, do not remember, I don‟t remember any leaflets on 
EGPA I think a written leaflet is essential‖. 
 
P17  ―You must inform the patients what on earth are they in for. I think 
this is really important ―.  
 
P5  ―Some information over the top, conflicting information, 
chemotherapy, I was told to get up in the night and drink water‖. 
 
P6  “You feel a little sick, visions of no hair, a lot of the side effects of 
drugs are close to some of the symptoms.‖ 
 
P8  ―Drug regime, maintenance therapy, That‟s another concern I have 
what damage are the drugs doing‖. 
 
P13    ―Cataracts, nobody told me of side effects, to be told side effects 
medication”. 
 
This participant talked openly about the significant impact that a diagnosis 
of AAV had on her life. 
 
 
P8  ―Counselling. Or some form of psychological help. Definitely – for 
the patient and the relatives, you know because I think it‟s really – 
you know, my life really changed overnight. And not just mine my 
families it had a tremendous knock-on effect financially and 
emotionally. In all aspects really. One thing that would be very 
useful would be the side-effects of the drugs and maybe for others – 
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is it contagious? Because people think if you‟ve got a weird disease, 
and that‟s what it‟s been classed to me as a weird disease – when I 
went to the hospital I was told - you‟re the woman with the weird 
disease. I thought that‟s good! So I mean, I think personally there 
needs to be more information given over in the media and to GPs. 
My GP knows very little or much about it at all. Of course the 
general public, they don‟t.Symptoms aren‟t clear.They could be 
appertaining to so many other things I suppose. Research is very 
important. People do not have enough information about their 
condition and society is not well informed. Support and information 
are most important for patients. And I‟m a nurse‖.  
 
This participant also wanted support but was unsure who to turn to.     
 
P8  ―Support group, very supportive part of getting better. Dr x helped 
me. There was very little help at all. No I had to find it out for myself. 
I think that‟s what I wanted (HOPE). I just don‟t know anybody my 
way to talk to.There is nobody to turn to, to talk to or get to know 
anybody who has a similar problem”. 
 
Several respondents used the internet to find information about their 
disease and treatments but reported that they found the information 
frightening.  
 
P18  “Sometimes looking at the internet doesn‟t help because it puts the 
wind up you, I‟ve stopped looking at that, you think oh my 
goodness, I‟ll start writing my last will and testament. I was a little bit 
weepy to begin with, particularly when I looked on the internet, well 
it was frightening, it didn‟t give me long really, I thought oh dear, and 
then you realise, it‟s treatable”. 
 
P6  ―I kept moaning I don‟t know enough about it, I found information on 
web frightening”. 
 
P4      ―I found information on the web frightening.‖ 
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Participants wanted information so that they could regain some control over 
their life and know when to seek help. 
 
P9    “You need to know that there is help out there you know, I mean 
some days having read the leaflets that they gave me at the outset, 
you should look for change in your own self as you feel unwell. But I 
don‟t know what these changes are I haven‟t got a clue. I mean a lot 
of days I feel awful and I think should I phone the GP, no I‟II see 
how it goes. And I just go like that cause I mean twice it‟s flared with 
me it has always been in the eyes. And I can tell by all of a sudden 
blurred vision, something‟s happening and then I get in touch with 
them. I mean other people will probably have different symptoms it‟s 
knowing what to look for I find that confusing. Knowing when to ring 
the doctor.You want to keep ringing the doctor every 5 minutes”. 
 
P22    ―Just anything really to help you to do things for yourself ”.  
 
P6   “Any information re diet, exercise, alcohol, what can we do for 
ourselves, want info re boundaries‖. 
 
P16  ―More information about blood tests, need to know about tests and 
how   vasculitis is diagnosed”. 
 
P2  “I was given a paper with lots of information, a leaflet abouit the 
Stuart Strange Trust. I‟d like to look at a leaflet and be given the 
opportunity to discus it with someone. I felt I wanted someone to 
reassure me I would be alright, but then I needed to get a bit better 
before I wanted all the information”.     
 
6.33 Access to knowledgeable practitioners”  
 
The third theme to be identified from the data analysis was ―access to 
knowledgeable practitioners―. Many participants recognized that the 
healthcare professionals they met in primary care (their GP and practice 
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nurses) and some doctors and nurses in secondary care had none or very 
limited knowledge of AAV.  
 
P11     ―GPs should know a little about it. About 50 doctors, not one of them 
had heard of it.You have to explain to doctors what your condition 
is, I might forget something that is important, don‟t know medical 
terms. She had never heard of it”. 
 
P13  ―My own honest feeling was that nobody seemed to know that 
much or they didn‟t give you the impression that they knew a great 
deal”. 
 
P3 ”I do find, I„ve got one doctor in our practice who was unhelpful, 
because I unfortunately broke my ankle, so I was still working at the 
time and I went in and he came into the surgery and he just looked 
at my notes and he said I don‟t know why you‟ve come here for to 
see me because I know nothing about your complaint and I was 
furious, well a good job because I‟ve come about my ankle, you 
know I was really really cross”.   
 
P2  ―Yes, nurses often don‟t know and doctors don‟t. I‟ve had doctors go 
and look it up, you know‖. 
 
Participants valued having access to practitioners who had real knowledge 
and experience of dealing with this AAV. 
 
P15 ‖I think knowing that I have got somebody on the end of a phone, if I 
want to get hold of nurse X, then I can or I perhaps have to leave a 
message for here at rheumatology , but nine times out of ten 
somebody will get back to me. I think knowing that or I could even 
come up here perhaps to the out patients, just knowing that these is 
somebody, who understands the situation, that does relive you but I 
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can‟t think of something else just knowing that there is somebody up 
here, who can understand what‟s going on‖.     
  
P12  ―The ones that do know, know an awful lot and the ones that don‟t, 
don‟t know anything about it‟. 
 
P5  ―The rheumatology helpline, I‟ve found that really good, I would go 
to rheumatology; I would initially ask rheumatology because they 
have the expertise‖. 
 
P4         ―If I have a problem I ring up X (nurse at hospital) rather than the 
               doctors”  
 
P6          “Access to knowledgeable nurse practitioners” 
 
P7  ―When I meet a brick wall at the doctors, anytime you want advice 
you‟re stuck It doesn‟t have to be a doctor, educate GP students, 
don‟t seem willing to pass on information back to us”. 
 
P3  “I never ever go to the doctor about ECPA I ring up nurse x. Well if 
you have a patient at the surgery with that complaint they should 
read up about it at least”.  
 
Conducting the one to one interviews did not yield any new information but 
validated the findings from the focus groups.  
 
6.4 Discussion 
 
This is the first study to explore what it is like to receive a diagnosis of AAV. 
The key findings are: i) when given the initial diagnosis, all patients 
described themselves as being too ill to take in information and later found 
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it difficult to recall what information they had been given; ii) the isolation of 
patients with AAV in coping with a rare disease that few people have heard 
of; iii) the uncertainty of a condition that will relapse and remit and the side 
effects and risks of complex medication regimes. The findings were similar 
to those of Waldron et al.,(2011) who studied the information needs of 
patients with systemic lupus erythematosus. These patients also had 
difficulty taking in information and wanted in-depth information and access 
to knowledgeable professionals. There are also some similarities with the 
informational needs of cancer patients, whose life threatening diagnosis 
causes them anxiety and fear and who also seek more information to 
enable their active involvement in their care, and to access accurate 
literature about their disease, investigations and treatments (Grahn & 
Johnson, 1990, Wingate & Lackey, 1989, Galloway et al.,1997,Liao et al., 
2007, Templeton & Coates, 2003). 
 
Receiving the diagnosis of a life-threatening disease, as well as being in 
pain, made it difficult for participants to understand information. One 
participant felt that experiencing such traumatic events affected her recall of 
the information she had been told. Thus for these patients, the timing of the 
information is significant to its value for them. This is a similar finding to 
cancer patients who when confronted with a poor prognosis did not recall 
much information after receiving the bad news (Jansen et al , 2008). 
Another participant described how the unfamiliarity of the circumstances 
meant that she did not know the questions to ask to get the information she 
wanted. Other participants had difficulty understanding some of the medical 
terminology used highlighting that information given to patients must be in a 
language they understand. Information sharing is seen to be a two way 
process and not simply a question of conveying specialist information to 
less informed people. Participants needed time to absorb information at 
their own pace to inform the basis for their questions. Written information 
would support this education process by giving time for patients to 
appreciate the meaning and then to internalise what it means to them. They 
could then prepare their questions ahead of meeting the doctor. For 
participants the diagnosis of a rare condition was frightening and this may 
have impeded their ability to retain information, as anxiety is known to 
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reduce concentration and information recall (Gustafson et al., 1999, 
Kessels, 2003, Stephenson, 2006). 
 
6.41 Diagnostic delay 
 
Some participants experienced a delay in diagnosis of AAV and this was 
linked to their symptoms not being taken seriously when consulting with 
health care practitioners. Several participants felt that their symptoms were 
not being listened to and not believed and many were told that ―you‘re not 
ill‘. This led to frustration and as a consequence many participants had 
consulted several different doctors, had many investigations and tests 
before a diagnosis was reached. This difficulty and delay in diagnosis 
meant that some patients sought validation of their symptoms and for them 
not to be dismissed. For some people it was a relief to know they had 
something wrong and for others it was anger at the way they had been 
treated. These findings support Main‘s four reasons that patients consult 
with health care practitioners namely to seek reassurance, to get a cure or 
relief from their symptoms, get a diagnosis and legitimisation of their 
symptoms (Main et al., 2010).  
 
It is recognized that AAV is difficult to diagnose due to the wide spectrum of 
clinical presentations that may mimic many diseases (Watts & 
Dharmapalaiah, 2012). Patients can present with life threatening illness 
requiring urgent medical treatment or with general symptoms of fever, 
malaise, weight loss, headache and arthralgia that are common and could 
be due to a number of other conditions (Scott & Watts, 2000). Furthermore, 
diagnostic delay is common in rare diseases (Eurordis, 2008, Huyard, 
2009, Jayne 2009, DH, 2013) and one study reports 46% of patients 
waiting more than a year to get a diagnosis, 20% over five years and 12% 
over ten years (Limb & Nutt, 2011). Because of the rarity of AAV, GP‘s are 
likely to have little knowledge or experience of vasculitis and many may not 
even have seen a case of AAV before.  Besides it would be unrealistic to 
expect GP‘s to be knowledgeable about all rare diseases as there are more 
than 600 rare conditions. One participant recognized this and was not 
critical of his GP as he felt that they had a difficult job (P6:120). However, 
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for some participants their GP recognized that their condition was serious 
and they were referred promptly to a specialist for early diagnosis. This first 
theme identifies that patient education begins very early on the disease as 
soon as the patient receives the diagnosis (Kohen & Esdaile, 2008). 
However this can be a challenging time for patients as the majority of 
patients were anxious and frightened and this can impede information 
recall. Therefore, clinicians should be aware of a patient‘s emotions during 
a consultation and deal with then before imparting information (Sep et al., 
2014).    
 
6.42 Finding out about Disease Management 
 
The second theme was ―finding out about disease management‖. It was 
clear that participants wanted information about their disease, medications 
and how to manage their condition. However, while participants explicitly 
discussed their need for ‗information‘, the evidence showed that this had 
two dimensions: one concerned AAV-specific factual information (product) 
and the other concerned the educational process of internalizing and using 
the information that had been given in actively managing their lives. 
Patients with AAV often face an initial challenge when being told that they 
have a potentially life-threatening disease requiring urgent therapy with 
potentially toxic drugs. Consequently, any education at this time typically 
focuses on starting their urgent treatment and securing consent for their 
chemotherapy. This may explain why many were confused as to why they 
required chemotherapy, and associated this with cancer. A possible 
explanation is that they were familiar with the term ―chemotherapy‖ and 
knew that this was used to treat cancer. It is likely that they were frightened 
and anxious and just heard the word ‗chemotherapy‘ and focussed on that 
without listening to the rest of the conversation. It is possible that due of the 
seriousness and complexity of their condition, doctors were concentrating 
on preserving life and organ function that they did not check the patient‘s 
understanding of what was said to them.This is a crucial time for patients 
and supports the need for information at this time, so that they can 
understand why they are receiving chemotherapy but how this is handled is 
extremely important as it may heighten patients‘ fears. 
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Therefore, it is important to acknowledge that patients psychological needs 
may be as important as their physical ones in the management of AAV and 
should no longer be ignored (Koutantji et al.,2003). Research has shown 
that AAV patients have reduced health-related quality of life, both physically 
and emotionally (Hoffman et al.,1998, Koutantji et al.,2003, Carpenter et al., 
2009, Basu et al., 2010, Walsh et al., 2011, Basu et al., 2013, Grayson et 
al.,2013. There is a psychological burden of disease associated with AAV 
and health care professionals should assess individuals‘ psychosocial 
status and quality of life during routine follow up (Flossman et al .,2007, 
Miller et al., 2010). 
    
While participants highlighted the need for psychological support, they also 
wanted information about their disease, medications and how to manage 
their condition.Most participants received verbal information about their 
disease from the doctor who treated them in hospital. However, a worrying 
number of participants reported not receiving any information at any stage 
of their illness. Participants said that they wanted a wide range of 
information concerning their disease, treatment and side effects.This 
supports the research by Thorpe et al. (2007, 2008), who assessed the 
self-management behaviours of AAV patients and found that patients 
experienced difficulty in being able to self-manage medication side effects, 
infection avoidance and knowing which symptoms to report to doctors. 
Carpenter and colleagues found that doctors were the most frequently used 
source of medicines information, followed by the internet and lastly 
pharmacists (Carpenter et al., 2012). This is supported by the comment 
made by respondent (P2:122), she kept asking the doctor questions about 
her medication to learn more about her treatment. Conversely, respondent 
(P14: 123) did not receive any medicines information other than the insert 
in the medicines package and did not realise that he could have asked the 
pharmacist for more information. This supports the findings from 
Carpenters study where the participants rarely used pharamacists to seek 
more information. This could be because of the rarity of AAV, patients may 
feel that like GP‘s, pharmacists have little knowledge or experience of 
vasculitis.  Although, several respondents used the internet to find 
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information about their disease and treatments, they found the information 
frightening. However, the credibility of the websites visited was not 
assessed.    
  
A recent study found that respondents had poor knowledge of the side 
effects of medications used to treat AAV (Brown et al., 2012). This is 
worrying as infection secondary to therapy in the early stages of the 
disease increases mortality in the first year (Little et al., 2010). It is vital that 
patients are informed of the risks associated with medications used to treat 
AAV so that early recognition of side effects can occur. 
 
On the other hand, there is a significant amount of information for patients 
to absorb and try to understand at the time of diagnosis and patients forget 
between 40-88% of information given to them (Anderson et al., 1979, Ley, 
1989, Kessels, 2003, Jansen et al., 2008). One of the early studies was of 
patients attending a rheumatology clinic and more than half wrongly 
remembered medical information given (Anderson et al., 1979). Older age 
has been associated with less recall in cancer patients when large amounts 
of information are given (Jansen et al., 2008). Furthermore, time constraints 
especially during in-patient says have resulted in patients being 
overwhelmed with medical explanations and jargon (Schillinger et al., 2003; 
Street, 1992; Maddock et al., 2011). Therefore, timing and the amount of 
information given is crucial if we are not to overload patients with vast 
amounts of information. One participant (P:118) explains that information 
needs to be given in bite sized chuncks so that patients can take it in and 
make sense of it and build upon this information.  This is a similar finding to 
Donovan & Blake (2000) who found that patients attending a rheumatology 
clinic needed to make sense of what the doctor had told them and 
internalise what it meant for them.   
 
A systematic review of interventions to improve cancer patients recall of 
medical information found that adapting information to individual needs plus 
the use of audiotapes or the use of a question prompt sheet were more 
effective in patient recall of information, but the number of studies included 
in the review were small (Van der Meulen et al., 2008). Some doctors are 
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now sending patients a copy of the out-patient clinic summary letter that is 
sent to the GP, so that patients have a record of what was discussed during 
theconsultation. Whilst this is good practice, the information included in the 
letter is likely to be full of medical terminology and may be difficult for 
patients to understand. The systematic review concluded that there is little 
research into the effectiveness of providing patients with summaries of 
copy letters, however this is an area for future research (Van der Meulen et 
al., 2008). 
 
Participants also wanted to know more about their condition and 
medications. Some talked about the complexity of medication regimes and 
what this meant for them in terms of dealing with the disease and possible 
side effects of medication. Despite these overwhelming needs for 
information, education about these issues was not a routine part of their 
disease management. For those that had been given information about 
their medications some received conflicting information from two different 
doctors and were confused as to which advice they should follow. This 
supports Carpenter et al‟s (2010) finding that over half of AAV patients 
received conflicting medication information and that vasculitis doctors 
differed greatly in what information they gave patients about the risks and 
side effects of medications (Cozmuta et al., 2013). Participants appreciate 
the need for information so they can manage their own drug regime and 
any side effects. Yet for many their only source was the printed information 
on drug packaging, creating considerable anxiety for patients, and under-
confidence when managing their medication. Patients need to understand 
the importance of taking their medication as prescribed as non-adherence 
is linked to poor outcomes (WHO, 2003).  
 
6.43 Internet 
 
The internet is increasing being used as a medium for accessing health 
information and some participants in the absence of information given to 
them searched for this on the web and this heightened their anxiety. 
Patients may not be aware of the accuracy, currency or applicability of what 
information they have found. It seems poor practice to leave these patients 
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to search for material themselves, which might not be accurate, when it 
could be given to them by their consultant or a specialist nurse. These 
patients should be signposted by health care professionals to endorsed 
websites where information is accurate and reliable. GP‘s and other 
primary care staff also need to know where to access such information. 
This is recognized as a problem and one of the recommendations in the 
Rare Disease UK Strategy is that experts should signpost patients and 
health care professionals to recommended websites for further information 
(DH, 2013).  
  
6.44 Knowledgeable practitioners  
 
Participants reported that they wanted access to, advice from and 
treatment by knowledgeable practitioners. However, many expressed their 
frustration at the low levels of knowledge of both primary and secondary 
healthcare practitioners about the diagnosis and management of AAV.This 
mirrors a survey of approximately 600 patients and families, carried out by 
Rare Disease UK, which found several shortcomings in care. Just under 
half (46%) had waited one year to be diagnosed, 52% had not received 
sufficient information about their condition and 37% had had no one to 
contact regarding questions about their illness (Limb & Nutt, 2010). Of 
those who had received information (65%), this had been provided by a 
specialist doctor.  
 
Rare diseases pose numerous challenges to both healthcare professionals 
and the patients. Ignorance of individual rare conditions is common 
amongst both groups.Because of the rarity of AAV, GPs are likely to have 
little knowledge or experience of vasculitis. Therefore, patients may need 
support and information about how to access the expertise that they seek 
within the complex system of AAV healthcare management, which is likely 
to be outside their previous experience. While they may expect to gain 
most of their treatment and advice from their GP, they may not realize that 
they can also access the AAV specialist who is responsible for managing 
their condition. They also may not be aware that they can ask their GP to 
refer them to medically expert advice and care, or that their GP‘s may not 
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have adequate knowledge, skills or experience to deal with their 
informational needs or concerns and what they need to do within the 
system to access it. 
 
The rarity of the condition means that patients have no ready sources of 
information from within their community, as it is very unlikely that there will 
be another person with AAV within their social network. This exacerbates 
the lack of knowledge within the non-specialist medical community. 
Patients expressed the wish for specific forms of information. They wanted 
positive but direct information in booklet format which they could revisit 
when they felt ready. Serious, possibly life-threatening illness causes 
anxiety and fear, and this can impede information retention, assimilation, 
understanding and recall. Patients wanted the unfamiliar terminology that 
they were now encountering to be clarified. Having an education booklet 
would be in keeping with numerous other conditions, both common and 
rare, for which such booklets are available. Given the limited information 
that study participants with AAV received, this is likely to be of enormous 
value at both the acute and chronic stage. Participants also wanted the 
opportunity to discuss such information with a knowledgeable health care 
practitioner.  
 
Despite participants high informational needs and their need for general 
support to help them live with their condition, they were, in the main, unmet 
by doctors and nurses.These deficits may be partially addressed by 
developing networks of multi-disciplinary professionals with expertise who 
can be called upon to provide advice. A number of recent documents have 
highlighted the need for patients with rare and complex conditions to be 
managed in networks (DH, 2013, Rare Disease UK, 2012, EU 2009). 
 
6.5 Limitations  
 
There are some limitations of the first phase of the study. ―All vignettes 
declare their constructedness, loud and clear‖ (Spalding & Phillips, 2007). 
Not only are the vignettes to some extent fabrications, the occasions where 
they are used are deliberately set up as a research-specific event. 
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Therefore it is important to acknowledge that they influenced, at least 
initially by the subject of the focus group discussions. This vignette could be 
seen to be validated because it was found to be, for many, reflective of their 
individual experiences and thus it stimulated them to tell their stories to 
getting diagnosed. The few patients who had not had difficulty getting a 
diagnosis of AAV were also happy to highlight that the vignette was not like 
their experience so the discussions were not limited by the vignette. Neither 
were the discussions limited to diagnosis events, because the participants 
having been stimulated to reflect on their experience of getting a diagnosis, 
could then think about what would have helped them during this period of 
finding out about their illness and what education they would have valued, 
which was the point of the research. Thus the use of vignettes was found to 
be an very suitable method to generate discussions amongst a group of 
individuals who had never met in this way before, who may have been shy 
about sharing difficult personal circumstances, and who may not have been 
able to suggest informational needs if they had not had access to a vignette 
to stimulate their reflections. Whether the vignette was or was not wholly 
representative of every individual experience, it did stimulate insightful 
discussion in the focus groups. 
  
Although, participants were purposefully chosen to represent different 
disease subtypes and different disease durations. There were more 
females than males in the focus groups, unfortunately three males declined 
at the last minute and replacement participants were not able to be found at 
short notice. There were more patients with GPA in the sample.    
 
6.6 Conclusion 
 
The diagnosis of a rare, life-threatening disease causes extreme anxiety 
and fear, impeding information retention and recall.  Additionally, the timing 
of information is crucial, as patients have difficulty assimilating information 
when acutely ill.  All participants desired information about their diagnosis 
and treatment and wanted written information but value having the 
opportunity to discuss it with a knowledgeable healthcare practitioner. 
Patient education needs to be tailored to individual needs on the illness 
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pathway. Respondents expressed their frustration at the lack of knowledge 
and awareness of rare conditions amongst health care professionals. 
Participants reported that they wanted access to, advice from and 
treatment by knowledgeable practitioners. The consequence of a diagnosis 
of AAV is significant and impacts many aspects of individuals‘ lives and 
should not be underestimated by health care professionals‘.   
 
6.7 Summary 
 
In summary, the first phase of the study highlighted that these participants‘ 
needs were often overlooked in routine practice. If we are to implement the 
first key area of improvement in the governments‘ Rare Disease Strategy 
UK  that of ‗empowering patients‘ (DH, 2013). First we need to understand 
what patients want to know about their illness so that information and 
education can be tailored to meet their needs and priorities, so that they 
can truly participate in shared decision making and make informed choices.  
As we know very little about the informational needs of this group the 
themes from the first phase were used to guide and inform the 
development of a Vasculitis Informational Needs Questionnaire which was 
used in the second quantitative phase to survey the membership of VUK 
and the VCRC. The next chapter will present the results of the second 
quantitative phase of the study. 
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Chapter 7 Survey results 
 
This chapter will present the results of the second quantitative phase of the 
study. The characteristics of the two samples will be described and the 
results for the VINQ will be presented for the two groups.    
 
7.1 Results   
 
A total of 600 questionnaires were posted with the regular newsletter to the 
membership of VUK.  A total of 397 were returned, 63 were excluded 
because they did not have a diagnosis of AAV, and 40 were returned 
unopened by the Royal Mail as individuals no longer lived at the mailing 
address. A total of 314 questionnaires were available for analysis, a 52% 
response rate, of these 255 had (GPA), 46 (EGPA) and 13 PAN (Figure 
11). 
 
 
Figure 11 Survey response Vascuiltis UK 
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An email was distributed to 2740 registrants of the VCRC with two 
reminders to those who had not replied after three and six weeks. There 
were 387(14.1% response rate) respondents from the VCRC, of whom 114 
reported a diagnosis other than AAV. The remaining 273 (10%) 
respondents from the VCRC with a diagnosis of AAV were included in the 
study (Figure12). 
Figure 12 Survey response VCRC 
 
7.2 Demographics of respondents  
 
The demographic characteristics of both groups of respondents are shown 
in table 12. The disease subtype distribution was representative of the 
whole survey population. The total sample population for inclusion in the 
study was 587, with 287 (49%) male and 300 (51%) female, 448 (76%) 
GPA, 105 (18%) EGPA and 43 (6%) MPA with a median age of 60 (range 
51-67). The VUK group had 314 respondents, 198 (63%) male and 116 
(37%) female, 255 (81%) GPA, 46 (15%) EGPA and 13(4%) MPA with a 
median age of 63 (range 52-70). The VCRC group had 273 respondents, 
88 (33%) male and 184(67%) female, 193 (71%) GPA, 59 (22%) 
EGPA and 21(8%) MPA with a median age of 58(range 49-64). The VUK 
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respondents were older than those from the VCRC, and the VCRC sample 
had a greater proportion of women than the VUK sample. There were more 
respondents with GPA (255) in the VUK group but the VCRC group had 
more MPA (21) and EGPA (59).  
 All 
Subjects 
Vasculitis 
UK 
VCRC 
Study Group Characteristics    
Group Size 587 314 273 
Age: median (range) 60 (51-67) 63 (52-70) 58 (49-64) 
Males  287 (49) 198 (63)   89 (33) 
Women n (%)  300 (51) 116 (37) 184 (67) 
GPA n (%)  448 (76) 255 (81) 193 (71) 
MPA n (%)    34 (6)  13    (4)   21   (8) 
EGPA n (%)  105 (18)  46   (15)   59 (22) 
Self-reported ethnicity white 560   (95%)  295 (94%) 265 ( 97) 
Table 10 Demographics of respondents of VUK and VCRC 
The age range of the sample is shown in figure 12 .There were seven 
respondents aged <24 years (1%), 27 aged between 25-34 (5%), 57 aged 
35-44 (10%),103 aged 45-54 (17%),198 aged between 55-64 (43%),136 
aged 65-74 (23%) and 59 aged over 75 years (10%). One third of the 
sample were < 54years, one third were between 55-64 and another third 
were over 65 years.  
 
Figure13 Ages of respondents of VUK and VCRC 
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The distribution of disease duration (self- reported date of diagnosis to date 
of questionnaire completion) is shown in figure 14 and is seen to be shorter 
in the VCRC group than the VUK group, 16.4% of the VCRC had a disease 
duration of < 1 year compared with 6.1% of the VUK group. However, the 
VUK group had more respondents with longer disease duration >11-15 
years 77(24.5%) and 47(15%) over 15 years, compared to the VCRC group 
of 35(12.8%) and 18(6.6%). The VCRC respondents reported their origin as 
86% North American (86%) and European (12%). 
 
Figure 14 Disease duration of respondents 
 
7.3 Time to diagnosis  
 
In this sample time taken to be diagnosed varied, over a quarter (189)were 
diagnosed within three months of the onset of symptoms, over a third 
received a diagnosis  within a year (220) and a further  92 were diagnosed 
within one to two years. However for some it took three to five years to 
obtain a diagnosis (44) and for others it took more than five years to be 
diagnosed (42) (Figure 15). 
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Figure 15 Time to diagnosis 
 
7.4 Educational attainment 
 
In the VUK cohort, 118/314 (37.5%) were educated to school- leaving age 
(14-16 years depending on date of birth) without necessarily obtaining any 
qualifications, 121/314 (38.5%) had A levels or some further education but 
not to bachelor‘s degree level, 53/314 (16.8%) had a bachelor‘s degree or 
higher. In the VCRC cohort, 32/273 (11.7%) were only educated to high 
school leaving or lower, 91/273 (33.3%) had received some further 
education but not to bachelor‘s degree level and 154/273 (54.9%) were 
educated to bachelor‘s degree level or higher (Table 11).  
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Table 11 Educational attainment of participants 
 
7.5 Information at diagnosis 
 
Nearly all respondents reported that they had never heard of AAV before 
(VUK 96% and VCRC 95%). When first diagnosed 39.1% of VUK and 
30.7%% VCRC respondents reported not receiving any information. Of 
those that did receive information about their condition, the majority 
received this information from a doctor (60% VUK and 68% VCRC), a 
nurse (4% VUK and 11% VCRC), and one participant in each group 
received information from a relative and other sources (10% VUK and 19% 
VCRC). Within the group of others a number received information from a 
support group. 
 
 
Figure 16 Who provided you with information at diagnosis? 
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Figure 17 How was information provided?  
 
7.6 Informational needs 
 
The informational needs of both groups of participants are high (Figure 18, 
table 12), with all questions about specific needs scoring at least 3.0/ 5.0. 
The domains that were given the most importance covered questions about 
diagnosis,investigations and treatment (median 4.5), with psychosocial 
aspects given least importance (median 3.1). There was no difference in 
the pattern of responses between the VUK and VCRC groups (p>0.717). 
There was no difference in informational needs by gender as shown in 
figure 19 (p>0.139) and largely self- reported disease subtype (p> 0.304) 
(Figure 20).  
However disease duration and age did show some differences but these 
were not staitistically significant (p>0.928)(Figure 21). Those with a short 
disease duration of <6 months scored lowest in the psychosocial domain 
with a median score between 2.6 and 3.0 indicating that they were only 
moderately important. Those who had their disease for one to two years 
scored a median of 4.0 for all the questions in the psychosocial subset 
indicating that this was very important to them. Those with longer disease 
duration >3 years appeared to still have high information needs in all of the 
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domains, with a median score of 4.5 for disease, investigations and tests 
and treatment, physical 4.0 and psychosocial 3.5.  
Variances were seen for two questions in the disease subset and one 
question in the physical subset for those with a short disease duration of <6 
months. The question ―Whether my vasculitis is hereditary‖ scored a 
median of 3.9 (p>0.233)and the question ―If vasculitis is contagious‖ scored 
a median of 3.8 (p>0.181) compared to a median of 4.5 for all other groups. 
The question 27 ―If I can continue my usual sports and hobbies‖ scored a 
median of 2.7 (p>0.717) compared to a median of 4.2 for all other groups.
 
Figure 18 Median scores VUK and VCRC 
 
 All 
Subjects 
Vasculitis 
UK 
VCRC 
Ratings of Informational 
Elements 
   
Diagnosis (inc prognosis) 4.5 4.5 4.5 
Investigations (type + results) 4.5 4.5 4.5 
Treatments (inc side effects) 4.5 4.5 4.6 
Life style 3.6 3.5 3.7 
Patient support groups 4.5 4.4 4.6 
Psychological care 3.1 3.1 3.0 
Table 12 Median Score of subsets of VINQ 
 147 
 
 
 
 
Figure 19 Median scores male /female 
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Figure 20 Median score disease subsets means 
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Figure 21 Median scores disease duration 
 
 
7.7 Age Range 
 
In response to how the informational needs were perceived according to 
age, a few differences were observed in the younger patients (>24 years) 
but these were not statistically significant (p>0.231). These related to the 
domain of investigations and tests in which they scored these questions 
slightly lower than the rest of the age groups (median 4.0 v‘s 4.5) (Figure 
21).   
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Figure 22 Median scores by age range  
 
 
7.8 Comparison with cancer 
 
 
The informational needs of participants with AAV were compared with 
patients with cancer previously reported using the TINQ (Harrison et al., 
1999. Graydon et al.,1997). Patients with vasculitis and cancer both 
required high levels of information, particularly the disease and treatment 
domains. For both groups, information about psychological aspects was 
much less desired (Table 13).    
 
 
Subscale TINQ median %  VINQ median % 
Disease 89.2 90.1 
Tests 84.8 90.4 
Treatment 88.9 92.0 
Physical 80.8 86.0 
Psychological 70.9 59.0 
Table 13 Toronto cancer informational needs and vasculitis informational 
needs median scores by domain 
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7.9 Preferred for source of information. 
 
Participants in both the VUK and VCRC groups were highly desirous that 
information be provided by a doctor and supported by written material. In 
the VUK group the order of preference was: doctor and written material, 
written material alone, doctor alone, internet, group education, DVD, CD 
and 1-2 day course. In the VCRC group the order was Internet, doctor and 
written, doctor alone, written alone, education group, digital video disc 
(DVD), 1-2 day course and compact disc (CD).  
 
 
7.10 Internet  
 
All respondents in the VCRC group had access to the internet, compared to 
68% in the VUK group.  Just over a quarter (28%) of respondents in the 
VUK  group did not have access to the internet, of these the majority were 
over 65 years of age (59), thirteen were >55-65 years, seven were aged 
between 30-55 years and one participant was less than 30 years.  
 
7.11 Useful Information 
 
From the open ended question that asked respondents to provide details of 
any information that they had found useful about their condition.  A thematic 
analysis revealed that the internet was frequently used to find information 
and this was found to be invaluable. One responsent wrote ―Internet was 
terrific source of information, more so than doctor”. Support groups were 
another valued resource both online and face to face. Many reported that 
they had received excellent disease specific information from patient 
organisations in particular VUK and the Vasculitis Foundation.  Some 
respondents described accessing medical books and medical papers to 
discover more information. A few participants remarked that the specialist 
nurse was helpful and many commented that written material from the 
hospital, support groups and ARUK was very useful.      
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Although some respondents reported being given information at diagnosis, 
they also had difficulty remembering what was said to them and also used 
the internet to find information. One participant wrote:   
 
―The doctors at hospital X gave me a little information but I was 
really too weak, confused and attempting to put my life back 
together, to take much in. My cousin went on the VUK website to 
find information and at that point we realised all my mystery 
symptoms of the past 18 months were caused by EGPA‖. 
  
One participant who did not have access to the internet found it difficult to 
find information and wrote: 
 
“.Apart from the ARUK leaflet, unless you have access to a 
computer there is very little information available”. 
 
Some respondents read medical books and used the local library to copy 
pages from medical books.   
 
In summary, the second phase of the study highlighted that participants 
with AAV required a considerable amount of specific information 
concerning their disease, treatment regimens and side effects and the 
results of investigations and tests. Individuals preferred to receive this 
information from a doctor. The next chapter will discuss the results of the 
second phase of the study.   
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Chapter 8 Discussion 
 
 
This is the first study to explore the informational needs of participants with 
a rare chronic rheumatic disease and it makes a significant contribution to 
our knowledge about the education of patients with AAV. A cancer-specific 
informational needs questionnaire was adapted for use in AAV 
incorporating patient data from focus groups and one to one interviews. 
The VINQ demonstrated excellent survey reliability in two independent 
cohorts of participants. The results showed that respondents with AAV 
have significant informational needs that do not differ greatly by country of 
origin, sex, age, disease duration, or AAV subtype. 
 
8.1 Informational needs 
 
The results from the survey demonstrate that when diagnosed with a rare 
potentially life threatening illness, participants have significant informational 
needs about their disease, treatment and management. Participants ranked 
information about the disease as very / extremely important. They wanted 
to know certain information about their condition, such as the name of their 
vasculitis, its cause, whether it is hereditary or contagious.The diagnosis of 
a rare disease that respondents had never heard of before, meant that they 
sought information to try and understand what was happening to them. This 
was because they did not have any prior knowledge or experience of 
vasculitis to draw upon. 
 
The participants also desired accurate information about AAV for example 
what the symptoms are and how is it diagnosed. Participants in both the 
VUK and the VCRC groups wanted a great deal of information about 
investigations and tests, they needed to know why they had x-rays, 
biopsies, scans and blood tests and the results of these. This is not 
surprising as many investigations and tests will have been requested and 
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performed by various clinicians in trying to establish a diagnosis of AAV. 
Nonetheless, it is important that clinicians explain to patients why they are 
requesting certain tests and investigations and the results and significance 
of these. In fact during the pilot of the VINQ, none of the participants with 
AAV had heard of the antibody ANCA, which is a test that can be helpful to 
aid diagnosis of AAV.   
Similarly, respondents with AAV consistently ranked information related to 
treatment as either very important or extremely important. They wanted to 
know the names of drugs used and their side effects. This is also supported 
by comments made in the qualitative first phase (P2, P7, P16: p118). They 
desired detailed advice on side effects of medications, what side effects to 
report to the doctor or nurse and who they should call if they have any 
concerns. Furthermore, they wanted information on how long they would 
require treatment, the evidence base for the treatment decision and how to 
prepare for treatment. These findings are important because medications 
are vital to patient survival but are associated with increased risk of serious 
toxicity (Phillip & Luqmani, 2008). Cyclophosphamide and steroids are 
commonly used to induce remission, but patients need careful monitoring to 
observe for potential side effects (e.g. bone marrow suppression, 
haemorrhagic cystitis, infections, increased risk of bladder cancer, infertility 
and malignancy (Monach et al., 2010). Once remission is achieved an 
immunosuppressant such as azathioprine or methotrexate or leflunomide or 
MMF are used as maintenance therapy for at least 12-18 months. These 
medications also have to be monitored for possible side effects such as 
bone marrow suppression (Appendix A).      
In the first year of diagnosis AAV still has a mortality of 11.1% (Little et al., 
2010). The major causes of death were active uncontrolled vasculitis, 
infection secondary to therapy in the early stage of disease and 
cardiovascular disease during the chronic follow up phase (Luqmani et al., 
2011). It is vital that patients are fully informed of the reason and need for 
medication, the possible side effects and the monitoring process. They 
should receive information on what signs or symptoms to look out for, what 
to report to the doctor or nurse so that prompt treatment of infection or early 
recognition of drug toxicity occurs. They should also know when to have 
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regular blood tests for monitoring of immunosuppressant medication. It is 
known that patient‘s poor understanding of their condition and medications 
is linked to non-adherence with medications and poor health outcomes 
(NICE, 2009). Providing patients with written instructions of their medication 
regime, including how and when to take medications, has shown to be 
effective in aiding adherence and in reducing the incidence of adverse drug 
reactions (NPC, 2007, NICE, 2009). 
AAV often presents with a fulminating life-threatening illness requiring 
urgent therapy and there may not be time for much education before 
treatment is begun. Additionally, this can be an extremely emotional and 
stressful time for patients who are trying to come to terms with the 
diagnosis of a serious illness, as described by the participants in the first 
phase of the study. Nonetheless, it is important that clinicians recognize 
that patient‘s informational needs are great and provide them with 
information about their medications and potential side effects. Key 
information may need to be given first and this should then be followed up 
later with more detailed information about their medications and side effects 
and supported with written materials as they cannot remember everything 
that they were told. This is supported by Kessels who advocates that the 
most important information should be given first (Kessels, 2003).  
 
Respondents in this study had a great need for information on their 
disease, medications and side effects. This is supported in the cancer and 
rheumatological lliterature (Donovan, 1991, Galloway et al., 1997, Neville et 
al., 1999, Fraenkel et al., 2001,Templeton & Coates, 2003, Adad et al., 
2004, Arvidsson et al., 2005, Naeme et al., 2005, Makelainen et al., 2009, 
Schouffoer, 2011, van der Vaart et al., 2013). It is widely accepted that 
people with cancer want information (Girgis et al., 2000, Sanson-Fisher et 
al., 2000, Tamburini et al., 2000). In particular, they want information on 
their disease (Wingate & Lackey, 1989, Grahn & Johnson, 1990, Galloway 
et al., 1997, Liao et al., 2007, Sutherland et al., 2009) investigations (Cook 
& Gotay, 1984, Derdiarian, 1986, Liao et al., 2007) and treatments 
(Galloway et al., 1997, Jones et al., 1999, Liao et al., 2007). A systematic 
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review of cancer patients information needs by Rutten et al., (2004) found 
the most important need was for information on treatment. 
 
A survey of Canadian rheumatology patients found that 90% were very 
interested in receiving information about their disease and treatments 
(Neville et al., 1999) and this is supported by Fraenkel and Neame who 
found that patients desired a great deal of information about their 
medications and side effects (Fraenkel et al., 2001, Naeme et al., 2005). 
Similarly, Adab et al., (2004) found that 79% of patients wanted information 
on side effects of medication available in an arthritis education resource 
centre. In contrast only 38.4% of health care professionals felt this should 
be provided. The exact reasons for this discrepancy are unknown but it 
may be that there was an expectation that this information would have 
already been provided by the doctor who diagnosed their arthritis. Or it 
could simply be that health care professionals underestimate the amount of 
information patients want. Or that there is a mis match between what the 
health care professionals think /assume the patients need to know and 
what patients actually need to know (Sullivan et al., 2001).  
 
It was clear that participants with AAV wanted a great deal of information 
about their medications and possible side effects. This finding is relevant 
because a lack of information and understanding of medication regimens 
can lead to non-adherence and poor clinical outcomes (Carpenter et al., 
2011, Carpenter et al., 2013). A study in the USA found that patients with 
AAV had difficulty adhering to complex medication regimens and were slow 
to report symptoms and medication side effects (Thorpe et al., 2008). This 
may be attributed to patient‘s poor knowledge of the side effects of 
medication (Brown et al., 2013). Or it could be because they are taking 
many different medications such as immunosuppressants, anti-
hypertensives, treatment for other chronic illnesses and found it difficult to 
remember large amounts of information. Another possibility could be a 
deficit in education provision by health care professionals, or a lack of 
understanding of the potentially serious side effects of medications used to 
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treat AAV. An inpatient vasculitis education program in Germany showed 
that improvements in a patient‘s knowledge of medications and side effects 
led to an increase in health related quality of life (Herlyn et al., 1997). 
Patients with AAV have have to manage the challenges and complexities of 
living with a long-term condition and its unpredictability (DH, 2005). 
Aqualitative study of 20 rheumatology in-patients in Sweden showed that 
patients wanted more information about their medications and wanted to be 
more involved in their care (Arvidsson et al., 2005). Although, some 
patients were relieved that the nurse was responsible for administering their 
medications during their stay, others questioned why they could not self-
medicate, as when they were discharged this would become their 
responsibility. It is surprising that during a three to four week hospital stay 
patients still had information needs. It could be that nurses underestimate 
the amount of information patients want or they do not have the knowledge, 
skills and competencies to deliver such information. A qualitative study of 
in-patients perceptions of medication information provided by rheumatology 
nurses in Sweden found that there was variation in the amount of 
information given to patients (Makelainen et al., 2009). Some patients were 
satisfied with the information given to them and participated in shared 
decision making but others were dissatisfied with the lack of information 
given to them. Many reported not receiving adequate information, with 
some only being told the name of the new drug they had been prescribed. 
The reasons for dissatisfaction were attributed to a lack of time, information 
provided was standardised and not tailored to patient‘s individual needs.  
This was a small qualitative study of 15 patients in one hospital and the 
findings may be different in different units. Nonetheless, the results are 
similar to the study by Arvidsson et al., (2005). 
 
A lack of personalised care for people living with a long-term condition has 
recently been recognised (Coulter et al., 2013). The report by The Kings 
Fund identifies the need for a radical redesign of the way services are 
delivered to patients with a long-term condtion in England (Coulter et al., 
2013). They propose a ‗house of care model‘ in which the patient is at the 
centre of care. In this model patients are actively encouraged to develop 
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personalised care plans supported by shared decision making with their 
clinicians.  Key to this process is the sharing of information between the 
patient and the clinician to maximise the patients‘ preparedness for their 
consultation. In order that patients are prepared for their consultations, they 
are sent out the results of tests and inverstigations and they are signposted 
to additional credible information sources. So that when they come to their 
consultation, they have prepared a list of questions that address their 
concerns and needs.   
 
The informational needs of the VUK and the VCRC group are high (Figure 
18, table 12), with all questions about specific needs scoring at least 3.0/ 
5.0. The domain given the least importance with a median score of 3.1 was 
psychosocial. We know that many aspects of quality of life are impaired in 
AAV, with significant levels of depression and anxiety (Koutantji et al., 
2003, Herlyn et al., 2010, Tomasson et al., 2012, Basu et al., 2013, 
Brezinova et al., 2013). Despite the psychological burden of disease 
associated with AAV, participants were relatively less interested in 
receiving information related to the psychological aspects of disease 
management, a finding that parallels the informational needs of patients 
with cancer (Graydon et al., 1997, Templeton & Coates, 2003).  
 
This is a surprising finding as the results from the first phase of the study 
suggest that the psychological impact of a diagnosis of AAV is significant, 
causing anxiety and distress. One explanation for the lower priority of 
psychological support found in this study could be due to the fact that this 
reflects the questions asked in the VINQ and TINQ and that the VINQ 
inadequately assessed the psychological needs of these patients. As 
participants may have been inhibited by the use of the word psychological, 
however, only one question directly asked about accessing psychological 
support. It is also possible that participants, by joining a group, are getting 
informal psychological support and therefore feel less need to know about 
the availability of other sources of such support. Alternatively, group 
members may be more independent and may not need further support. In 
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contrast, prior to setting up a general arthritis education resource, support 
was high on a list of desired features in a needs assessment of what should 
be provided conducted (Adab et al., 2004). Likewise, a large postal survey 
of 12,000 patients from eighteen European countries with eight rare 
conditions, found that 87% wanted psychological support at diagnosis (Kole 
& Faurisson, 2009). The question in this survey asked ‗should 
psychological support be provided at diagnosis?. So it appears that the 
word psychological did not put respondents off answering this question, as 
many individuals interpret the word psychological as being ‗in your head‘.  
Although this was a large survey, only a small number of rare diseases 
were studied and AAV was not one of them. So the fact that respondents 
with AAV reported lower priority for psychological support, these results 
should not be interpreted that these participants may not need 
psychological support as only 15% of respondents rated it as not important 
and 12% as slightly important, with the remainder 73% rating it as 
moderate to extremely important. The lower scores on the psychological 
questions reflect lower priority relative to other dimensions of illness but do 
not necessarily suggest a low psychological burden of disease. 
  
There are mixed results in the literature regarding the psychological impact 
of AAV, with rates of anxiety and depression reported to be between 19%-
43% (Hoffman et al., 1998, Koutanji et al., 2003, Herlyn et al., 2010, , Hajj –
ALI et al., 2011). Kountanji and colleagues found that 43% of patients with 
AAV were anxious and 25% were depressed as assessed by the Hospital 
Anxiety and Depression questionnaire (Koutantji et al., 2003). This is 
supported by Herlyn and co-workers who found that 19% were anxious 
(Herlyn et al., 2010) and Hoffman describes rates of depression between 
33%-43% (Hoffman et al., 1998). Similarly, depression is known to be 
higher in EGPA patients compared to the general population 23.6% v‘s 7.6 
% (Hajj-Ali et al., 2011). However, Kountanji et al., (2003) found that 
compared to controls there was no significant difference in mental health 
using the SF36. Similarly, Basu and colleagues found no difference in 
mental health in AAV patients compared to the general population using the 
SF-8, which is a validated shortened version of the SF36 (cases mean 
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49.3, controls mean 49.0) (Basu et al., 2010). They also found similar rates 
of psychological distress (cases 8% and controls 6%) and depression 
(cases 15% and controls 21%) between the two groups. The exact reason 
for this discrepancy is largely unknown but may reflect the use of generic 
and symptom –specific tools used in the studies. Or it may be attributed to 
the differences in the response rates of the two groups (80% for cases and 
39% for controls). A study of 692 vasculitis patient‘s illness perceptions 
found that a quarter reported negative illness beliefs. This was associated 
with younger age, history of depression, poor health and active disease 
(Grayson et al., 2013). It is not surprising that some patients will experience 
anxiety and depression, as this is a common feature of many chronic 
conditions (Kunik et al., 2005, Rosso et al., 2013).  
 
8.2 Ethnicity  
 
In the VUK / VCRC cohorts nearly all the participants were Caucasian 
(95%), however, all of the non-Caucasian population were from the VCVR 
cohort in which there were three American Indians, six Asians, three Black 
African/ American and one native from Hawaii. This is relevant as health 
care professionals need to be aware that there are differences in the beliefs 
about medications between different ethnicities. South Asian patients in the 
UK (defined as Indian, Pakistani or Bangladeshi) with RA and SLE are 
more concerned about their DMARDs and worried about potential side 
effects (Kumar et al., 2008). They also were concerned about the overuse 
of DMARDs compared with their white/ Irish counterparts. They believed 
that overall medicines were dangerous. This study identified that cultural 
influences need to be taken into account when educating South Asian 
patients about their disease and treatment as they thought that their health 
was in the hands of god or it was just their fate. Moreover, South Asians 
are known to stop their DMARDs earlier than North European counterparts 
(Helliwell & Ibrahim, 2003). 
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A qualitative study exploring the beliefs of medications in 32 South Asian 
patients with RA and SLE (Kumar et al., 2011) found that they had several 
concerns about DMARDs, in particular the necessity of long term 
medication, they were worried about the side effects of medication and 
were concerned about a lack of efficacy. Only one male decided to take 
part and males may have different opinions. The study did not examine 
beliefs about individual drugs and it is possible that participants may have 
had different views about biological agents compared to DMARDs. 
Nonetheless, this study highlights the importance of understanding patient‘s 
health beliefs as this can impact adherence to treatment.  
 
Non- adherence has serious health and financial issues such as poor 
clinical outcomes and waste of medicines dispensed (WHO, 2003). 
Adherence to therapy can improve a patient‘s quality of life and life 
expectancy, particularly in AAV where medications are critical to survival. 
Patients with AAV need to be aware of the benefits, risks, and 
complications associated with their disease and treatments. Respondents 
in this study wanted more information on the benefits and risks of 
treatments prescribed. In addition, they wanted to know how to prevent / 
ease side effects, what side effects and when to report them to the doctor 
or nurse. However, information that was provided to them about their 
medications lacked consistency between primary and secondary care and 
pharmacists. This is a similar finding to Carpenter et al., (2010) who studied 
228 vasculitis patients and found that just over half received conflicting 
information regarding their medication. It is essential that health care 
professionals are consistent in the information given to patients about their 
medications, so that misunderstandings do not happen.  
It has been shown that patient involvement in decisions regarding their 
medications is vital (Bitten et al., 2000). In the Thorpe study participants 
believed wrongly that their medication side effects would go away (Thorpe 
et al., 2008). This is worrying as some of the side effects are serious and 
potentially life threatening. Moreover, clinicians need to explore the 
patient‘s beliefs and fears about medication as this can impact adherence 
to treatment. Patients with long term conditions such as AAV are 
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encouraged to self-manage as much as possible but in order to do this they 
will require information and knowledge about their disease and treatments. 
Thorpe et al., (2008) explored some of the barriers to effective self-
management and suggested that one of the barriers was a lack of effective 
patient education, in particular information about symptom monitoring and 
reporting of medication side effects. Successful self-management will only 
be achieved if patients have access to comprehensive and clear 
information that they understand. 
It is not unsurprising that AAV patients have significant information needs 
as nearly all respondents reported that they had never heard of AAV before 
(VUK 96% and VCRC 95%). This is to be expected as this is a rare 
condition with a prevalence of 2/10,000 (Watts et al., 2012) and there is a 
general lack of awareness within the population regarding many rare 
diseases (EUORDIS, 2009). These results are also consistent with 
previous research that patients with rare diseases have high information 
needs (EURODIS, 2009, Budych et al., 2012). 
 
Generally, there were relatively little differences in informational needs 
between the two groups. However, in response to how the informational 
needs were perceived a few differences were observed in the younger 
patients <24 years. These related to the domain of investigations and tests 
in which they scored these questions slightly lower than the rest of the 
group (mean 4.0 v‘s 4.5). However, these results need to be interpreted 
with caution because of the small sample size of seven. This study found 
that they there were no differences in information needs despite gender. 
This is a different finding to the literature which reports that females try to 
find information more than males (Rutten et al., 2005, Mayer et al., 2007, 
Carpenter et al., 2012). This may be attributed to the fact that these are 
rare conditions that few people have heard of and it was difficult to find 
accurate information easily (EUORDIS, 2009, DH, 2013).  . 
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8.3 Educational attainment  
 
There were differences in the educational level of the two cohorts. In the 
VCRC group 54.9% were educated to degree level or above compared to 
just 16.8% in the VUK group. This could be due to the fact that the median 
age of the VUK cohort was higher at 63 years compared to 58 years in the 
VCRC group and therefore this generation would be much less likely to go 
to university with university intake around 10% of the age group (Table11). 
Despite educational differences, the two cohorts had similar informational 
needs across all domains. The delivery routes for education may need to 
be different as the VCRC cohort preference for delivery of information was 
via the Internet. This probably reflects the fact that this group was surveyed 
over the Internet. This is consistent with other Internet surveys in which the 
preference for information is via the Internet (Nulty, 2008, Carpenter et al., 
2011a).  
 
8.4 Population differences  
 
The results of the survey show that there appear to be no population 
differences in the informational needs of patients with AAV. This is 
surprising as the health care systems of the UK and the USA are very 
different. The UK has a national health service where health care is free at 
the point of contact and use is not limited. In the USA, the majority of health 
care provision is private and covered by private health care insurance or 
the ability to pay (Chua & Rutledge, 2006). Therefore, those that are 
uninsured or have a low income they may be less inclined to seek medical 
care. On the other hand, the reason for no differences in informational 
needs could be because these are rare diseases and many people find it 
difficult to find accurate information (EUORDIS, 2009, DH, 2013). 
Alternatively, it may be that the search for information is a priority to enable 
patients to cope and live with these rare conditions.  
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8.5 Who provided information? 
 
Most participants in both groups received verbal information about their 
disease from the doctor who treated them in hospital. However, a problem 
with giving verbal information only, is that it assumes that the information 
has been received, processed and understood (Silverman & Kurtz, 2013). 
The results from the first qualitative phase found that participants had 
difficulty assimilating information when acutely ill. Giving verbal information 
however does allow for questions to be asked. A worrying number of 
respondents (39.1% of VUK and 30.7%% VCRC) reported not receiving 
any information at any stage of their illness. This figure is consistent with 
The National Audit Office (2005) report that in general up to 40% of patients 
and carers are still not offered information at diagnosis and 20% leave the 
hospital without any discharge information. This is supported by Kole and 
Faurisson (2009) who found that 25% of participants with a rare disease did 
not receive any supplementary information about their diagnosis other than 
the name. Even when discharged from hospital patients ranked information 
about their illness and treatment as high (Suhonen et al., 2005, Arvidsson 
et al., 2005, Makelainen et al., 2009). It may be, there is an assumption that 
patients expect to receive adequate information whilst in hospital in relation 
to their disease and its management (Jones et al., 1999, Valimakie et al., 
2002).  
 
This may be attributed to the fact that patients are a captive audience and 
they expect health care professionals to have the time to communicate 
relevant information to them. On the other hand, acutely ill patients maybe 
looked after by many different specialists and bombarded with information 
that they are unable to understand or recall. Alternatively, it may be that 
they were looked after by non-specialists, who lacked the confidence and 
expertise to answer their questions.  Or it could simply be because there 
are reduced opportunities for information sharing as patients are spending 
less time in hospital now and this reduces contact time with health care 
professionals. Another explanation is that ward nurses or junior doctors 
may not be the right people to provide information to patients with rare 
conditions as they may lack sufficient knowledge. 
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It is not known why so many participants reported not receiving information 
at diagnosis. It could be attributed to the fact that many reported being 
anxious and this is known to affect information recall (Gustafson et al., 
1999, Kessels, 2003, Stephenson, 2006, Mooney et al., 2013). Or possibly 
that they were not given additional information other than the name of their 
condition or because many had their condition for over ten years (40% VUK 
and 20% VCRC) and at that time there was a general lack of patient 
information available. Of those that did receive information about their 
condition, the majority received this information from a doctor (60% VUK 
and 68% VCRC), a nurse (4% VUK and 11% VCRC), and one participant in 
each group received information from a relative and the remainder from 
other sources such as the internet or support groups (10% VUK and 19% 
VCRC). It is not surprising that doctors were the main source of information 
provision at diagnosis as this is in keeping with other studies (Rutten et al., 
2004, Neville et al., 1999, Carpenter et al., 2011a). Following diagnosis 
there is no reason that an experienced and knowledgeable vasculitis 
specialist nurse could not provide patient education.   
 
8.6 Role of the rheumatology nurse  
 
Patient education is an important part of managing any rheumatic condition 
and is   routinely provided by rheumatology specialist nurses for a number 
of conditions (Ryan, 1996, Cornell & Oliver, 2004, Hill, 2007, Brown, 2012). 
The role of the rheumatology nurse practitioner is well documented in the 
UK (Phelan et al., 1992, Hill et al., 1994, Ryan, 1997, Carr, 2001, Goh et 
al., 2006, Oliver & Leary, 2010). The first mention in the literature was in 
the early 1980‘s in Leeds where nurses were employed in research studies 
(Bird, 1983). Their role developed to include running nurse led clinics for 
patients with RA. By the end of the 1980‘s rheumatology nursing clinics 
began to emerge in the UK. A national survey of the role of the 
rheumatology specialist nurse in 1992 revealed that 96% undertook drug 
monitoring and education of colleagues and 86% provided patient 
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education (Phelan et al., 1992). Many rheumatology nurses also provide 
advice, information and support via telephone helplines (McCabe et al., 
2000, Hughes et al., 2002, Brown et al., 2006, Thwaites et al., 2008).  
 
A survey by Carr (2001) found that 82% of rheumatology nurses routinely 
gave information and advice to patients, 52% carried out drug monitoring 
and 35% performed joint counts.  Goh and colleagues used a postal 
surveyed to establish the roles of 95 rheumatology nurse practitioners in 
the UK (Goh et al., 2006).  A total of  95/ 200 questionnaires met the entry 
criteria, the majority of nurses were providing care for RA  patients (96.8%) 
and psoriatic arthritis (PA)(95.8%), OA (63.2%), AS (62.8%), SLE (51.6%) 
and scleroderma (34.7%). The majority of rheumatology nurses (80%) 
regularly provided patient education and drug monitoring. It would appear 
from this study that no nurses were involved in caring for patients with 
ANCA vasculitis.  A limitation of this study was that the British Health 
Professionals in Rheumatology (BHPR) handbook was used to identify 
respondents and this may not be a true representation of all nurses working 
in rheumatology.  A survey by the Royal College of Nursing in 2009  of  272 
rheumatology nurses found that they had expanded their role and 
contribute to the management of many different rheumatological conditions, 
(78%) RA, (73%) PA, (72%) sero- negative RA, (61%) AS, (55%) 
seronegative arthritis, (42%) SLE, (40%) OA  and other connective tissue 
diseases 35% (RCN, 2009). In this study 91% reported that counselling 
patients about their medications formed the main part of their role and 95% 
routinely provided patient education. The majority spent their time 
managing RA patients, 95% provided psychological support and 84% 
DMARD monitoring. The low response rate of 17.6 % makes it difficult to 
generalise the findings, and the sample population was members of BHPR 
and the Royal College of Nursing (RCN) Rheumatology Nursing Forum, so 
the sample may be skewed as many nurses working in rheumatology are 
not members of these organisations.  Again, the questionnaire did not 
specifically ask about ANCA vasculitis making it difficult to map out the role 
of the specialist vasculitis nurse. Nonetheless, it does provide valuable 
insight into the variation in the roles of rheumatology nurses with the 
majority of the role restricted to RA.  
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The effectiveness of rheumatology nurse practitioners in the UK compared 
to consultant rheumatologists in managing RA patients has been evaluated 
and found to be safe and effective (Hill et al., 1994, Ndosi et al., 2013). In 
Hill‘s study those attending the nurse clinic had reduced pain, improved 
knowledge and increased satisfaction. The consultant however saw more 
patients. A multi-centre study also found that the nurses were as effective 
as doctors (Ndosi et al., 2013). However, the nurse appointments were five 
minutes longer than the doctors but nurses provided more patient 
education. An evaluation of an expert rheumatology nurse run monitoring 
clinic for DMARDs compared to an out-patient clinic nurse for 71 RA 
patients showed that patients attending the expert nurse clinic reported 
better coping mechanisms and control over their RA (Ryan et al., 
2006).The role of the rheumatology nurse specialist is well documented in 
the UK and it has been evaluated.   
 
In contrast, very little is known about the role of the rheumatology nurse in 
the USA. Hooker cites the first use of a nurse practitioner in rheumatology 
in the USA as over 30 years ago in 1976 (Hooker, 2008a). Similar to the 
UK experience the nurse practitioner was employed as a clinical trials 
research nurse.  A study to explore the roles of 112 physician assistants in 
rheumatology using a web based survey and telephone interviews found 
that nearly all undertook the first consultation with a patient and nearly all 
initiated DMARDs and half participated in clinical trials research (Hooker & 
Rangan, 2008b). Surprising, there is no mention in this study of physician‘s 
assistants providing patient education. The recruitment for the study may 
be an under representation as it is not known how many physicians 
assistants work in rheumatology. Solomon et al., (2013) carried out an e-
mail and postal survey of 482 nurse practitioners and physicians assistants 
working with RA patients in the USA to establish their role. There were 174 
replies, a 30% response rate, two thirds had their own caseload and nearly 
all provided patient education (98%), almost all adjusted medications (97%) 
and virtually all undertook physical examinations (97%). There were some 
differences in the roles, nurse practitioners ran more infusion clinics than 
physician‘s assistants (31% v‘s 15%). However, the low response rate 
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makes it difficult to make direct comparisons. Nevertheless, it is clear that 
nurses have become an integral part of the multi-disciplinary team in 
rheumatology.  
 
The European League Against Rheumatism (EULAR) has published ten 
recommendations on the role of the rheumatology nurse in the 
management of inflammatory arthritis (Van Ejik – Hustings et al., 2012). 
These include that patients should have access to a nurse for education, to 
have access to a nurse as part of on-going disease management and to 
see a nurse for psychosocial support including self-management.  Although 
patient education is considered a key role of the nurse in inflammatory 
arthritis, it appears that in AAV this is often an overlooked aspect of care. 
There is little mention of the role of the nurse in ANCA vasculitis in either 
the UK or the USA. Yet, nurses are ideally placed to be involved in the care 
of these patients, to help patients understand their condition and provide 
advice and support (Brown, 2012). There is considerable scope to develop 
this area of practice and patients should have access to specialist / 
consultant nurses who have the knowledge and expertise to be involved in 
the management of their care. Of course, it would be unrealistic to expect 
all nurses to be able to undertake this educational role in AAV as it is a 
highly specialised and complex area.  
 
8.7 Whose role is it to provide patient education?  
 
Whilst patients should be informed about their disease and treatments, 
there is some confusion as to whose role it is in the USA. A recent large 
survey of the attitudes, beliefs and information needs of 2,795 RA patients, 
500 doctors and 101 nurses showed that 68% of nurses thought that it was 
their responsibility to provide information to patients about the side effects 
of medications, compared to only 14% of doctors (Furfaro et al., 2013). 
There was also a discrepancy between the groups in the levels of patient 
knowledge about medications, as 87% of doctors and 90% of nurses 
believed that patients had high levels of knowledge compared to only 50% 
of patients. 
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A study by Moret et al., (2008) examined the roles of 302 doctors and 533 
nurses in the conveying of medical information to hospital in-patients in 
France. When asked whose responsibility it was to provide information to 
patients they found that 85% of doctors and 92% of nurses thought it was 
the doctor‘s sole responsibility to provide information on diagnosis and 
prognosis. However, 55% of the nurses felt that they lacked adequate 
medical knowledge to communicate with patients. There were differences 
of opinions in who should provide information regarding investigations and 
tests with nurses indicating they had an important role to complement 
doctors and doctors believing that it was their sole responsibility. This study 
also found that a quarter of patients thought that they did not receive 
adequate information on the risks and benefits of treatment. Although, the 
doctor may see it as their responsibility to provide information on diagnosis, 
prognosis and treatment, often they do not have enough time to do this 
effectively. Time constraints and staff shortages have been cited as a 
barrier to patient education (Albano et al., 2010). Furthermore, the 
healthcare team need to be clear on individual roles and responsibilities in 
coordinating patient education. Doctors may perceive that it is their role or 
delegate it solely to nurses. If this is the case then, nurses should have the 
experience and knowledge to educate these patients. All patients should be 
provided with written information about their condition and treatment and 
given the opportunity to discuss this with a knowledgeable practitioner. 
 
8.8 Preferred source of information 
 
Participants in both the VUK and VCRC groups were highly desirous that 
information be provided by a doctor and supported by written material. 
However, participants did not want written information to be a substitute for 
a conversation with their doctor and this is a similar finding in a systematic 
review of the effectiveness of written information leaflets (Raynor et al., 
2007). It is not surprising that the doctor was the most preferred source of 
information as this is consistent with other studies (Neville et al., 1999, 
Carpenter et al., 2010, Limb & Nutt, 2010). Nurses were not a significant 
source of information and this is not unexpected as the majority of nurses 
 170 
 
do not have the expertise or knowledge to deal with patient‘s questions 
regarding AAV.  Although there are some specialist vasculitis nurses who 
will have this knowledge and experience but these will be in the minority. 
For patients with a rare disease such as AAV there is much less 
educational provision, as the majority of health care practitioners do not 
have the experience and knowledge to educate these patients on an on-
going basis. This means that it is the responsibility of the consultant to 
address patients‘ concerns. This may cause tensions because of the 
demands on consultant time and the reluctance of patients to seek such 
advice at this level. If specialist nurses received relevant training to provide 
such advice, this would help to address such tensions.  
 
8.9 Diagnostic delay  
 
Diagnostic delay is common in rare diseases and in this study over a 
quarter of respondents were diagnosed within three months of the first 
presenting symptom and just over a third were diagnosed within a year. A 
further 15% were diagnosed within one to two years. However, for five per 
cent it took three to five years to obtain a diagnosis and a further five per 
cent waited more than five years for a diagnosis. There were slight 
differences in diagnosic delay between the two groups, the VUK group 
were diagnosed earlier than the VCRC, with of 35% of VUK v‘s 18% of 
VCRC diagnosed within <3 months and 66% of  VUK compared to 50% of 
VCRC within 6 months.  At one year 79% of VUK compared to  61% of  
VCRC had received a diagnosis and by 1-2 years 90% of the VUK group 
and  69% of the VCRC cohort were diagnosed. This is a similar finding to 
Abdou and colleagues who found diagnostic delay in AAV to be between 
three to 12 months (Abdou et al., 2002). The findings are also consistent 
with results from a large survey of a patients and families living with a rare 
condition in which 46% of patients waited more than a year to be 
diagnosed, 20% waited over five years and 12% over ten years (Nutt & 
Limb, 2010). Diagnostic delay is common in rare conditions, ranging from 
one year for cystic fibrosis and amyotrophic lateral sclerosis to 14 years for 
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Ehlers Danlos- syndrome (Kole & Faurisson, 2009). Early diagnosis was 
associated with the availability of specific diagnostic tests that confirms the 
diagnosis. Similarly, in AAV a tissue biopsy result confirming vasculitis 
provides a definitive diagnosis (Miller et al., 2010). An explanation for the 
shorter delay in diagnosis seen in the VUK cohort may be attributed to the 
fact that in the UK health care is free at the point of contact compared to 
the USA where it is covered by private health care insurance or the ability 
to pay and this may have contributed to responsents not seeking help 
earlier. Or it could be the fact that respondents were referred earlier in the 
UK to specialists compared to respondents in the USA.   
 
Although, it can be difficult to diagnose AAV, a delay in diagnosis and 
treatment can affect the patient‘s outcome. A delay in diagnosis was 
associated with more severe disease, more hospital admissions, higher use 
of steroids and immunosuppressive therapy (Sokolowska et al., 2013). 
Diagnostic delay in rare conditions is associated with frequent consultations 
with many different doctors and specialists, numerous investigations and 
tests, patients are often mis-diagnosed before a diagnosis is finally reached 
(Kole & Faurisson, 2009). This is supported by some of the comments from 
the participants in the qualitative first phase who struggled to get a 
diagnosis and were seen by many doctors (P7, P21:p120). All of this leads 
to frustration and loss of confidence in the health care system by patients 
(Kole & Faurisson, 2009). Likewise, poor knowledge of health care 
professionals about rare conditions attributes to this diagnostic delay. 
 
8.10 Use of the Internet  
 
The internet is increasingly being used as a medium for accessing health 
information. The results from question number 17 in the VINQ revealed that 
the internet was frequently used to find information and this was found to 
be invaluable by participants (Appendix T). However, in this study just over 
a quarter (88) of the VUK participants did not have access to the internet 
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and of these 57 were aged over 65 years. Consequently, a considerable 
number of participants would not be able to do this and therefore would be 
deprived of further information. This is important as the AAV‘s have a peak 
age of onset of between 65 -74years (Watts et al., 2012) and health care 
professionals should not assume that everybody has access to the internet 
especially those over the age of 65 years. Vasculitis experts are 
encouraged to signpost patients to accurate sources of information on the 
web (DH, 2013). However, for those who do not have access to the 
Internet, they should be provided with written information or printed pages 
from the Internet from recognized credible sources. 
 
It has been suggested that good quality web-based patient education 
materials may lead to better health status and health care use for patients 
(Lorig et al., 2008, Nahm et al., 2012, Meesters et al., 2012). Maloney and 
colleagues evaluated the quality of OA health information websites and 
found that they were of a poor quality as measured by the DISCERN tool ( 
Maloney et al., 2005). This tool judges the quality of information on 
websites against 16 criteria on a five point Likert scale (1=poor to 5=good 
quality). Medical search engines however were associated with higher 
quality websites.  An evaluation of the readability and suitability of credible 
web based patient education materials used in rheumatology found that 
most materials were written at readability levels above the recommended 
sixth-grade reading level and have only adequate suitability (Rhee et al., 
2013). Of these, the vasculitis foundation resource had the highest reading 
age of 12.5. This could be be due to the fact that AAV are complex 
conditions and some of the terminology used may be difficult to understand.   
 
Low health literacy in musculoskeletal conditions is reported to be between 
7%-42% (Loke et al., 2012). Of 194 patients attending a US rheumatology 
clinic, 10% could not read the words ‗cartilage, diagnosis, rheumatologist, 
symptom or inflammatory‘ (Swearingen et al., 2010). Health care 
professionals should be aware that low health literacy may impair an 
individual‘s ability to understand written educational material and that 
includes web based materials. Clearly there are challenges in producing 
suitable web-based educational materials that patients can understand.  
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Rhee and colleagues conclude that effective educational resources are 
needed to educate patients but are lacking (Rhee et al., 2013). One 
solution is to involve patients in the design of educational materials as 
these are likely to be more acceptable and relevant to patients (Kennedy et 
al., 2003). This should include ethnic minority groups as well so that they 
are not disadvantaged (Samanta et al., 2103). A Health Literacy Universal 
Precautions Toolkit for Rheumatology (HLUTR) has been produced for use 
by all members of the rheumatology team to improve patient‘s health 
literacy.  (www.nchealthliteracy.org/toolkit/Rheum/toolkit.pdf). This toolkit 
not only deals with written materials but addresses spoken communication 
and medication adherence. A small study evaluating its effectiveness in the 
US in four rheumatology and cardiology practices found that over half of the 
staff felt that the tools were useful for assessing low health literacy and all 
agreed that it improved patient care (Callahan et al., 2013). More research 
with larger numbers of centres are needed for further evaluation. Even so, 
this is a free tool that can be downloaded, with access to video clips, 
educational materials and pictures and may be a useful start to assess the 
effectiveness of existing materials and rheumatology services.   
 
A recent study by van der Vaart et al., (2013) found that 85% of patients 
with SSc and RA had used the internet to search for information about their 
condition, 58%-63% for information about medications and lifestyle issues 
and 57% to find a support group. However it can be difficult, frustrating and 
time consuming to find correct, comprehensive and relevant information 
(Langille et al., 2010, Culver & Chadwick, 2005). Signposting patients to 
credible web based resources should not be considered good patient 
education. As some participants in the focus groups and the one to one 
interviews who searched for information on the web, found that this 
heightened their anxiety. Patients should be given an opportunity to discuss 
any information on the web with a health care practitioner, so that their 
concerns can be addressed.  
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8.11 Challenges for rare conditions  
 
There are several challenges for clinicians and patients when faced with 
dealing with a rare, potentially life threatening illness such as AAV. 
Diagnostic delay is common, there is an increased risk of morbidity and 
mortality and relapse is common (Jayne, 2009). The rarity of these 
conditions means that they are unlikely to be diagnosed or managed solely 
by general practitioners, junior doctors or doctors with little knowledge or 
experience in vasculitis (Ingelfinger & Drazen,  2011, Veyckemans et al., 
2011). Many doctors and nurses have never heard of GPA, EGPA or MPA 
and have no experience of these conditions.   
 
In recognition of the many challenges facing patients with rare conditions in 
the USA, the National Organisation for Rare Disorders (NORD) was 
established in 1983 to fight for the unmet needs of these patients. This 
organisation is a collection of patient support groups whose aim is to 
improve the care and quality of life for individuals living with a rare 
condition. They were instrumental in getting the Orphan Drug Act passed to 
support the development of new treatments for rare conditions. In 1997 an 
umbrella group was formed in Europe called the European Organization for 
Rare Diseases (EUORDIS). Together they have campaigned for the rights 
to early diagnosis, better access to treatments and services. They have 
published several reports that have led to the development of national 
plans for rare diseases in every country in Europe by the end of 2013. 
France and the UK has embraced the challenges facing patients with rare 
conditions and developed a national strategy to improve early diagnosis, 
recognition of rare diseases as a specialty, the development of patient and 
health care professional information materials and research into the 
epidemiology and treatment of these conditions (EUORDIS, 2006, DH, 
2013). It is clear that the diagnosis of AAV is significant and impacts many 
aspects of patients‘ lives. The next chapter will present the conclusion of 
the study, the strengths, limitations and recommendations. 
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Chapter 9 Conclusion, strengths, limitations and 
recommendations 
 
This chapter is the last part of the thesis in which the results of the study 
will be revisited and the original contribution to knowledge in the field of 
AAV will be considered as well as the implications for patients and health 
service delivery. The first section of this chapter examines the first issue of 
‗receiving a diagnosis of AAV‗. The second section looks at the 
informational needs of patients with AAV and the third section examines the 
strengths and limitations of the study and how this research has contributed 
to the knowledge and understanding in this area. Lastly is to consider how 
the research findings can be put into practice and discuss areas for further 
research. 
 
9.1 To understand what it is like to receive a diagnosis of AAV  
 
The first two chapters looked at what is AAV, its prognosis, management 
and the risks associated with treatment and the impact of this disease on 
individual‘s lives. The first qualitative phase of this mixed method study was 
designed to answer the research question ‘What is the experience of 
receiving a diagnosis of a rare potentially life threatening condition such as 
AAV‘.    
The results of the first qualitative phase found out that receiving the 
diagnosis of a rare potentially life threatening disease causes anxiety and 
fear and this can impede information retention, understanding and recall. 
Therefore, timing of information is crucial, as patients have difficulty taking 
in information when acutely ill. The need for emotional support at diagnosis 
was often overlooked by doctors and nurses, patients reported being 
frightened, highlighting that the psychological needs are just as important in 
the management of AAV and should not be ignored.  
All participants desired information about their diagnosis and treatment and 
wanted written information but value having the opportunity to discuss it 
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with a knowledgeable healthcare practitioner. Respondents expressed their 
frustration at the lack of knowledge and awareness of rare conditions 
amongst health care professionals. Participants‘ symptoms were often not 
taken seriously or dismissed as not serious. When consulting with health 
care practitioners, they described positive and negative experiences. 
Positive experiences were associated with knowledgeable practitioners 
who have expertise of AAV and negative experiences were linked to 
patient‘s symptoms not being listened to or taken seriously and being told 
that ‗you‘re not ill‘. Participants reported that they wanted access to, advice 
from and treatment by knowledgeable practitioners. In conclusion, the 
consequence of a diagnosis of AAV is significant and impacts many 
aspects of individuals‘ lives and should not be underestimated by health 
care professionals. 
 
9.2 Informational needs of participants with AAV 
The second quantitative phase of the study was designed to answer the 
following questions: 
 A) What are the informational needs of patients with AAV? 
B) How do patients with AAV prioritize their informational needs? 
C) How is information provided to patients and by whom? 
D) What sources of information are preferred? 
E) Are there any differences in the informational needs of patients in the UK 
and USA?   
 
The second part of the study highlighted that people with AAV required a 
considerable amount of specific information concerning their disease, 
treatment regimens and side effects and the results of investigations and 
tests. Individuals preferred to receive this information from a doctor. Most 
participants received verbal information about their disease from the doctor 
who treated them in hospital. However, a significant number of respondents 
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reported not receiving any information at any stage of their illness. There 
were no significant differences in informational needs between the two 
cohorts of participants regardless of country of origin, sex, age or disease 
subtype. The findings from the study support the need for patients with rare 
conditions to be educated in a similar manner to patients with more 
common chronic conditions, as both have very similar educational needs.  
 
9.3 Health service delivery 
 
When the author embarked on this research project she expected to be 
advocating that patient education programmes for people with AAV should 
be implemented similar to those for RA. However, on reviewing the 
evidence base for patient education in more common rheumatic conditions 
there is conflicting benefits. Patient education programmes and self- 
management programmes cannot solely provide patients with the skills to 
be able to manage their condition without the support and help of others. 
The management of AAV requires access to a multidisciplinary team of 
experts. Complex conditions are more difficult to self-manage and they 
should be managed in conjunction with specialists. This does not mean that 
patients cannot become experts of their own condition but it will take time, 
knowledge and experience. Rather than using the term patient education, 
we should be thinking about ‗The Patient Information Sharing Journey‘. 
This enables health care professionals to tailor information to suit the needs 
of the patient at each stage of the disease pathway and also to adapt it to 
their readiness to learn. The author has challenged her own assumptions 
that a generic patient education programme for AAV is a good thing and 
should be implemented.  It is clear that due to the complex nature of AAV 
and the many different disease presentations, the education of these 
patients has to be done on an individual basis.  First we need to understand 
the patient‘s information needs in order to improve the educational 
strategies and outcome measures used. 
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Although, patient education in rare diseases poses unique challenges, the 
informational needs in these patients are high and need to be met. At 
diagnosis, neither health care professionals nor patients may have access 
to much detailed information. The patient may feel isolated because friends 
and relatives to whom patients often turn to for help are unlikely to have 
heard of the condition, given the lack of general awareness regarding many 
of these diseases. Health care professionals, unless working in the relevant 
sub-specialty, may have limited understanding of the disease and may not 
be able to help patients understand and contextualize relevant information. 
Yet, doctors and nurses need to help patients understand information so 
that patients can internalise the information and contextualise what this 
might mean for them. Participants clearly expressed a desire for 
information to be provided by knowledgeable professionals, to whom 
access can be especially difficult.  
 
The recently published report ―The UK Strategy for Rare Diseases‖  aims to 
improve the quality of life for people with rare conditions with a focus in five 
areas,  empowering patients, recognizing and preventing rare diseases, 
diagnosis and early treatment, coordination of care and the role of research 
(DH, 2013). The report recommends that patients should have access to 
specialist multidisciplinary teams who provide coordinated care and 
support. This should include a specialist nurse who has the skills and 
knowledge to educate and support patients. The focus is to improve the 
whole patient experience from the first point of contact, which is usually the 
GP, to diagnosis and follow up care. It recognizes how valuable the 
patient‘s experience is and this has many information sharing opportunities. 
The diagnosis and management of AVV is complex and therefore 
partnership-building with specialist teams will be needed to improve the 
patient experience. 
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9.4 Strengths of the study 
 
 
The study has a number of strengths. Using a mixed methods approach in 
which the results from the qualitative first phase were are used to guide and 
inform the development of the VINQ ensured that relevant items in the 
questionnaire were included.  Mixed methods allow a more flexible 
approach to the study design and have a greater potential to extend the 
impact of the research to a wider community (Sandelowsk, 2000). An 
established questionnaire was adapted and validated for use in patients 
with rare auto-immune diseases. This study includes large numbers of 
participants with rare diseases, with equal numbers of women and men, 
there is consistency between cohorts despite the differences in recruitment 
strategies and response rates, suggesting that the findings are 
generalizable to the AAV community as a whole and supporting the 
argument for needs –led education provision. The two study populations 
enabled comparisons with two different countries.   
 
9.5 Study limitations  
 
The study has several potential limitations. Although the same 
questionnaire was used in both groups, it was administered differently to 
each. While the response rates differed (52% postal VUK, there was only a 
10% response rate from the internet survey (VCRC). Although e-mail 
reminders were sent, a better response rate may have been achieved by 
putting an advert on the Vasculitis Foundations website and also in their 
quarterly newsletter, as well as advertising the survey at support groups 
and patient conferences. It is noteworthy that very similar results were 
obtained from both a written survey and an internet administered survey 
suggesting that for this type of survey the method of administration makes 
little difference.  However, the low response rate of 10% from the internet 
survey means that there is a bias towards the postal questionnaire. 
Therefore it makes direct comparisons very difficult due to the low numbers 
of the internet survey, so it is difficult to make generalizations as the 
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internet sample may not be truly representative of the whole USA 
popualtion. Also, the internet responders may also be highly motivated, 
have joined a rare disease registry and be used to participating in internet 
research. There may be recall bias for the questions which asked about 
information provision at diagnosis. Clearly each group of respondents is 
self- selected and only represents those who have joined a disease specific 
patient group and access and respond to requests for participation in 
research studies. The VCRC group is further selected by requiring access 
to the Internet. The diagnosis is self-reported and was not independently 
checked, therefore there is the potential for misdiagnosis classification 
which could have influenced the results.  There is a disproportionate 
representation of GPA in both groups, which is to be expected, as GPA is 
the most common type of ANCA vasculitis. In both groups MPA is under 
represented. Prevalence data suggests that in white Caucasian populations 
GPA is the most common, with EGPA being the least common, in a ratio of 
7:3:1 (Watts et al., 2012). In the VUK cohort this may reflect the 
development of the organisation, which originally was established as a 
support group for patients with GPA. Also, the study did not measure 
information needs over time. The self- reported vasculitis diagnosis was not 
confirmed by a doctor. However, for the rare types of vasculitis include in 
the study this is highly unlikely but possible. The results of the study cannot 
be generalizable to the USA population due to the small numbers and this 
study needs to be replicated with larger numbers.  
 
9.6 Recommendations 
 
9.61 That patients with AAV are educated about their condition  
Now that patients with AAV are surviving the critical phase of the illness 
and attaining disease remission, they need to be treated like other chronic 
illnesses where patient education has been recognized as an important 
aspect of chronic disease management and the cornerstone of good quality 
care. It is now best practice, to provide patient information for chronic 
illnesses, and patient education has been acknowledged for some time as 
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being a vital part of patient care (North et al., 1999, Barlow et al., 2000, 
Albano et al., 2010). Indeed, the shortcomings in care provided to patients 
with rare conditions have been recognized and it is now government policy 
to provide patients with timely information about their disease and 
treatments (DH, 2013). Patients with AAV are similarly entitled to be 
educated about their condition, to the level that they need to manage their 
lives. All patients should be provided with written information about their 
condition and given the opportunity to discuss this with a knowledgeable 
practitioner. Participants had difficulty understanding some of the medical 
terminology used highlighting that information given to patients must be in a 
language they understand. Participants needed time to absorb information 
at their own pace to inform the basis for their questions.  Written 
information would support this education process by giving time for patients 
to appreciate the meaning and then to internalise what it means to them. 
They could then prepare their questions ahead of a meeting with the doctor 
or nurse.  
Patient education begins very early on, in fact as soon as the patient 
receives the diagnosis (Kohen & Esdaile, 2008). However, the timing of this 
information is crucial as patients have difficulty assimilating information 
when acutely ill and this can impede information recall. Furthermore, 
clinicians should be aware of a patient‘s emotions during a consultation and 
deal with then before imparting information (Sep et al., 2014).   Key 
information may need to be given at diagnosis and followed later with 
additional information. The optimal time for more in –depth information 
should be when the patient has had time to digest and make sense of what 
is happening to them. The exact timing of this will be different for each 
individual but clinicians need to assess a patient‘s readiness to learn.  A 
separate consultation should be arranged to explain the patient‘s diagnosis 
and treatment with enough time allocated to do this. This can help make 
the most of each patient encounter through the use of good 
communication, thereby  increasing patient satisfaction and improving 
outcomes (Steel et al .,2012, Marcusen,  2010).  
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9.62 To ensure that patients understand the importance of their 
medication and possible side effects  
Medications are the mainstay of treatment in AAV but are associated with 
serious toxicity. It is essential that patients are fully informed of the reason, 
the need for the medication, possible side effects and the monitoring 
process.  As non-adherence has serious health and financial repercussions 
such as poor clinical outcomes, medicines waste (WHO, 2003). Patients 
should be provided with written and verbal information about the name of 
their medication, what it is for, when to take it and how and how long for, 
what the side effects are, what signs or symptoms to look out for and what 
to report to the doctor or nurse so that prompt treatment or early recognition 
of toxicity occurs. In addition, patients should know about any 
contraindications with other medicines and any special monitoring such as 
blood or urine tests. Adherence to medications can be encouraged with the 
supply of pill cards, pill charts and dosset boxes. Health care professionals 
also need to understand the patient‘s health beliefs as this can impact 
adherence to treatment. Adherence to therapy can improve patient‘s quality 
of life and life expectancy, particularly in AAV where medications are critical 
to patients‘ survival. It is essential that health care professionals are 
consistent in the information given to patients about their medications, so 
that misunderstandings do not happen.  Patients will need information and 
education to help them to self- manage and participate in informed decision 
making. Furthermore, the healthcare team need to be clear on individual 
roles and responsibilities in coordinating patient education and all patients 
should have a personal management plan.    
 
9.63 Information about AAV needs to be easy to access for patients 
and health care professionals  
Patients and health care professionals should have access to written 
information about AAV. All patients should be provided with written 
information about their disease and treatment, as well as information on 
where to access additional information. This written information should be 
easy to read and understand and written in plain English without jargon. It 
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can be difficult to search for accurate medical and patient information for 
rare diseases and judge whether it is from a reliable source. Experts should 
signpost patients and healthcare professionals to accurate sources of 
information on the web as well as endorsed patient organisations and 
support groups. Web based education materials should be written in simple 
language that patients can understand.  People with low health literacy may 
benefit from other educational strategies where individual verbal education 
is critical and supported with pictures, audio tapes and video clips. All 
educational material should be assessed for readability and suitability for 
patients. 
 
9.64 Patients should be provided with psychological support   
The consequence of a diagnosis of AAV is significant and impacts many 
aspects of individuals‘ lives and should not be underestimated by health 
care professionals.  Emotional support at diagnosis was often overlooked 
by clinicians. Routine follow up should include an assessment of 
individuals‘ psychosocial status and quality of life. Patients should be 
offered help and support to cope with their condition, including counselling 
and referral to a psychologist if appropriate.  A specialist nurse has a 
valuable role to provide support and advice to patients and their families.  
Patients should be provided with details of patient support organisations 
that provide education and support to members. Some organisations 
provide support via telephone helplines that are manned by specialists or 
other patients with similar conditions.  Another way of providing 
psychological support is through online disease specific support groups, 
which can help minimise the patients feelings of isolation.  
 
9.65 To raise awareness of AAV  
Respondents expressed their frustration at the lack of knowledge and 
awareness of rare conditions amongst health care professionals. 
Participants‘ symptoms were often not taken seriously or dismissed as not 
serious. Better education of practitioners in primary and secondary care to 
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recognize and diagnose AAV early is needed to improve patient outcomes 
and the patient experience. There is a need to raise awareness of AVV 
within the health care profession and the general public. This could be 
through education, for example teaching student nurses and trainee 
doctors about these conditions during their training. Media campaigns can 
be used to raise awareness of AAV for the general population and the 
medical community. There are a number of vasculitis patient support 
groups that raise awareness of vasculitis nationally and this needs to be 
recognized and promoted. Clinicians need to work with support groups to 
raise awareness of AAV and work with them in developing coordinated care 
pathways and service redesign (Coulter et al., 2013,  NHS England , 2013) 
Clinicians with expertise in vasculitis should recognize their educational role 
and promote an exchange of knowledge from experts to non-experts. This 
could include encouraging colleagues to sit in on specialist clinics. Patients 
should be involved in teaching medical and nursing students about their 
condition. Clinicians, researchers, patients and their families should work 
together to raise awareness of AAV. Patients should be encouraged to 
have their voice heard so that we can improve the quality of care delivered 
to individuals with a rare condition. 
   
9.7 How is this study going to change clinical practice? 
 
To my knowledge this is the first study to explore what it is like to receive a 
diagnosis of AAV. Until now, very little was known about what it is like to 
receive the diagnosis of AAV or what the informational needs of these 
patients are. The findings from this study can be used to improve the 
communication between patients and health care providers. The timing of 
information is crucial as patients have difficulty assimilating information 
when acutely ill. It is important to understand the impact that a diagnosis of 
AAV has and the difficulties patients encounter when dealing with non-
experts. Patients with AAV require a considerable amount of information to 
help them manage their disease and that they have significant information 
needs and we as health care professionals need to address this. Effective 
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communication skills are needed if health care professionals are to improve 
the patient‘s understanding of their illness, increase adherence to treatment 
and enhance patient communication (Back et al., 2005, Maguire, 1999, 
Viller et al., 1999). It is clear that patients faced many challenges and 
doctors and health care professionals need to be aware of these.  
 
Although patient education is considered an essential role of the nurse, it 
appears that in AAV this is an overlooked area of care. This is mainly due 
to the complex nature of the disease, its rareness and the management is 
consultant led.  Nonetheless, there is considerable scope to develop this 
area of specialist practice and patients should have access to specialist / 
consultant nurses who have the knowledge and expertise to be involved in 
the management of their care. The findings from this study can be used to 
influence health care policy for patients with rare conditions such as AAV. 
With the advent of clinical commissioning groups these will become the 
gatekeeper for people with rare conditions and treatment pathways may 
limit access for this group of patients to other specialists.  The results from 
the study can be used to inform the development of a ‗Patient Information 
Sharing Journey‘ directive in vasculitis that is driven by the patient‘s needs. 
The results can be used to inform commissioning decisions made in the 
NHS but more importantly to help clinicians understand their patients‘ 
needs better. With efficiency savings in the NHS, it is likely that patient 
education may be seen as a nice add on rather than a fundamental part of 
care. The results from the study can be used to strengthen the argument 
that patients with a rare condition need educating just like patients with 
other more common chronic illnesses. We need to improve the delivery of 
clinical care for this group of patients and this includes the patient 
experience and sharing of information. The results from this study have 
been included in the updated guidelines for management of AAV with the 
recommendation that all patients should receive tailored information and 
education (Nataski et al., 2013).  
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This study can improve clinical practice as the more knowledge and 
understanding we have of what it‘s like for patients to cope with a rare 
disease the better we can improve the quality of care provided to patients. 
This knowledge can enable us to target resources more effectively to 
improve the patient experience. This study contributes to the understanding 
from a patients‘ perspective of what it is like to receive a diagnosis of a rare 
potentially like threatening illness. It is clear that patient education needs to 
be tailored to individual needs on the illness pathway.  It is vital that patients 
are provided with information so that they can truly participate in shared 
decision making and make informed choices. Patient education for AAV 
should be recognized and supported.  
 
9.8 Areas for further research 
 
This study highlights the need for more research into rare conditions so that 
we can understand the difficulties encountered by patients and their 
families. More research is needed into the financial impact of AAV, the 
reasons for diagnostic delay and the valuable role that patient associations 
have in imparting knowledge and educating members. It is unclear as to 
what are the most effective educational strategies to be used when 
educating patients, as well as which outcome measures should be used to 
test interventions. The use of web based educational materials in educating 
patients with AAV has not been studied.  Further exploration is needed to 
determine which patients require psychological support and at what point in 
the disease trajectory is this most important for them. 
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Appendix A  Medications used in AAV 
Medication name Type / route of 
administration  
Side effects  Monitoring  
Cyclophosphamide  Cytotoxic  
Oral or intravenous 
Bone marrow 
suppression 
Haemorrhagic 
cystitis Increased 
risk of  infections( 
upper respiratory 
tract, urinary tract)  
Bladder cancer 
Lymphoma 
Infertility 
Alopecia 
Amenorrhea 
FBC, U&E’s, 
LFT’s 
CRP/ESR 
Urinalysis 
Infection  
Glucocorticoids Synthetic hormone  
Oral, intravenous, 
intra articular 
Weight gain 
Hypertension 
Increased risk of  
infections 
Cataracts 
Diabetes 
Osteoporosis 
Mood swings 
Peptic ulceration 
Myopathy 
Avascular necrosis 
BP and 
weight 
Known side 
effects  
 
Azathioprine  Immunosuppressant 
Oral 
Bone marrow 
suppression 
Increased risk of  
infection 
Dizziness 
Diarrhoea 
Nausea 
Rash 
Impaired liver 
function 
Cancer 
Hypersensitivity 
FBC, U&E’s, 
LFT’s 
CRP/ESR 
Infections 
Methotrexate  Cytotoxic 
Oral or 
subcutaneous 
Bone marrow 
suppression 
Diarrhoea 
Nausea 
Stomatitis 
Headaches 
Impaired liver 
function 
Teratogenic 
Pneumonitis 
FBC, U&E’s, 
LFT’s 
CRP/ESR 
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Leflunomide Immunosuppressant 
Oral 
Bone marrow 
suppression 
Diarrhoea 
Nausea 
Stomatitis 
Impaired liver 
function 
Potentially 
teratogenic 
Hypertension 
Rash 
FBC, U&E’s, 
LFT’s 
CRP/ESR 
BP and 
weight 
Mycophenolate mofetil Immunosuppressant 
Oral 
Bone marrow 
suppression 
Malignancy 
Increased risk of  
infection 
Anaemia 
Gi manifestations 
 
 
FBC, U&E’s, 
LFT’s 
CRP/ESR 
Infections 
Rituximab Monoclonal  
antibody   
Intravenous 
Infections 
(encephalitis) 
Bone marrow 
suppression 
Anaemia 
Infusion reaction 
Hypertension 
Bronchospasm 
Cancer 
 
FBC, U&E’s, 
LFT’s 
CRP/ESR 
Infections 
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Appendix B Structured Clinical Assessment in AAV  
  
Structured Clinical Assessment    
Physical examination  All systems 
Bloods  
FBC, U&E’s, LFT’s 
 
CRP/ESR 
 
General health status /organ function 
Toxicity of medication 
Inflammatory markers, measure 
response to treatment /Active disease   
Urinalysis 
Dipstick 
 
 
24 hour protein 
Egfr  
 
Infection: nitrates. leucocytes 
Haematuria / proteinuria: decline in 
renal function or toxicity of 
cyclophosphamide  haemorrhagic 
cystitis  
Assessment of kidney function 
BP Hypertension 
Reducing renal function 
Cardiovascular risk factor 
ANCA antibodies  Disease  
BVAS 
VDI 
Disease assessment  
Damage  
Radiology  
Chest  
 
Lung infiltration 
Nodules/ cavities 
Lung haemaorrhage 
Tissue biopsy 
Kidney 
Nerve 
Confirm diagnosis 
Focal segmental necrotizing vasculitis  
Imaging  Inflammation, assessment of organs 
SF36 
HAQ 
General health 
Disability  
Toxicity of treatment 
Infection 
Bone marrow suppression 
Hypertension 
Diabetes 
Osteoporosis 
Avascular necrosis  
Abnormal LFT’s 
Pneumonitis 
Haemorrhagic cystitis 
Bladder cancer 
Skin cancer 
Observe for any of these  
CVD assessment Yearly 
Psychosocial support and education  Ongoing 
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Appendix C Studies for Literature review  
 
Author  Study Design  Results  Limitations 
Herlyn K, Höder J, 
Gross WL, 
Reinhold-Keller E 
(2002) Article in 
German abstract in 
English  
An evaluation of a new 
patient education 
programme for vasculitis  
An interdisciplinary education programme to 
provide information on disease, therapies, side 
effects, coping strategies and nutrition. A  patient 
and physician-administered questionnaires 
assessing socioeconomic, knowledge and disease-
related outcome-parameters was designed. Patients 
are trained in closed groups (n = 10-15) and asked 
to complete questionnaires at baseline, 4 weeks 
and 6 months after training.  
Statistically significant 
improvement of knowledge and 
HRQL.Information on disease, 
drugs, side effects ,coping 
strategies, nutrition, physiotherapy.   
In patient education programme 
in a tertiary referral centre. 
Not based on CBT  
Most education programmes are 
out patient based. Captive 
audience 
Group education. How can 
standardised be considered 
patient centred and holistic?  
Herlyn K, Höder J, 
Gross WL, 
Reinhold-Keller E 
(2008) Article in 
German abstract in 
English 
Longitudinal effects of 
structured patient 
education programs for 
vasculitis patients 
Prospective study in a 
pre/post design 
Assessment before, 4 
weeks, 6, 12 and 24 
months after participation 
Knowledge (16 questions, Score 0-45)Health-
related quality of life (SF-36) Functional capacity 
(NRS 0-10) 
Self- efficacy (9 item scale, Hasenbring et al.) 
Socioeconomic factorsDisease extent index (DEI)  
Patients were trained in closed groups (n=10-15) 
and completed the questionnaires at baseline, 4 
weeks, 6 and 12 months following participation 
102 patients, 10 groups 2001-
2006.70% female. Mean age 55 
years.  A statistically significant 
increase in their knowledge in the 
three aspects of medicine, therapy 
and side effects, nutrition and 
physiotherapy. Health-related 
quality of life in all dimensions 
increased considerably. Both self-
efficacy and the patient-assessed 
health status improved. 
Group education and not disease 
specific.  
In patient setting tertiary referral 
centre. 
Thorpe et al (2007) 
 
 
 
 
 
 
Development of a tool to 
assess the self- 
management behaviours 
of AAV.  
43 items: 8 domains, medication adherence, health 
services adherence, infection avoidance, diet, 
exercise, symptom monitoring, reporting 
symptoms and side effects and adjusting activities. 
Likert scale 1-5 how often they performed the 
behaviour 1= none – 5 all the time.   
 Did not include support groups. 
Needs further validation. Only 
those barriers to activities stated 
by at least 10% were included. 
Convenience sample, biased 
towards kidney involvement, 
under representative of EGPA. , 
Recently diagnosed under 
represented. Disease duration 6 
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years.   
Thorpe, C T (2008) 
Rheumatology:47:
6:881-886   
 
 
 
 
 
To characterize patient 
perceptions, related to 
eight self-management 
behaviours for adults with 
(ANCA-SVV), and to 
determine if these 
perceptions were 
associated with 
performance of each 
behaviour 
 
Cross-sectional, observational study, 202 
participants completed the VSMS questionnaire.  
Assessed 8 self-management behaviours, also 
perceptions about these behaviours, socio-
demographics, clinical factors and social 
desirability bias. 
Perceived barriers to medication, 
health services, diet and exercise 
adherence were similar to those in 
other illnesses. Insight into barriers 
experienced by patients in 
performing behaviours (infection 
avoidance, symptom monitoring, 
reporting symptoms and side-effects 
and adjusting activities.  
 
Carpenter, D.M, 
DeVellis, R.F, 
Hogan, S.L, Fisher, 
E, DeVellis, 
Jordan, J (2010) 
Patient Education 
& Counseling. 
81(2): 169-76  
The effect of conflicting 
medication information 
and physician support on 
medication adherence for 
chronically ill patients. 
228 vasculitis patients, online questionnaire, Two 
on line questionnaires completed. Data collected 
on conflicting information, adherence, self- 
efficacy, outcomes , physician support and 
medication adherence 
Over half of patients received 
conflicting medication information 
(51.3%). AAV patients who 
received contradictory advice about 
medications were less adherent than 
those who did not receive 
contradictory advice 
 
Carpenter, D.M, 
DeVellis, R.F, 
Hogan, S.L, Fisher, 
E.B, DeVellis, 
B.M, Jordan, J.M 
(2011) Journal of 
Health 
Communication. 
16(6): 629- 
 
Use and perceived 
credibility of medication 
information sources for 
vasculitis patients: 
Differences by gender.  
 
Online questionnaire, 232/253 patients (92%) 
completed the questionnaire .Asked how often 
they obtained medication information from 12 
sources during the previous year and rated the 
credibility of 6 sources. physicians, pharmacists, 
nurses, brochures and pamphlets, medicine 
 
Patients used physicians and the 
Internet most to obtain medication 
information and rated them as the 
most credible sources. Female 
patients were more likely to use 
medication package inserts and the 
Internet and were less likely to use 
nurses than were male patients. 
Support groups and nurses were 
used less. Patients had been living 
Non–Internet users may  have 
different opinions. Recall bias 
over medication sources over a 
year. Biased towards females 
69%, and white 91%, 59% had 
AAV.. Group was highly 
educated with 66% M and 58% 
F, college graduates.  Mainly 
GPA M 725, f 54%,only 11% 
css M, 13% F, MPA 7% m, 8% f 
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with vasculitis for an average of 6.5 
years, and 27.6% were currently 
experiencing a relapse or flare.  
Differences between male and 
female participants are noted 
included 7% females with 
Takayasus, quality of 
information on internet variable 
and quality not judged.  
 
 
 
Carpenter, D.M, Kadis, JA, Hogan, 
S.L, DeVellis, R.F, Jordan, 
J.M(2011)Journal of 
Rheumatology, 38(4): 709-15 
 
 
 
 
 
 
 
 
 
The effect of medication 
related support on the 
quality of life of vasculitis 
patients in relapse and 
remission.  
Same population as above.28.4% were 
experiencing a relapse and 71.6% were 
in remission Medication support. was 
measured as 1=does not do this to 
4=does this a lot 
Both groups reported equally 
moderate amounts of support from 
their doctor and partners 
(mean=2.1). Those experiencing a 
relapse had reduced quality of life 
in seven out of the eight domains, 
apart from physical role 
limitations. Greater doctor support 
was associated with better quality 
of life in 6 domains apart from 
bodily pain and energy.  Similar 
results are seen with partner 
support 
We do not know if the pain was 
related to their vasculitis or if 
the patients were taking any 
analgesia 
Pepper JK, Carpenter D.M., & 
DeVellis R.F. (2012) Journal of 
Behavioral Medicine, 35: 115-123 
Does adherence-related 
support from physicians and 
partners predict medication 
adherence for vasculitis 
patients?  
Tested the informational – Motivation 
behaviour model developed for HIV on 
172 vasculitis pts,  
  
Carpenter, D M (2013) :164:51 -52  
Predictors of medication non-
adherence for vasculitis patients: 
From demographic factors to 
interpersonal influences: Clinical 
and experimental immunology  
To document which 
demographic, clinical, 
regimen-related, 
intrapersonal and 
interpersonal factors affect 
medication adherence for 
vasculitis patients.  
ASSIST sample pop. Regimen-related 
(experience of side effects), 
intrapersonal (depressive symptoms), 
and interpersonal (adherence-related 
support from family and friends) 
factors were measured at baseline 
Results. Younger age (r=-0.23, 
p<0.001), female sex (r=0.16, 
p<0.05), experience of side effects 
(r=0.15, p<0.05), and more 
depressive symptoms (r=0.22, 
p<0.001) were associated with 
more medication non-adherence. 
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In the regression model, younger 
age (β=-0.01, p=0.01) and more 
depressive symptoms (β=0.01 
p=0.02) predicted worse adherence 
UhIfelder ML, Waimar Tun j , 
Stone J H , Hellmann DB  1999 
Abstract 
A vasculitis webpage  role 
in patient education and 
clinical research  
 
304 visitors completed questionnaires,  
 
205 (67.1%) vasculitis, 77 
(25.3%)relatives. 188(64.6%)  
female, 103 (35.4%)male. Mean 
age 44.B years (range 16-83 years) 
mean age at diagnosis 43.3 years. 
Forty-two (16.8%) were from 21 
different countries outside U.SA, 
including Canada, India, Vietnam, 
Italy, Brazil, and Australia. 
Diagnosis CNS vasculitis 03.5%. 
PAN 10.5%, leukocytocJastic 
vasculitis 8.2%, GPA 7.6%, RA 
vasculitis 5.3%, Behcet's 3.6%, 
HSP 3.6%, GCA 3.0%, and 
hypersensitivity vasculitis 3.0%. 
Seventy-eight responses (25.6%) 
uncertain of their diagnosis. 
Did not just include AAV but 
other vasculitis, 25% uncertain 
of diagnosis. Low response rate  
Carpenter D.M., Blalock S.J., 
DeVellis R.F.Journal of the 
American Pharmacists 
Association(2013)  
 
Do patients with a rare 
illness use pharmacists as 
sources of medication 
information?  
Vasculitis patients (n = 232) who were 
taking at least one medication. Online 
survey. Same sample population as 
ASSIST. 
Participants consulted physicians 
and the Internet more than 
pharmacists for medication 
information; 96 participants 
(41.4%) ever used pharmacists for 
vasculitis medication information.. 
Pharmacists were perceived as a 
less credible source of medication 
information than physicians and 
the Internet. Participants used 
physicians and/or the Internet 
more than pharmacists for five of 
eight types of medication 
information, including adverse 
Vasculitis patients consulted 
sources other than pharmacists 
for medication information. 
Several factors, including 
perceived pharmacist credibility 
and a noncommunity-based 
pharmacy, may contribute to 
infrequent patient use of 
pharmacists as a medication 
information source.  
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effects and drug effectiveness 
Brown N, Bruce I, Venning M ( 
2012) Abstract BSR  
Prevention of treatment 
related morbidity in anca-
associated vasculitis: The 
patient‟s perspective:  
A questionnaire was distributed to 
Vasculitis UK members. This 
questionnaire assessed patient 
awareness of potential side- effects 
associated with vasculitis therapy, as 
well as uptake of screening and 
prophylactic approaches to reduce these 
complications 
Response rate 347 (49.6%). Of 
these 306 responses were analysed 
from patients with PSV . 241 
(79%) GPA , 41 (13%)EGPA, 15 
(5%) MPA  and 9 (3%) other . 190 
(62%)mean age of 61.7 (range 15-
87 years). Treatment received ; 
oral steroids 96%, oral 
cyclophosphamide 49%, 
intravenous cyclophosphamide 
41%, azathioprine 69%, 
mycophenolate mofetil 28% and 
Rituximab 14%. Of potential 
adverse events, the best recognized 
were bone problems (20.9%) and 
weight gain (19.3%) with 
awareness of increased infection 
risk only 10.5% and general 
increased cancer risk 7.5% (skin 
cancer 6.5% and bladder cancer 
3.9%).  
A lack of awareness of potential 
side effects of therapy amongst 
vasculitis patients, particularly 
with regards to infection and 
cancer risk. Variability in 
reported practice in terms of 
infection prevention strategies 
and cancer 
screening/prevention. In 
particular skin cancer awareness 
was very low. There may have 
been recall bias and self- 
reported AAV.  
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Appendix D Ethical approval for the study from the East Norfolk and 
Waveney Research Ethics Committee 
East London and the City Research Ethics Committee 1 
3rd Floor 
Aneurin Bevan House 
81 Commercial Road 
London 
E1 1RD 
 
 
Tel: 020 8223 8602 
Fax:  
Dr Richard Watts /Janice Mooney  
Senior Lecturer 
Norwich 
NR4 7TG 
21 September 2007 
 
Dear Dr Watts/ Ms Mooney 
 
Study title: What Are The Information Needs Of Patients 
With Primary Systemic Vasculitis? 
Development Of An Educational Programme 
REC reference: 07/Q0603/9 
Amendment number: 1 
Amendment date: 06 July 2007 
 
The above amendment was reviewed at the meeting of the Sub-Committee 
of the REC held on 21 September 2007. 
 
Ethical opinion 
 
The members of the Committee present gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form 
and supporting documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
 Document  Version  Date  
Questionnaire  1.0  06 July 2007  
Amendment 1  1.0  06 July 2007  
Notice of Substantial 
Amendment (non-CTIMPs)  
1  06 July 2007  
Covering Letter    06 July 2007  
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Membership of the Committee 
 
The members of the Committee who were present at the meeting are listed 
on the attached sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the 
R&D office for the relevant NHS care organisation of this amendment and 
check whether it affects R&D approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees (July 2001) and complies 
fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK. 
 
07/Q0603/9:     Please quote this number on all 
correspondence 
 
Yours sincerely 
 
 
 
Miss Sandra Burke 
Senior Research Ethics Committee Administrator 
East London and The City Research Ethics Committee 1 
 
 
 
 
Copy to: Ms Sue Steel,   University of East Anglia 
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East London and the City Research Ethics Committee 1 
 
Attendance at Sub-Committee of the REC meeting on 21 September 
2007 
 
Name   Profession   Capacity    
Dr Chandan Alam  Experimental Pathology  Expert  
Dr Arthur T. Tucker  Principal Clinical Scientist & 
Honorary Senior Lecturer  
Expert  
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Appendix E Ethical approval from the University of South Florida 
 
 
 
 
March 26, 2012  
 
 Denise Shereff, M.L.I.S., A.H.I.P.  
University of South Florida  
USF College of Medicine  
3650 Spectrum Blvd, Suite 100  
Tampa, FL 33612  
 
   
Dear Ms. Shereff,  
 
Educational Needs of Patients with Systemic Vasculitis- an international 
survey (RDCRN# 5534, protocol version date 15Feb12) has met all 
requirements for activation. Official signoff has been received from the 
Study Chair for the following: all data online CRF forms, all required special  
technical modules.  
 
 As of today‘s date, this protocol has been activated with the DMCC.  
  
Please remember to register this protocol at clinicaltrials.gov. For more 
information on how to register a protocol on clinicaltrials.gov, please refer to 
the following website: http://clinicaltrials.gov/ct2/invest.  
 
  
Please do not hesitate to contact the DMCC with any comments, questions 
or concerns.  
 
  
 
 
Jeffrey Krischer, Ph.D.  
Professor and Chief  
Division of Informatics and Biostatistics  
Director, Pediatrics Epidemiology Center  
University of South Florida  
3650 Spectrum Boulevard, Suite 100  
Tampa, Florida 33612  
E-mail: jpkrischer@epi.usf.edu / Telephone: (813) 396 9512 /Fax: (813) 
396 9601 
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Appendix  F       : INFORMED CONSENT TEMPLATE 
 
Informed Consent Form 
 
Title: Educational Needs of Patients with Systemic Vasculitis- an 
international survey 
 
Sponsor: The National Institutes of Health (NIH) 
   Vasculitis Clinical Research Consortium (VCRC) 
 
What you should know about this study 
You are being asked to take part in a research study. This consent form 
explains the research study and your part in the study. Please read this form 
carefully. It tells you what you need to know about the research study. If 
you agree to take part in this study, you will need to agree to participate at 
the end of this form. 
 
This consent form may contain words that you do not understand. Please 
contact the study staff to explain any words or information that you do not 
understand. Contact information can be found at the end of this consent 
form. 
 
Why is this research being done? 
The purpose of this study is to learn about the information needs you may 
have about your vasculitis and the way you would like to learn more about 
your vasculitis. 
 
 
People 18 years or age and older with one of the following diseases may 
take part in the study: 
 
 Polyarteritis Nodosa  Churg-Strauss Syndrome 
  
  
 Granulomatosis with 
polyangiitis  
 
(Wegener‟s granulomatosis)  
 Microscopic Polyangiitis   
 
What does this study involve? 
This study consists of an online survey located on the Vasculitis Clinical 
Research Consortium website. After reading and understanding this consent 
form, if you decide to participate, you can agree to participate and you will 
be directed to the survey. 
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You will be asked to provide answers to a series of questions related to your 
vasculitis. The survey will contain multiple choice questions, and some 
questions which will require a brief answer. You may choose to skip any 
 question(s) that make you feel uncomfortable. At the end of the 
survey you will be asked to click the submit button in order for your 
responses to be stored in our secure database. It should take approximately 
10-15 minutes to complete the survey. 
 
How many people will be in this study? 
You will be one of approximately 2000 adults asked to participate in this 
study. 
 
What are the possible risks of the study? 
Your responses to the questions on this survey will be anonymous. Some of 
the questions are personal and might make you feel comfortable. You do not 
have to answer any question(s) that you don‟t want to. 
 
None of the information you enter can be linked back to you, we will not 
know who you are when we receive your answers. 
 
Are there benefits to being in the study? 
There are no direct benefits to you for completing the survey. By taking part 
in this survey you may contribute to knowledge about the way patients with 
vasculitis think about their illness. 
 
Will taking part in this research study cost me anything? 
There are no costs to you for participating in this research study. 
 
What are your options if you do not want to join the study? 
Your alternative to participating in this study is not to participate in the 
study. If you do not participate in this study, your regular medical care will 
not be affected. 
 
Confidentiality 
None of the information you enter can be linked back to you, we will not 
know who you are when we receive your answers. 
 
The data you do enter will be kept in a database. The database has 
passwords and security so only researchers and authorized people (including 
the Principal Investigator, study coordinator, and all other research staff) 
will be able to see the data. Certain government and university people who 
need to know more about the study may also look at the data. For example, 
individuals who provide oversight on this study may need to look at your 
records. This is done to make sure that we are doing the study in the right 
way. They also need to make sure that we are protecting your rights and 
safety. The USF Institutional Review Board (IRB) and its related staff who 
have oversight responsibilities for this study, staff in the USF Office of 
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Research and Innovations, USF Division of Research Integrity and 
Compliance, and other USF offices who oversee this research. 
 
The investigators conducting this survey are committed to making the 
results of the research public through scientific presentations and 
publications of research articles. Information from this study may be used 
for research purposes and may be published; however, your name will not 
be used in any publication. 
 
To help us protect your privacy, we have obtained a Certificate of 
Confidentiality from the National Institutes of Health. With this Certificate, 
the researchers cannot be forced to disclose information that may identify 
you (for this study, we will not be able to identify you because the 
information you enter will not be linked back to you and is anonymous), 
even by a court subpoena, in any federal, state, or local civil, criminal, 
administrative, legislative, or other proceedings. The researchers will use 
the Certificate to resist any demands for information that would identify 
you, except as explained below. 
 
The Certificate cannot be used to resist a demand for information from 
personnel of the United States Government that is used for auditing or 
evaluation of Federally funded projects or for information that must be 
disclosed in order to meet the requirements of the federal Food and Drug 
Administration (FDA). 
 
You should understand that a Certificate of Confidentiality does not prevent 
you or a member of your family from voluntarily releasing information 
about yourself or your involvement in this research. If an insurer, employer, 
or other person obtains your written consent to receive research information, 
then the researchers may not use the Certificate to withhold that 
information. 
 
Event with the Certificate of Confidentiality, the investigators continue to 
have ethical and legal obligations to report child abuse or neglect and to 
prevent you from carrying out any threats to do serious harm to yourself or 
others. If keeping information private would immediately put you or 
someone else in danger, the investigators would release information to 
protect you or another person. 
 
Department of Health and Human Services (DHHS) personnel may request 
identifying information for purposes of performing audits, carrying out 
investigations of DHHS grant recipients, or evaluating DHHS funded 
research projects. 
 
Right Not to Participate or to Withdraw 
Participation in this research study is voluntary.  You may choose not to 
take part in this study, or if you agree to take part, you may stop at any time.  
You will not suffer any penalty or lose any benefits if you decide not to take 
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part in the study. You may also skip questions that you do not feel 
comfortable answering. If you begin the survey, and then decide you do not 
want to complete it, your answers will not be stored. In order for your 
answers to be stored, you must click the “Submit” button at the end of 
the survey. 
 
Who do I contact for questions? 
This study is being conducted by researchers at Boston University and the 
University of South Florida in collaboration with other investigators within 
the Vasculitis Clinical Research Consortium. 
 
If you have questions or concerns about this study or about the survey, 
please contact: 
In the United States: 
Dr. Peter Grayson, MD   Denise Shereff, MLIS, AHIP 
Boston University Medical Center  University of South Florida 
College of Medicine 
Division of Rheumatology    Department of Pediatrics 
peter.grayson@bmc.org   denise.shereff@epi.usf.edu 
Tel: (617) 414-2508    Tel: (813) 396-9557 
 
In the United Kingdom: 
Dr. Richard Watts, MD   Janice Mooney, M.Sc. 
University of East Anglia   University of East Anglia 
Norwich School of Medicine   School of Nursing Sciences 
Richard.watts@uea.ac.uk.   j.mooney@uea.ac.uk 
Tel: +44 1473 702131   Tel: + 44 1603 597108 
 
If you have questions about your rights as a research subject, please contact: 
University of South Florida Institutional Review Board 
12901 Bruce B. Downs Blvd., MDC35 
Tampa, FL, USA 33612-4799 
Phone +1 (813) 974-5638; Fax +1 (813)974-7091 
 
Statement of Consent 
I understand the purpose of this study, the procedures to be followed, the 
potential risks and the potential benefits.  I have had the opportunity to ask 
questions, and my questions have been answered to my satisfaction. I have 
been told whom to contact if I have additional questions. I have read this 
consent form and agree to participate in this study, with the understanding 
that I may withdraw at any time. 
 
I certify that I am at least 18 years of age and that I am the vasculitis patient. 
By clicking the “yes” button below, I consent to participate in this research 
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Appendix  F  Study Protocol VCRC 
Educational Needs of Patients with Systemic Vasculitis – an 
international survey 
 
Vasculitis Clinical Research Consortium (VCRC) 
VCRC Protocol 5534 
 
This protocol is for research purposes only, and should not be 
copied, redistributed or used for any other purpose. The procedures 
in this protocol are intended only for use by Consortium 
investigators in carefully controlled settings. The Chair of this study 
should be consulted before using or attempting any procedures in 
this protocol. 
Study Chairs 
Richard A. Watts, D.M. 
Senior Lecturer 
Norwich School of Medicine 
University of East Anglia 
Norwich Research Park 
Norwich NR4 7TJ 
Tel: 01473 702131 
Email: Richard.watts2@me.com 
Peter C. Grayson, M.D. 
Rheumatology Fellow 
Boston University School of Medicine 
Boston University Vasculitis Center 
72 East Concord Street, E-533 
Boston, MA 02118 
Tel: 617-414-2508 
Email: peter.grayson@bmc.org 
Janice Mooney, M.Sc. 
Lecturer 
School of Nursing Sciences 
University of East Anglia 
Norwich Research Park 
Norwich NR4 7TJ 
Tel: 01603 597108 
Email: j.mooney@uea.ac.uk 
Peter A. Merkel, M.D., M.P.H. 
Professor of Medicine 
Boston University School of Medicine 
Boston University Vasculitis Center 
72 East Concord Street, E-533 
Boston, MA 02118 
Tel: 617-414-2501 
Email: pmerkel@bu.edu 
Denise Shereff, M.L.I.S., A.H.I.P. 
Principle Investigator 
University of South Florida 
3650 Spectrum Blvd., Suite 100 
Tampa, FL 33612 
Tel: (813) 396-9557 
Email: denise.shereff@epi.usf.edu 
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PARTICIPATING INSTITUTIONS/INVESTIGATORS TABLE 
(CONTACT INFORMATION) 
 
Boston University Principal Investigator: Peter C. Grayson, M.D. 
Contact: Peter C. Grayson, M.D. 
Institution: Boston University Medical Center 
Address: 72 East Concord Street, E-533 
Phone: (617) 414-2508 
Fax: (617) 414-2510 
Email: peter.grayson@bmc.org 
  
  
University of South Florida Principal Investigator: Denise Shereff, M.L.I.S., 
A.H.I.P. 
Contact: Denise Shereff, M.L.I.S., A.H.I.P. 
Institution: University of South Florida 
Address: 3650 Spectrum Blvd, Suite 100 
Phone: (813) 396-9557 
Fax: (813) 910-5940 
Email: denise.shereff@epi.usf.edu 
  
  
Vasculitis Clinical Research Consortium Principal Investigator: Peter Merkel, 
M.D., M.P.H. 
Contact: Carol McAlear, M.A. 
Institution: Boston University School of Medicine 
Address: 72 East Concord Street, E-533 
Phone: (617) 414-2505 
Fax: (617) 414-2510 
Email: pmerkel@bu.edu 
  
  
Data Management and Coordinating Center Principal Investigator: Jeffrey 
Krischer, Ph.D. 
Contact: Renée Leduc, Research Project Manager 
Institution/ 
Department: 
Data Management and Coordinating Center (DMCC); 
Pediatrics Epidemiology Center; University of South 
Florida 
Address: 3650 Spectrum Blvd, Suite 100; Tampa, FL 33612 
Phone: (813) 396-9308 
Fax: (813) 910-5944 
Email: renee.leduc@epi.usf.edu 
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Appendix  1.  PROTOCOL SYNOPSIS 
 
Protocol Number: 5534 
Protocol Title: Educational Needs of Patients with Systemic Vasculitis 
– an international survey 
Study Chairs: Janice Mooney; Richard Watts; Peter Grayson; Peter 
Merkel; Denise Shereff 
Statistician: Peter Grayson  
Consortium: Vasculitis Clinical Research Consortium (VCRC) 
Participating Sites: N/A 
Activation Date:  
Sample Size: 2000 
Target Enrollment 
Period: 
3-6 months 
Study Design: Registry 
Primary Study Objective: To find out how information is provided and by whom 
and to explore the informational needs and sources 
used by patients with systemic vasculitis in an 
international setting. 
Secondary Study 
Objective: 
To compare the informational needs of patients with 
vasculitis from the United States to patients from the 
United Kingdom. 
Study Population and 
Main Eligibility/ Exclusion 
Criteria: 
Inclusion Criteria 
 Enrolled in VCRC Contact Registry 
 Patient reported diagnosis of granulomatosis 
with polyangiitis (Wegener‘s granulomatosis), 
Microscopic Polyangiitis, Churg-Strauss 
Syndrome, Polyarteritis Nodosa 
 18 years of age or older 
 English speaking 
Exclusion Criteria 
 Inability to provide informed consent and 
complete survey 
Primary Outcome 
Measures: 
1. Relative ranking of the importance of the 
components of patient educations and 
preferred method of education. 
Sponsors (federal, state, 
foundation and industry 
support): 
National Institutes of Health (NIH) 
 
 
1.1 OVERVIEW 
The purpose of this study is to learn about the informational needs of patients with 
systemic vasculitides and their preferred method of education. 
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2. OBJECTIVE 
The aim of the proposed study is to find out how patients with vasculitis are 
provided information about the disease and to explore the informational needs and 
sources used by patients with systemic vasculitis. 
 
2.1 BRIEF PROJECT DESCRIPTION 
A cross-sectional study design and online questionnaire will be used to assess the 
informational needs in patients with several different types of systemic vasculitis.  
Patients will be recruited from within the Vasculitis Clinical Research Consortium 
(VCRC) online Patient Contact Registry
1
.   Survey response from participants in 
the VCRC Patient Contact Registry will be compared to responses from a similar 
survey recently administered to patients within a United Kingdom (UK) based 
vasculitis support group (Vasculitis UK). 
 
2.2 DETAILED DESCRIPTION 
All patients enrolled in the Vasculitis Clinical Research Consortium‟s Contact 
Registry will be invited via email to participate in this study.  The Contract 
Registry includes people who self-identify as having one of the following types of 
vasculitis: granulomatosis with polyangiitis (Wegener‟s), microscopic polyangiitis, 
Churg-Strauss syndrome, polyarteritis nodosa, Takayasu‟s arteritis, giant cell 
arteritis, Behcet‟s disease, Henoch-Schöenlein purpura, or CNS vasculitis. People 
voluntarily enroll in this Registry with the understanding that they will receive 
information about clinical studies for which they might be eligible.  The 
introductory email will include basic information about the study and all of the 
required elements for informed consent in a brief format.  Once participants agree 
to participate in the study, then they will be directed to the online questionnaire. 
  
When completing the questionnaire, the patients will be asked a series of 
questions.  The questionnaire content is included as an appendix. The online 
questionnaire version will be thoroughly tested for usability. 
  
It is expected that most participants will require approximately 10-15 minutes to 
complete the questionnaire. 
  
The survey data will be stored by the Rare Diseases Clinical Research Network 
Data Management and Coordinating Center (DMCC) at the University of South 
Florida.  The data will be de-identified. Names or other personal health information 
will not be collected. 
 
2.3 AIMS/HYPOTHESES 
 
We hypothesize that the informational needs and sources of information sought by 
patients are similar despite differences in local health care provision and country of 
origin.  
 
 
3. BACKGROUND 
 
 260 
 
Modern therapy has converted the systemic vasculitides from conditions with a 
very poor outcome to chronic diseases, which relapse and remit. Little is known 
about the informational needs of this group of patients. Patients with rare diseases 
often experience difficulty accessing accurate information about their condition 
because their attending physician may not have experience of the condition, nor do 
members of their social network. We have conducted a postal survey of 329 
members of a UK based patient support group (Vasculitis UK). There were 255 
Granulomatosis with polyangiitis (GPA) patients, 46 Churg Strauss, 15 
polyarteritis nodosa and 13 microscopic polyangiitis. The survey was developed 
using three focus groups and eight face: face interviews. It was then piloted using 
further 20 patients to check for language and content.  We demonstrated that 
patients want accurate up to date information delivered by an experienced 
healthcare professional, and that this education needs to be given in two phases
2
. 
Patients ranked information designed to improve their knowledge about the disease 
most highly and were less interested in receiving information about psychosocial 
support. Patient informational needs during the acute phase of the illness were very 
different from those in the later chronic phase. We wish therefore to compare our 
results from the UK with an international group of patients.  
 
4. STUDY DESIGN AND METHODS 
 
There are no interventions for this study. Participants will complete an online 
survey. Once the participant has completed the survey, no follow-up contact will 
be made. 
 
Data will be collected and stored by the Rare Diseases Clinical Research 
Network‟s Data Management and Coordinating Center at the University of South 
Florida. Analysis will be done in collaboration with Peter Grayson at Boston 
University Medical Center.  
 
4.1 INCLUSION CRITERIA 
 Enrolled in the VCRC Contact Registry 
 Patient reported diagnosis of granulomatosis with polyangiitis (Wegener‟s 
granulomatosis), Microscopic Polyangiitis, Churg-Strauss Syndrome, 
Polyarteritis Nodosa 
 18 years of age or older 
 English speaking 
 
4.2 EXCLUSION CRITERIA 
 Inability to provide informed consent and complete survey 
 
4.3 PATIENT RECRUITMENT  
Patients will be recruited from within the Vasculitis Clinical Research Consortium 
(VCRC) Patient Contact Registry to participate in an online questionnaire. More 
than 3000 patients, representing all the different types of idiopathic vasculitis, are 
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currently enrolled into the on-line registry. The different types of vasculitis 
available for study include: granulomatosis with polyangiitis (Wegener‟s 
granulomatosis), microscopic polyangiitis, Churg-Strauss Syndrome, polyarteritis 
nodosa, giant cell arteritis, Takayasu‟s arteritis, Henoch-Schöenlein purpura, 
Behçets disease, and CNS vasculitis.  
 
VCRC Contact Registrants by Disease (as of November 2011) 
Disease N Percent 
Granulomatosis with Polyangiitis 
(Wegener‟s) 
1424 46% 
Microscopic Polyangiitis 151 5% 
Churg-Strauss Syndrome 526 17% 
Polyarteritis Nodosa 243 8% 
Giant Cell Arteritis 159 5% 
Takayasu‟s Arteritis 322 10% 
Henoch- Schöenlein Purpura* 23 0% 
Behçets Disease 220 7% 
CNS Vasculitis* 20 1% 
Other 27 1% 
Total 3115 100% 
* Recruitment into Contact Registry only recently commenced. 
 
Online Questionnaire Design and Implementation: 
The Data Management and Coordinating Center (DMCC) at the University of 
South Florida serves as the coordinating center for data management and analysis 
infrastructure for the Rare Diseases Clinical Research Network. The DMCC has 
expertise in web based recruitment and referral tools and maintains the VCRC 
Patient Contact Registry. The DMCC will assist in the development and 
implementation of the questionnaire for this project. At present, one VCRC 
questionnaire study has been successfully completed online through the Contact 
Registry, and recruitment efforts were extremely encouraging.  
 
Online Questionnaire Elements: 
We will conduct an internet survey of members of the VCRC Contact Registry. We 
will use the same questionnaire that we used for our survey of members of 
Vasculitis UK. The language used in the survey has been modified for international 
use but the content has been preserved. The survey is divided into three sections: i) 
how information is given at diagnosis and by whom; ii) patients are asked to rank 
using a 5 point scale how important it is to be given information on the following 
categories: disease, medication and side effects, disease management, investigative 
tests and psychosocial care (1= not important to 5 = extremely important); iii) asks 
about the preferred method of information delivery. 
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5. SAFETY MONITORING 
If participants contact USF to report an adverse reaction to the survey, USF will 
report the adverse event via the adverse event data monitoring system (AEDAMS). 
Otherwise patients will not be solicited for adverse events. 
 
5.1 DATA AND SAFETY MONITORING PLAN 
The study protocol will be reviewed by the National Institutes of Health (NIH). 
Participant enrollment may only begin with an IRB approved protocol and consent 
form. 
 
This is an observational/survey study that meets the federal definition of minimal 
risk.   
 
5.2 STUDY OVERSIGHT 
The Study Chair has primary oversight responsibility of this clinical trial. The NIH 
has oversight responsibility of the Data Safety Monitoring Plan (DSMP) for this 
study. The Study Chair will review accrual, patterns and frequencies of all adverse 
events (if applicable) and protocol compliance after the accrual period has ended. 
 
5.3 DEFINITIONS AND STANDARDS 
The Rare Diseases Clinical Research Network defines an adverse event as: “…an 
unfavorable and unintended sign, symptom or disease associated with a 
participant‟s participation in a Rare Diseases Clinical Research Network study.” 
 
Serious adverse events include those events that: “result in death; are life-
threatening; require inpatient hospitalization or prolongation of existing 
hospitalization; create persistent or significant disability/incapacity, or a congenital 
anomaly/birth defects.” 
 
An unexpected adverse event is defined as any adverse experience… the specificity 
or severity of which is not consistent with the risks of information described in the 
protocol. 
 
Expected adverse events are those that are identified in the research protocol as 
having been previously associated with or having the potential to arise as a 
consequence of participation in the study. 
 
All reported adverse events will be classified using version 3.0 of the Common 
Terminology Criteria for Adverse Events (CTCAE) developed and maintained by 
CTEP at National Cancer Institute. 
 
Only those events associated with the conduct of the study and as defined above 
are reportable. 
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5.4 REPORTING TIMELINE 
 Within 24 hours (of learning or the event), investigators must report any 
reportable Serious Adverse Event (SAE) that: 
o Is considered life-threatening/disabling or results in death of 
subject 
-OR_ 
o Is Unexpected/Unanticipated 
 Investigators must report all other reportable SAEs within 5 working days 
(of learning of the event). 
 Al other (suspected) reportable AEs must be reported to the RDCRN 
within 20 working days of the notification of the event or of the site 
becoming aware of the event. 
 
Local institutional reporting requirements to IRBs, any GCRC oversight committee 
and the FDA, if appropriate, remain the responsibility of the treating physician and 
the Study Chair. 
 
5.5 RDCRN Adverse Event Data Management System (AEDAMS) 
Upon entry of a serious adverse event, the DMCC created Adverse Event Data 
Management System (AEDAMS) will immediately notify the Study Chair, the PIs, 
the Medical Review Officer, and any additional agencies of any reported adverse 
event via email. 
 
Serious adverse events: The NIH appointed Medical Review Officer (MRO) 
determines causality (definitely not related, probably not related, possibly related, 
probably related, definitely related) of the adverse event. The MRO may request 
changes to the protocol or consent form as a consequence of the adverse event. A 
back-up notification system is in place so that any delays in review by the MRO 
beyond a specified period of time are forwarded to a secondary reviewer.  The 
Adverse Event Data Management System (AEDAMS) maintains audit trails and 
stores data (and data updated) and communication related to any adverse event in 
the study. 
 
The DMCC will post aggregate reports of all adverse events (serious/not serious 
and expected, unexpected) for site investigators and IRBs. 
 
5.6 STUDY DISCONTINUATION 
This study will not have any discontinuation rules as it is an observational/survey 
study.  The NIH and USF IRB have the authority to stop or suspend this trial at any 
time. 
 
5.7 SUBJECT DISCONTINUATION 
This is a one-time anonymous survey. All survey data submitted will be included 
in the primary analysis. 
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5.8 DATA QUALITY AND MONITORING MEASURES 
As much as possible data quality is assessed at the data entry point using intelligent 
on-line data entry via visual basic designed screen forms.  Data element 
constraints, whether independent range and/or format limitations or „relative‟ 
referential integrity limitations, can be enforced by all methods employed for data 
input. QA reports assess data quality post-data entry.  As we note, data quality 
begins with the design of the data collection forms and procedures and incorporates 
reasonable checks to minimize transcription and omission errors. Of the more 
important quality assurance measures are the internal validity checks for 
reasonableness and consistency. 
 
6. STATISTICAL CONSIDERATIONS 
Data will be collected by the Rare Diseases Clinical Research Network‟s Data 
Management and Coordinating Center at the University of South Florida.  Analysis 
will be done in collaboration with Peter C. Grayson and investigators from the 
University of East Anglia. 
 
6.1 STATISTICAL METHODS  
We will describe the VCRC group as a whole compare the results with the UK 
group for differences basic demographics, vasculitis education received, the 
relative ranking of the importance of the components of education (q16) and their 
preferred methods of education. In addition we will conduct a subanalysis to 
compare the USA patients with the UK patients. The majority of the UK study 
participants had GPA and we will therefore specifically analyze this group 
separately. We will also compare the different types of vasculitis within the VCRC. 
Where appropriate we will determine a p value using chi-squared test. The 
information needs importance questionnaire (q16) is a Likert scale with 5 points 
and will be analyzed using the Mann-Whitney U test for each individual 
subquestion. P values of <0.05 will be considered significant. 
 
6.2 ESTIMATE OF RESPONDENTS NEEDED 
The UK study had 255 GPA patients and we would hope for a minimum of 255 
GPA respondents from the VCRC to give 1:1 sample size.  The VCRC has 3115 
participants in November 2011 (1424 GPA registered participants) so we do not 
anticipate any problem in obtaining sufficient numbers of responses from non-UK 
based responders. Some UK GPA patients may be VCRC participants and 
therefore we will exclude UK based respondents. For the other disease types with 
in the VCRC we will only perform comparisons for those with samples sizes 
greater than 250. 
 
7. DATA MANAGEMENT 
Data will be entered directly into the electronic case report form. All study data 
will be collected via systems created in collaboration between the RDCRN Data 
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Management and Coordinating Center, the VCRC and Boston University and will 
comply with all applicable guidelines regarding patient confidentiality and data 
integrity. 
 
7.1 DATA ENTRY 
Data collection for this study will be accomplished via an online electronic case 
report form. Using encrypted communication links, on-line forms will be 
developed that contain the requisite data fields. 
 
7.2 DATA QUALITY CONTROL 
As much as possible data quality is assessed at the data entry point. The majority of 
the survey questions are close ended questions. Data elements constraints, whether 
independent range and/or formal limitations or „relative‟ referential integrity 
limitations, can be enforced by all methods employed for data input. QA reports 
assess data quality post-data entry.  As we note, data quality begins with the design 
of the data collection forms and procedures and incorporates reasonable checks to 
minimize transcription and omission errors. Of the more important quality 
assurance measures are the internal validity checks for reasonableness and 
consistency. In addition to those described above, we propose to build these checks 
into the initial tables and cross tabulations that should reveal any remaining data 
quality issues. 
 
8. HUMAN SUBJECTS 
8.1 GCP STATEMENT 
 
This clinical trial will be conducted in accordance with the ethical principles that 
have their origin in the Declaration of Helsinki, and that are consistent with Good 
Clinical Practice and all applicable regulatory requirements. 
 
8.2 RISKS 
This study poses minimal risk to participants. There is no physical risk to 
answering the study questions. The participant will have the option to skip any 
question(s) which make them feel uncomfortable. 
  
A potential, however extremely unlikely, risk is a risk of loss of privacy. The data 
collected will be anonymous and will not include personal health information. The 
investigators believe that there will be no breach in privacy and have designed this 
survey to ensure risk to privacy is negligible. No PHI will be collected. 
Additionally, all data collected is stored according to strict security protocols (as 
described above). 
 
8.3 BENEFITS 
There is no direct benefit for participating in the study. 
 266 
 
 
8.4 RECRUITMENT 
Participants that are part of the VCRC Contact Registry will be contacted via email 
and asked if they are interested in participating in this one time survey. 
 
8.5 INFORMED CONSENT 
Informed consent will be obtained from each participant before the participant will 
have access to the study questionnaire and after the participant has been able to ask 
questions regarding the aims, methods, anticipated benefits, and potential hazards 
of the study. The participant‟s willingness to participate in the study will be 
documented. The participant will need to agree to participate in the study via the 
electronic consent form. There will be no hard copy informed consent forms 
(ICFs). The informed consent document will convey to the participants that they 
are free to refuse entry into the study and free to withdraw from the study at any 
time without prejudice to future treatment. Written and/or oral information about 
the study in a language understandable by the participant will be given to all 
participants. 
 
8.6 PROCESS OF CONSENT 
Potential participants will be contacted via email. The consent process will occur 
online. The introductory email will contain the informed consent document with all 
of the required elements of informed consent. The participant will need to agree to 
participate in the study prior to the participant accessing the online survey. 
 
The online system will not collect the subject‟s name, only the fact that the 
participant agreed to participate.  We are not collecting subjects‟ names on the 
consent form/during the ICF process as this would be the only link (PHI) to the 
subject as the study is designed. 
 
Potential participants will be able to read the consent information in the privacy of 
their own home or other location where they access the internet. Potential 
participants may take as much as is needed to read the consent form. In the 
introductory email, as well as on the VCRC website, study staff contact 
information (both phone and email) will be provided so participants can contact the 
study staff with any research related questions.  The VCRC Contact Registry and 
the survey are voluntary.  The study will not be presented to the participant by the 
person who controls the health care of the participants. Potential participants who 
do not read English will not be able to participate. 
 
8.7 CERTIFICATE OF CONFIDENTIALITY 
To help protect participant privacy, a Letter of Confidentiality has been obtained 
by the National Institutes of Health (NIH). With this Certificate, the researchers 
cannot be forced to disclose information that may identify a study participant, even 
by a court subpoena, in any federal, state, or local civil, criminal, administrative, 
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legislative, or other proceedings. The researchers will use the Certificate to resist 
any demands for information that would identify a participant, except as explained 
below. 
 
The Certificate cannot be used to resist a demand for information from personnel 
of the United States Government that is used for auditing or evaluation of Federally 
funded projects or for information that must be disclosed in order to meet the 
requirements of the federal Food and Drug Administration (FDA).  Even with the 
Certificate of Confidentiality, the investigators continue to have ethical and legal 
obligations to report child abuse or neglect and to prevent an individual from 
carrying out any threats to do serious harm to themselves or others. If keeping 
information private would immediately put the study participant or someone else in 
danger, the investigators would release information to protect the participant or 
another person. 
 
Department of Health and Human Services (DHHS) personnel may request 
identifying information for purposes of performing audits, carrying out 
investigations of DHHS grant recipients, or evaluating DHHS funded research 
projects. 
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Appendix G     Focus group interview guide  
 
 
 
1. What struck you most about this story? 
(Facilitate easy discussion not necessarily from each member) 
 
2. What is it like being told you have vasculitis? 
 
 
3. How can this be changed to help more with the experience of being 
told ? 
 
4. What is it like living with vasculitis? 
 Resources? What actions would be helpful? Why?) 
 
5. What knowledge or information do you think should be available to 
help you manage living with vasculitis? 
 Contacts?  Resources helpful? What actions would be 
helpful/unhelpful? Why?) 
 
 
Closing Discussion (NB Allow about 10 mns) 
 
- Has taking part in today‘s discussion changed your views?  If so, 
what? 
- Is there anything we have talked about that now strikes you as 
particularly important?  If so, what? 
 
Conclusion 
Informal – fit with tone and topics covered. 
- Value the work they have done 
- Underline the value of the evidence they have produced 
- Emphasise that the work will be eventually reported widely, 
including articles and workshops and will have real outcomes in 
redesigned information and training for health and social care 
professionals working with people with vasculitis. 
 
 
Thank you so much for coming to talk to us today. 
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Appendix H     One to one interview guide  
 
 
1. What struck you most about this story? 
 
2. What is it like being told you have vasculitis? 
 
3. How can this be changed to help more with the  
 experience of being told ? 
 
4. What is it like living with vasculitis? 
 Resources? What actions would be helpful? Why?) 
 
5. What knowledge or information do you think should  
 be available to help you manage living with  
vasculitis? Contacts?  Resources helpful? What 
actions would be helpful/unhelpful? Why?) 
 
 
 
 
Thank you so much for coming to talk to us today. 
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Appendix I Information sheet and consent 
 
 
 
What Are The Information Needs Of Patients With Primary 
Systemic Vasculitis? Development of an Educational 
Programme 
 
Please take time to read the following information carefully and 
discuss it with others if you wish. Ask us if there is anything that is 
not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. 
 
Thank you for reading this information sheet. 
 
What is the purpose of the study? 
 
The purpose of the study is to explore the educational needs of 
patients with primary systemic vasculitis, so that the researchers can 
develop an education programme that is patient centred and reflects 
patient‘s needs. 
 
 
Why have I been chosen? 
 
You have been chosen to take part because you have been 
diagnosed with a condition of vasculitis and your doctor thinks you 
are suitable for the study. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you do decide 
to take part, you will be asked to fill in the tear off slip at the bottom of 
the patient letter and to return it in the pre paid envelope.  
You will then be contacted by the researcher and asked to sign a 
consent form. If you decide to take part, you are still free to withdraw 
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at any time without giving a reason.  Any decision that you make to 
withdraw at any time or a decision not to take part will not affect the 
standard of care you receive and we will continue to look after you in 
the same way. Your doctor may withdraw you from this study if it 
appears to be in your best interest to do so. 
 
 
 
What will happen to me if I take part? 
You will be invited to participate in two separate discussion groups 
(called focus groups) or a face to face interview. The focus groups 
will take place at the Norfolk and Norwich University Hospital in a 
private room and will last between 1 and 2 hours each. The 
interviews will be recorded. 
 
The face to face interviews will take place in a private room at the 
Norfolk and Norwich University Hospital and will last 1 hour.  The 
interviews will be tape recorded. After the tapes have been 
transcribed you will be contacted by telephone by the researcher to 
confirm that the data transcription is correct. You will have been sent 
a written copy of this in advance. 
 
This will have no impact on your continuing care and treatment.  
 
Will I be reimbursed for any expenses? 
You will be reimbursed for your travel and parking expenses. 
  
What are the side effects of taking part? 
None are known of. 
 
What are the possible disadvantages and risks of taking part? 
There are no side effects associated with being involved in the study. 
 
What are the possible benefits of taking part? 
We hope that the study will provide information about the educational 
needs of patients with primary systemic vasculits, so that we can 
develop an educational programme around patients needs.  
 
 
What happens when the research study stops? 
This will be the first study of the educational needs of vasculitis 
patients in the UK. It will provide an educational resource for both 
patients and health professionals. The doctors looking after you will 
continue to look after you in the same way as before the study. 
 
What if something goes wrong? 
The study involves participation in discussion groups and a possible 
face to face interview. There are no special compensation 
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arrangements if anything were to go wrong. If you were harmed by 
someone's negligence then you may have grounds for a legal action 
but you may have to pay for it. Regardless of this, if you wish to 
complain or have any concerns about any aspect of the way you 
have been approached or treated during this study the normal NHS 
complaints mechanism will be available to you. 
 
Will my taking part in this study be kept confidential? 
All information collected in the focus groups and interviews will be 
kept strictly confidential. The information from the focus groups and 
interviews will be audio taped and transcribed word for word. The 
tapes will be stored in a locked cabinet and they will be labelled 
focus group Norwich, Birmingham or Romford. All of the information 
will be collected and stored in an anonymous form on a computer 
that will be only available to members of the study team, who will be 
present to analyse the data. The study team comprises of doctors, 
university lecturers and a research nurse. It will not be possible to 
identify you as an individual from any of the collected information that 
we are going to use for this research project.  You will not be 
identified in any report or publication arising from the study. 
 
What will happen to the results of the research study?  
At the end of the study, the information gathered will be analysed 
and used to produce a written education package that will be 
available via the internet. A report will also be written for a medical 
journal. We will also plan to talk about the research findings at 
academic meetings. It will not be possible to identify you as an 
individual in any of these written reports or talks. This will help to 
ensure that UK doctors and nurses are aware of the results so that 
patients with primary systemic vasculitis can be educated more 
effectively. The tapes will be destroyed after 5 years. 
 
Who is organising and funding the research? 
The central study organiser is Dr RA Watts at the School of 
Medicine, Health Policy and Practice, University of East Anglia, 
Norwich. The study is funded by the Arthritis Research Campaign. 
The doctors involved are not being paid for recruiting patients into 
the study. The researcher (Ms Janice Mooney) is planning to use the 
results of this study as part of her thesis for a PhD degree. 
 
What if I have any concerns? 
If you have any concerns or other questions about the study or the 
way it is being carried out, you should contact the local investigator 
(see below) at your local hospital or you may contact the Complaints 
Department at your local hospital, local health authority, or primary 
care trust. 
 
Contact for Further Information 
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You should keep this information sheet in a safe place. If you have 
any further questions about the study, you can contact: 
 
Dr Richard Watts (Consultant Rheumatologist) 01473 702362 
Ms Janice Mooney (Researcher) 01603 597108 
 
If you wish to get in touch with someone who can provide further 
information about the study with impartial advice please contact:  
 
Dr Suzanne Lane (Consultant Rheumatologist) on 01473 702131 
 
Thank you for taking the time to consider participating in this study. 
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Appendix J The Chapel Hill Consensus Conference definitions (Jennette et 
al., 1994) 
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Appendix K First Thematic Framework 
 
 
 
Physical
 Exhaustion
 Unwell
 Debilitating 
 Reduced mobility
 Impairment
 Side Effects medication
Long time to diagnosis
 Vague symptoms
 Seen by many doctors
 Please take me seriously I'm ill
 Validation of symptoms
 Reassurance and support
 
Treatment
 Medications
 Chemotherapy
 Side effects
 Monitoring
 Regimes
 Information at 
diagnosis
 Serious
 Rare
 Symptoms
 Prognosis
 How diagnosed
 Treatment options
 Investigations and results
 Biopsies
 Blood tests
 Anca
 X-rays
 Test results
DIAGNOSIS 
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Appendix L Example of Chart Road to Diagnosis 
 
 
Res   
 Chart 1               Road to Diagnosis 
 
 1:1Time To Diagnosis 1:2 Investigations 1:3 Symptoms 1:4 Validation of 
symptoms 
1:5Dr‟s Behaviour 1:6 Confirmation 
NP7 3 yrs Lots of tests 
The biopsies 
Vague that‟s a 
good heading 
   
NP6 Sent down lots of odd paths, I 
went away with another 
diagnosis 
Took 3/12‟s 
Kidney biopsy, 
blood tests, eye 
biopsy 
Lethargy, not 
being able to do 
anything, tired, 
quite ill. Feeling 
worse and worse 
VAGUE  
 Only when my liver started going  
wrong and that it showed in the 
blood test, they stared to take me 
seriously  
I‟m not critising GP‟s. who have a 
tough job in my opinion 
You are going to have to go to 
experts, we don‟t know what‟s 
wrong with you  
 
 
NP2 About 3 years Blood tests urine 
tests , full of tests 
Sleeping all day 
and night 
I told you I was ill. I 
thought I was going to die, 
I‟m not depressed, nothing 
wrong with my marriage, 
please do something 
I felt so ill, then I collapsed 
Treated like I was mental going off 
my head 
 
NP4 2-3 months  Being ill    
NP3   really ill, hardly 
walk up stairs 
 Lucky had young medic 
I‟ve got one dr in our practice who 
is unhelpful, he said I don‟t know 
why you have come to see me 
because I know nothing about 
you‟re complaint 
 
NP2    pains in  stomach, 
knees swollen, 
couldn‟t walk  
 I‟m bitter about it we called dr out, 
said why haven‟t you come down 
the surgery. He got hold of my arm 
dragged me off the settee, walked 
 
 278 
 
me across the room‟ there you can 
walk „Then he apologized to my 
husband 
NP5 We all seem to have had 
problems, starting with dr‟s, 
backwards and forwards to dr‟s  
We‟ll do a blood 
test straight away, 
you‟re going into 
hospital for 3 days 
for tests, had 
kidney biopsy, 
liver biopsy 
 
Had flu, lethargy, 
joint pains, didn‟t 
want to eat, sleep, 
went deaf 
You don‟t look so well, the 
heat in you‟re body, there‟s 
something going on here- 
we‟ll do a blood test 
straight away 
 I think I know what you‟ve got, 
its very rare, very unusual, I‟m 
going to ask then to test for 
Wegeners 
NP1      
Do you know it costs £50 to call me 
out this afternoon, would you have 
called me. I know all about a call 
out. I was furious  
We „re really angry how my wife 
was treated  
 
 
BP1     You go to you‟re doctor and he 
can‟t help you 
 
BP3 I was diagnosed 6/12 later       
BP4 My GP was very quick and sent 
me almost as soon as possible 
I was really lucky my gp was 
extremely quick to get me into 
hospital  
Blood tests, 
kidney biopsy  
  Dr x looked after me for 3 years , it 
was great 
 
BP5 Gp was on the ball, got me an 
appointment the next day 
Blood tests, tests 
galore, muscle 
biopsy 
Mysterious 
symptoms, 
difficult to walk, 
difficult to eat, 
difficult to use my 
hands, difficult to 
get up and down 
stairs, hearing 
going, ache all 
over. Polyps in my 
nose again l241 
Foot drop 
I was presented with pan as 
soon as I was diagnosed, 
that was a good start 
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BP2  X-rays, some tests High 
temperatures, 
hearing had gone , 
chest infection, 
sinuses , UTI, 
attacked my 
kidneys and lungs 
l353  
   
RP3 2 years biopsy you were still 
walking around, I 
didn‟t know why I 
felt so ill, earache, 
hole in my nose   
  My husband was really, we are 
going somewhere else to get a 
second opinion 
RP5 2/12  Just paralysis I wrote to my father and 
said unless you get me out 
of this hospital I won‟t 
have long to live 
Luckily a dr there had seen 
this case before and he said 
you‟re about one of the 6 
in the world. 
 Do you think you should get 
another second opinion 
RP4   Couldn‟t walk    
RP1  Blood tests, more 
blood tests, ecg, 
checked liver, 
checked bowel, 
checked nose, 
taken biopsies, 
excise lump 
Felt feverish, 
fainted, pains, 
can‟t eat, can‟t 
drink,  
How can it be in my mind, 
I get fever 
I‟m sorry they are showing nil 
nothing is wrong with you hr said it 
must be in you‟re mind  
The result is everything is clean but 
you have a lump it may be vasculitis 
I trust him implicitly he is a wise 
man so he must know what he is 
doing 
 
The Dr  says I‟ve got 
vasculitis, then I‟ve got 
vasculitis 
I still don‟t know to be frank 
554 
Well I don‟t know maybe I 
should have another opinion, 
but I am in the complete dark, 
zero dark 
I 1 I kept going to the dr‟s Bt‟s, Lost use of hands 
feet, stomach 
ache, lost weight 
 Angry- I an ill, kept going back, 
saw someone else, getting worse 
and worse, they were still giving  
you different things , you can see 
things aren‟t working  
 
12 4 days, that is the luckiest thing 
ever 
   Excellent at hospital  
13 3 days, absolutely wonderful, Blood tests biopsy Picked up on bt  Excellent at hospital Serious 
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Gp great  
I4 3 years Lots tests   Excellent dr Rare 
15 3 weeks Urgent scan, chest 
x-ray 
Dry throat, blisters 
in mouth, rash, 
joint pains, 
bleeding in lungs 
Oh you have nothing 
wrong with you, then my 
leg blew up, then I came 
into hospital, thought 
DVT, did chest x-ray I was 
bleeding into my lungs, 
realized I‟d got a big 
problem 
Looked after me wonderful in 
hospital  
 
16 18 months 6 operations on  
nose 
   Relief, now know what it is 
17       
18 Long time    Passed from one consultant to 
another, begged last one don‟t pass 
me over, excellent dr 
Serious 
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Appendix M  Mapping concepts from first qualitative phase sent to 
participants     
 
Information on Diagnosis  
• Symptoms 
• Serious  
• Rare 
• Prognosis 
• How diagnosed 
 
Investigations and results 
• Biopsies 
• Investigations 
• Test results 
• Blood tests 
 
Treatment 
• Chemotherapy 
• How doctors make treatment decisions 
• Side effects medication 
• Monitoring 
 
Management 
• Life changes 
• Drugs 
• Uncertainty 
• Research 
• Results 
• Follow up 
• Access to information / knowledgeable practitioners  
• Self help 
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Appendix N Letter re validation of thematic framework 
   
 
      Janice Mooney – arc Research 
Office 
Department of Rheumatology 
Norfolk & Norwich University 
Hospital 
Colney Lane 
Norwich 
NR4 7UY  
 
Dear 
 
             Regarding the study that you took part in „What Are The 
Information Needs Of Patients With Primary Systemic Vasculitis? 
Development of an Educational Programme‟ I am pleased to provide you 
with information on the study progress to date. I have collected and 
analyzed the three focus groups and data from the one to one interviews so 
far.  
  
I have included a diagram titled First Thematic Framework of Road to 
Diagnosis of PSV in which I have grouped together the common themes 
from the focus groups for your information. I would be grateful if you could 
look at it and consider if you feel it represents some / all of the things 
discussed.   
I have also included a sheet on Information on Diagnosis which again was 
drawn  
If you could either write the comments on the sheets included or write your 
comments on a separate sheet and return in the prepaid envelope provided 
or I can discuss the results with you in a telephone conversation if you 
prefer. 
 
Janice Mooney – arc Research Office 
Department of Rheumatology 
Norfolk & Norwich University Hospital 
Colney Lane 
Norwich 
NR4 7UY  
 
Thank you for spending the time to do this.   
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Appendix O Adaptaion of the TINQ               
Adaptation of the TINQ Adab et al 
2004  
Thorpe et al 
2008 
Themes from 
first phase 
What the symptoms are  
Yes, but more 
specific  
Yes but non 
specific 
Yes 
What causes my vasculitis Yes No Yes 
If my vasculitis is 
hereditary 
No No Yes 
If it is contagious No  No Yes 
How it is diagnosed   No No Yes 
The reasons why doctors 
suggest certain tests.e.g. 
x-rays, scans and biopsies  
No No Yes 
How will I  feel during / 
after investigative tests 
No No No 
The results of tests carried 
out 
No No Yes 
What the results of blood 
tests mean 
No No Yes 
How often I should have 
blood tests 
No No  
The names of drugs used 
to treat vasculitis  
Yes but 
changed to 
vasculitis 
No Yes 
How my treatment is given 
Yes, but more 
specific 
No Yes 
How my treatment was 
chosen 
No No Yes 
If there is evidence to 
support my treatment  
No No Yes 
How to prepare for my 
treatment  
No No No 
The possible side effects 
of treatment 
Yes Yes Yes 
If there are ways to 
prevent /ease treatment 
side effects 
No Yes Yes 
What side effects I should 
report to the doctor/nurse 
No Yes Yes 
If I have side effects how 
to deal with them 
No Yes Yes 
Who I should call if I have 
any concerns during 
treatment 
No Yes Yes 
How long will I require 
treatment 
No No Yes 
How the illness will affect 
my life  
Yes No Yes 
How my vasculitis will be 
monitored 
No Yes Yes 
How my illness could affect 
my life in the future 
Yes No Yes 
If there are any changes I 
should make to my lifestyle   
No Yes Yes 
If I can continue with my 
usual sports/hobbies 
No Yes Yes 
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Appendix P Permission to adapt the TINQ 
 
To: sales 
Subject: Permissions Request Received 
 
Permissions Request Received:  
ISBN: 9780826198594 
Title: Measurement Tools in Patient Education, Second 
Edition - 
Author: Barbara K. Redman, PhD, RN, FAAN 
 
Name: Janice Mooney 
Company: University of East Anglia 
Address: Edith Cavell Building  
         Colney Lane, Norwich , 0  NR4 7tl 
         United Kingdom 
 
Phone: 01603597108  Email: j.mooney@uea.ac.,uk 
 
Pages: 
249-255 ( only 32 item bit of questionnaire)  
 
Reason: 
to adapt the tool for use in primary systemic 
vasculitis patients as part of my PhD thesis 
 
Dear Janice,  
 
Thank you for your request to reproduce material from 
Springer Publishing's MEASUREMENT TOOLS IN PATIENT 
EDUCATION, SECOND EDITION. Due to the fact that this 
material will be used for academic purposes, to be 
included as a part of your PhD thesis, there is no 
charge to use this material. We only ask that you cite 
the original source and Springer Publishing Company as 
the copyright holder. If you have any further 
questions, please let me know.  
 
Best wishes,  
 
Carrie Neff 
Sales Administrator 
Springer Publishing Company, LLC 
www.springerpub.com 
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Appendix Q      Vasculitis Informational Needs Questionnaire (UK)                                                      
 
 
 
 
 
Dr Richard Watts and Janice Mooney are independent researchers working at the University 
of East Anglia and are carrying out a research project funded by the Arthritis Research 
Campaign (arc).This is called ‗What are The Information Needs of Patients with Primary 
Systemic Vasculitis? Development of an Educational Package. The purpose of the study is to 
explore the educational needs of patients with vasculitis, so that we can develop an education 
programme and materials that best reflect your needs.  
 
Please take time to help, by filling in this questionnaire. You do not need to give your 
name, and your answers are strictly confidential. You can tick to show your answer, 
or write in comments if you prefer. 
It may take approximately 10-15 minutes of your time to complete. 
We are grateful to the Stuart Strange Trust for giving us permission to include this 
questionnaire alongside the newsletter. 
 
 
1. What is your date of 
birth?  
       
 
2.    Are you?                   Male               
Female  
         
 
3.    Is English your first language? 
  
 
          
4.    Which postcode area do you live   
in?  
 
Add the first four letters of your postcode  
If you do not know it please write the town below 
 
 
Vasculitis Informational Needs Questionnaire 
Day   Month   Year   
  Yes            No  
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5. Please give your ethnic group? Please tick one. 
 
A White  B Mixed  
       British       White and Black Caribbean  
       Irish       White and Black African  
       Any other white Background       White and Asian  
       Any other mixed background  
    
C Asian or Asian British  D  Black or Black British  
   Any other Asian background  E  Chinese or other ethnic group  
 
 
6. What is the highest level of education you have completed? 
Please tick one box 
 
GCSEs                               Master's Degree   
    
A /AS levels or highers       Doctoral Degree   
    
College                                        None of the above   
    
Bachelor's Degree                               Other (please describe   
 
 
 
7. What is your vasculitis diagnosis, please tick one  box? 
 
Wegener‘s Granulomatosis                          Microscopic Polyangiitis   
    
Polyarteritis Nodosa                                   Churg Strauss Syndrome   
    
Takayasu Arteritis                                        Behçet‘s Disease    
    
Giant Cell Arteritis (Temporal Arteritis)                                     Henoch-Schönlein purpura   
    
Other (please describe)      
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8. How long did it take for your vasculitis to be 
diagnosed, from first reporting your symptoms to a health 
professional or doctor? 
 
 
less than 3 months               1-2 years  
    
3-  6 months               3-5 years     
    
7-12 months              more than 5 years  
 
 
9.    How long is it since you have been diagnosed with 
vasculitis? 
 
 less than 6 months                        3-5  years  
  
 7-12  months                                 6-10  years    
                    
 1-2 years                                              11-15  years                      
 
more than 15 years 
 
 
10. Had you ever heard of your kind of vasculitis before you 
were 
diagnosed?  
 
 
 
11. When you were first diagnosed with vasculitis were you 
provided with information about your vasculitis? 
 
 
 
              Yes        No  
        Yes              No  
 288 
 
12.    Who provided you with this information about your 
vasculitis? 
  
 
    Doctor               Nurse                    Relative                     
Other  
 
 
 
 
 
 
 
 
13.  How was this information about vasculitis provided? 
 
 
Verbally                                     Disease specific leaflet                
 
Arc vasculitis leaflet                        Pages from internet  
                   
 
Verbally together with a                 Written material 
produced  
written leaflet                                  by hospital     
 
 
 
14.  Where or how did you find out about your kind of 
vasculitis? 
  
  
Internet                                           Friend 
                   
Doctor                                             Support group        
  
Nurse                                             Written material   
 
Course                                           Other                
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15.  If English is not your first language, have you been able to 
find information about vasculitis in your own language?    
 
 
 
 
 
 
 
 
 
 
 
 
 
IMPORTANT INFORMATION FOR YOU  
 
16. Please read each of the following statements. Please tick the number that best 
describes how important it is/was for you to be provided with this information.  
 
1. Not important   
2 .Slightly important 
 3.Moderately important   
4. Very important  
5 .Extremely important 
 
                                                    
It is important for me to know:           
The name of my vasculitis  1 2 3 4 5 
What the symptoms are  1 2 3 4 5 
What causes my vasculitis 1 2 3 4 5 
If my vasculitis is hereditary 1 2 3 4 5 
If it is contagious 1 2 3 4 5 
How it is diagnosed   1 2 3 4 5 
The reasons why doctors suggest certain tests. 
 e.g. x-rays, scans and biopsies  
1 2 3 4 5 
How will I  feel during / after investigative tests 1 2 3 4 5 
The results of tests carried out 1 2 3 4 5 
What the results of blood tests mean 1 2 3 4 5 
How often I should have blood tests 1 2 3 4 5 
The names of drugs used in the treatment of vasculitis  1 2 3 4 5 
How my treatment is given 1 2 3 4 5 
How my treatment was chosen 1 2 3 4 5 
        Yes            No           Not Applicable  
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If there is evidence to support my treatment regime 1 2 3 4 5 
How to prepare for my treatment  1 2 3 4 5 
The possible side effects of treatment 1 2 3 4 5 
If there are ways to prevent /ease treatment side effects 1 2 3 4 5 
What side effects I should report to the doctor/nurse 1 2 3 4 5 
If I have side effects how to deal with them 1 2 3 4 5 
Who I should call if I have any concerns during treatment 1 2 3 4 5 
How long will I require treatment 1 2 3 4 5 
How the illness will affect my life  1 2 3 4 5 
How my vasculitis will be monitored 1 2 3 4 5 
How my illness could affect my life in the future 1 2 3 4 5 
If there are any changes I should make to my lifestyle   1 2 3 4 5 
If I can continue with my usual sports/hobbies 1 2 3 4 5 
If there are groups available to talk to other people 
who have vasculitis 
1 2 3 4 5 
If I can continue with my usual social and physical activities  1 2 3 4 5 
Where I can get help to deal with feelings about my illness  1 2 3 4 5 
How to talk to family/friends about my illness 1 2 3 4 5 
How to access other services eg. benefits, social services 1 2 3 4 5 
How to access psychological support 1 2 3 4 5 
 
 
17. Please tell us about an example of any type of information you found useful, if 
any please state below. 
 
 
 
 
 
 
18. Please tell us your order of preference for each of these methods of 
delivering educational materials by ticking one score for each item. (e.g. tick 
1 for your top preference, tick 8 for the item you least prefer) 
 
 1 2 3 4 5 6 7 8 
Internet                                                            
Doctor verbally 
Written materials 
Audio visual materials        
CD        
1-2 day course        
Educational group with other individuals         
Conversation with doctor with written materials         
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19. Does your household have access to the internet, so that you can search for 
information on the net?  
                                                  
 
It would be very helpful if you could return this questionnaire within the next 10 days in 
the pre-paid envelope enclosed to.  
 
Janice Mooney – arc Research Office 
Department of Rheumatology 
Norfolk & Norwich University Hospital 
Colney Lane  
Norwich 
NR4 7UY   
 
Thank you very much for your co-operation  
  
           Yes       No  
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Appendix R       Vasculitis Informational Needs Questionnaire 
VCRC 
Janice Mooney and Dr Richard Watts are independent researchers 
working at the University of East Anglia in the United Kingdom and 
are carrying out a research project. This is called ‗What are The 
Information Needs of Patients with Primary Systemic Vasculitis? 
Development of an Educational Package‘. The purpose of the study 
is to explore the educational needs of patients with vasculitis, so that 
we can develop an education program and materials that best reflect 
your needs. 
 
Please take time to help, by filling in this questionnaire. You do not 
need to give your name, and your answers are strictly confidential. 
You can check to show your answer. 
 
It may take approximately 10-15 minutes of your time to complete. 
 
1. What is your date of 
birth? 
____/____/____ (dd/mmm/yyyy) 
 
2. What is your 
gender? 
O 
Male 
O 
Female 
 
3. In what country do 
you live? 
-
_________________________________
_________ 
 
4. Is English your first 
language? 
O 
Yes 
O 
No 
 
For question 5, these questions may seem redundant, however, all 
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three sections need to be completed. 
5. Please give your ethnic group? (Select one)* 
 
O 
Hispanic, Latino or 
Spanish Origin 
O 
Not Hispanic, Latino, or 
Spanish Origin 
 
O 
Unknown or not 
reported 
O 
Refused 
 
    Race (check all that apply):* 
 
 
American Indian or 
Alaska Native 
 
White  
  Asian  Refused 
 
 
Black or African 
American 
 
Unknown 
  Native Hawaiian or Other Pacific Islander 
 
    Please provide your ethnic group again. (Check all that apply)* 
  African  Latin American 
  African American  Middle Eastern 
 
 
Asian 
(Indian/Pakistani/Bang
ladesh) 
 
Native Hawaiian/Pacific 
Islander 
  Black American  Turkish 
  Black Caribbean  White Caucasian American 
  Chinese  White Caucasian European 
  Japanese  Other ethnic group 
  Korean      
 
6. Please check the highest level of education you have 
completed? 
 
O 
No schooling 
completed 
O 
Some college credit 
 O Nursery grade to 4th O Associate degree 
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grade 
 O 5th to 8th grade O Bachelor‘s degree 
 
O 
9th to 12th grade (NON 
DIPLOMA) 
O 
Master‘s degree 
 O High school graduate O Doctoral degree 
 
 
7. What is your vasculitis diagnosis? (Please check one) 
 
O 
 
Granulomatosi
s with 
Polyangiitis 
(also called 
Wegener‘s 
Granulomatosi
s) 
O 
Microscopic Polyangiitis 
 
O 
Polyarteritis 
Nodosa 
O 
Churg Strauss Syndrome 
 
O 
Takayasu‘s 
Arteritis 
O 
Behçet‘s Disease 
 
O 
Giant Cell 
Arteritis 
(Temporal 
Arteritis) 
O 
Henoch-Schönlein purpura 
 
O 
Other (please 
describe) 
____________________________________
___ 
 
8. How long did it take for your vasculitis to be diagnosed, from 
first reporting your symptoms to a health professional or 
doctor? 
 
O 
Less than 3 
months 
O 
1-2 years 
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 O 3-6 months O 3-5 years 
 O 7-12 months O 5 years or more 
 
9. How long is it since you have been diagnosed with vasculitis? 
 
O 
Less than 6 
months 
O 
6-10 years 
 O 7-12 months O 11-15 years 
 O 1-2 years O 16 years or more 
 O 3-5 years      
 
10. Had you ever heard of your kind of vasculitis before you 
were diagnosed? 
 O Yes O No 
 
11. When you were first diagnosed with vasculitis were you 
provided with information regarding your vasculitis? 
 O Yes O No 
 
12. Who provided you with this information regarding your 
vasculitis? (Check all that apply) 
  Doctor 
  Nurse 
  Relative 
  Other 
 
13. How was this information provided? (Check all that apply) 
  Verbally  Disease specific pamphlet 
 
 
Vasculitis 
Foundation 
pamphlet 
 
Pages printed from internet 
 
 
Verbally 
together with a 
 
Written material produced by 
hospital 
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written 
pamphlet 
    Other 
 
14. Where/how did you find out about your kind of vasculitis? 
(Check all that apply) 
  Internet  Friend 
  Doctor  Support group 
  Nurse  Written material 
  Course  Other 
 
15. If English is not your first language, have you been able to 
find information in your own language? 
 O Yes O No O Not applicable 
 
 
IMPORTANT INFORMATION FOR YOU 
16. Please read each of the following statements. Please check 
the number that best describes how important it is/was for you 
to be provided with this information 
1. Not important 2. Slightly important 3. Moderately important 
4. Very important 5. Extremely 
important 
 
          
It is important for me to know: 1 2 3 4 5 
The name of my vasculitis O O O O O 
What the symptoms are O O O O O 
What causes my vasculitis O O O O O 
If my vasculitis is hereditary O O O O O 
If it is contagious O O O O O 
How it is diagnosed O O O O O 
The reasons why doctors suggest O O O O O 
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certain tests. 
e.g. x-rays, scans and biopsies 
How will I feel during / after 
investigative tests 
O O O O O 
The results of tests carried out O O O O O 
What the results of blood tests 
mean 
O O O O O 
How often I should have blood 
tests 
O O O O O 
The names of drugs used in the 
treatment of vasculitis 
O O O O O 
How my treatment is given O O O O O 
How my treatment was chosen O O O O O 
If there is evidence to support my 
treatment regime 
O O O O O 
How to prepare for my treatment O O O O O 
The possible side effects of 
treatment 
O O O O O 
If there are ways to prevent / ease 
treatment side effects 
O O O O O 
What side effects I should report to 
the doctor/nurse 
O O O O O 
If I have side effects how to deal 
with them 
O O O O O 
Who I should call if I have any 
concerns during treatment 
O O O O O 
How long will I require treatment O O O O O 
How the illness will affect my life O O O O O 
How my vasculitis will be 
monitored 
O O O O O 
How my illness could affect my life 
in the future 
O O O O O 
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If there are any changes I should 
make to my lifestyle 
O O O O O 
If I can continue with my usual 
sports/hobbies 
O O O O O 
If there are groups available to talk 
to other people who have vasculitis 
O O O O O 
If I can continue with my usual 
social and physical activities 
O O O O O 
Where I can get help to deal with 
feelings about my illness 
O O O O O 
How to talk to family/friends about 
my illness 
O O O O O 
How to access other services eg. 
welfare, social services 
O O O O O 
How to access psychological 
support 
O O O O O 
 
17. Please tell us about an example of any type of information 
you found useful, if any please state below. 
_______________________________________________________
_______________________________________________________
_______________________________________________________
_______________________________________________________
_______________________________________________________
____ 
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18. Please list in order of preference the most suitable method 
for you of delivery of educational materials, with a check in the 
box from 1-8, number 1 the least preferred and number 8 the 
most. 
 1 2 3 4 5 6 7 8 
Internet O O O O O O O O 
Doctor verbally O O O O O O O O 
Written materials O O O O O O O O 
Audio visual materials 
(DVD/tape) 
O O O O O O O O 
Compact Disc (CD) O O O O O O O O 
1-2 day course O O O O O O O O 
Educational group with other 
individuals 
O O O O O O O O 
Conversation with doctor with 
written materials 
O O O O O O O O 
 
19. Does your household have access to the internet, so that 
you can search for information on the internet? 
 O Yes O No 
If NO, does your household have other access to a computer for 
leisure or non-commercial use (e.g. through friends,  colleagues, or 
the library)? 
 O Yes O No 
 
Thank you very much for completing the Vasculitis 
Informational Needs questionnaire. 
 
Janice Mooney Richard Watts      
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 Appendix S  Reliability of the Vasculitis Informational Needs Questionnaire 
(VINQ) 
Item of question Cronbach’s Alpha if item 
Deleted 
Item 1 
.948 
Item 2 
.947 
Item 3 
.947 
Item 4 
.948 
Item 5 
.949 
Item 6 
.947 
Item 7 
.946 
Item 8 
.946 
Item 9 
.947 
Item 10 
.947 
Item 11 
.946 
Item 12 
.946 
Item 13 
.946 
Item 14 
.946 
Item 15 
.946 
Item 16 
.946 
Item 17 
.947 
Item 18 
.947 
Item 19 
.946 
Item 20 
.947 
Item 21 
.947 
Item 22 
.947 
Item 23 
.947 
Item 24 
.946 
Item 25 
.947 
Item 26 
.946 
Item 27 
.946 
Item 28 
.948 
Item 29 
.946 
Item 30 
.947 
Item 31 
.947 
Item 32 
.949 
Item 33 
.949 
Total Cronbach’ s Alpha = 0.957 
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Appendix T Quotes from comments made by respondents in the VINQ 
Examples of useful information found     Quote 
 
Internet                                   I understood my disease so much better after viewing  
          the information at         http://www.ancavasculitis.co 
         Material re research results published on  internet 
The NIH online site and the Mayo Clinic online site 
have very good       information 
Grateful Med (Med-Line) 
Vasculits website for information on symptoms, 
treatments 
After the original Rheumatologist information the 
internet has provided the main information 
Research articles accessed on internet 
Google search, government health site, 
PubMed has articles 
internet research on the side effects of the drug 
regimen prescribed as well as information regarding 
my disease 
Information on Wegener's, e.g. expected course/life 
span, etc. 
I found helpful information with an internet search 
NIH information on web 
UNC Kindney Center Site 
www.wegenersgranulomatosis.net 
Internet was terrific source of information, more so 
than doctor 
Medline plus was very useful 
I found the www,vasculitisfoundation.org website the 
best for information on GPA 
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Websites of major hospital rheumatology 
departments 
Support groups        Vasculitis foundation  on the internet 
Support groups on facebook 
Stuart Strange Trust (UK) 
I have received the most help from my support group for 
PAN - the information there is not just what 
I received a large package of written material from the 
Vasculitis Foundation that was very useful. 
Personal contact by phone with someone from vasculitis 
support group  
My support group and personal physician most helpful! 
The wegeners Association was really helpful with 
information etc 
The Vasculitis Foundation (when I finally found them!) 
was extremely helpful...sending me pamphlets 
Internet sites about my specific vasculitis 
I found a lot of information on the Internet, more than 
was given to me by my doctor 
I received the info packet from the vasculitis foundation, 
which was fabulous. 
Stuart Strange Trust, Now changed to Vasculitus UK 
Information from vasculitis groups online, medical journal 
articles, my   own medical records 
 When I found the group of Wegeners  patients online it 
was so helpful.   They actually answered more of my 
questions 
I recently went to another site and reread info on the 
disease, this was  helpful  
online forum, medical websites 
Found out lots of information from Wegener's Support 
Forum and Vasculitis websites 
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Facebook Support Group, Book titled "Vasculitis: Sick and 
Tired of being Sick and Tired" 
Facebook support group.  I felt less isolated and less of a 
freak. 
I found online support sites very useful. Because there is 
so little information out there, it helps and support group 
via the internet 
Medical books /Papers  In depth web -site research and medical books 
   Reading about autoimmunity 
Scientific reprints from journals, proceedings from 
scientific meetings published on the web 
Published medical studies available over the internet 
especially effectiveness of treatment regimens 
Information in health center library (1986) 
Academic research papers 
I work in a hospital so I found the medical journals very    
helpful 
Specialist nurse  Simple access to specialist nurse 
   Specialist nurse helping with clinical trial was the most  
   help for me 
 
Written material   ARC leaflet about Vasculitis 
                   The print out my nurse friend sent to me early on in my  
   illness 
      Mayo clinic print out of css 
       Living with vasculitis brochure from Stuart Strange 
 
 
